Investigating the role of CLU PICALM and CR1 in Alzheimer's disease by Lord, Jenny
Lord, Jenny (2014) Investigating the role of CLU 
PICALM and CR1 in Alzheimer's disease. PhD thesis, 
University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/14273/1/JennyLord_Thesis.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
  
 
 
Investigating the role of CLU, PICALM and 
CR1 LQ$O]KHLPHU¶VGLVHDVH 
 
 
Jenny Lord, BSc MSc 
 
 
Thesis submitted to the University of Nottingham 
for the degree of Doctor of Philosophy 
 
July 2014 
Abstract 
In 2009, two large genome wide association studies (GWAS) found 
associations between common single nucleotide polymorphisms (SNPs) at 
three loci (CLU, PICALM and CR1Ǽȱ ȱ£Ȃȱ ȱ ǻǼȱ ǯȱ ȱ
causal variants underlying these associations and how these impact on AD 
susceptibility remain unclear. Target enrichment and next generation 
sequencing (NGS) were used to completely resequence the three associated 
loci in 96 AD patients in an attempt to uncover potentially causative and rare 
variants that may explain the observed association signals. A pipeline was 
developed for the handling of pooled NGS data following a comparison of 
several different combinations of programs. 33 exonic SNPs were found 
within the three genes, along with over 1000 non-coding variants. To identify 
the variants most likely to be affecting AD risk, a two pronged approach was 
adopted. The variants were imputed in a large case-control cohort (2067 cases, 
7376 controls) to test for association with AD, and the likely functional 
consequences of the variants were assessed using in silico resources. Several of 
the analysed variants showed suggestive or significant association with AD in 
the imputed data, and/or were predicted to have consequences on the function 
or regulation of the genes, suggesting avenues for future research in AD 
genetics. The whole method of pooled, targeted NGS and prioritisation using 
imputed data for association testing and in silico resources for functional 
analysis represents a new strategy for tracking down the illusive causation of 
GWAS signals.   
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1. Introduction 
 
$O]KHLPHU¶V'LVHDVH 
 
£Ȃȱ ȱ ǻǼȱ ȱ ȱ ǰȱ ǰȱ ȱ
disorder, with numerous genetic and environmental risk factors, first 
described by Dr Alois Alzheimer in the early 1900s. Its prevalence has 
escalated since its discovery: in 2006, the worldwide prevalence of AD was 
estimated to be around 26.6 million, and it is thought this figure could rise 
fourfold in coming decades, to a predicted 107 million cases in 2050, as life 
expectancies across the world increase (Brookmeyer et al. 2007).  
 
In the UK alone, it is estimated there are around 820,000 people living with 
dementia. AD is the most common form of dementia, the cost of which to the 
UK economy each year is estimated to be a staggering £23 billion (Alzheimer's 
Research UK 2013) Ȯ a figure which is set to increase along with the growing 
numbers of AD sufferers forecast over coming years.  
 
1.2. AD in the clinic 
 
Symptoms and diagnosis 
Symptoms of early AD include memory loss, language difficulties, 
disorientation and behavioural or mood changes. As the disease progresses, 
these changes become more severe, often resulting in a complete inability to 
perform daily tasks or recognise loved ones, and constant care becomes a 
necessity. The symptomatic decline is accompanied by a shrinking of the brain 
and neuronal cell death. On average, AD patients live for around 8 years 
following diagnosis, with increasing cognitive impairment and weakening 
defences leaving them vulnerable to secondary infections, often pneumonia. A 
clinical diagnosis of possible or probable AD can be provided during the 
Ȃȱ , mainly on the basis of cognitive assessments, but there is 
considerable overlap with the symptoms of other forms of dementia, and a 
definitive diagnosis of AD can only be confirmed post mortem, upon the 
ȱȱȱȱ“? plaques and tau neurofibrillary tangles 
within the brain. The plaques and tangles are not specific features of AD, 
however, and can be seen in the brains of individuals without any cognitive 
impairment (Villemagne et al. 2008).  
 
Mini Mental State Examination 
There are a variety of tests used in the diagnosis of AD. The Mini Mental State 
Examination (MMSE) (Folstein et al. 1975) is often utilised as it is designed to 
ȱȱȱ ¢ȱȱȱȱ ȱȱȱȂȱȱǯȱȱȱȱřŖȱ
ȱ ȱ ȱ ȱ ȱ ȱ Ȃȱ ȱ ǰȱ ȱ
memory, attention and language skills. The test can be affected by educational 
status and cultural background, but in general, a score of over 27/30 is 
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indicative of normal cognitive function, while lower scores can be indicative 
of mild cognitive impairment (MCI, which can, but does not always progress 
to AD) or AD itself. Scores between 10 and 26 are suggestive of MCI or mild-
to-moderate AD, while scores below 10 are suggestive of severe AD. This can 
help guide treatment strategies. The test can be used over time to monitor 
decline or assess effectiveness of treatments (information from 
http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=
121). 
 
Often, the results of such tests are taken in to consideration alongside other 
lines of evidence, such as personal and family history, physical examinations 
or brain scans (which can help identify alternative causes of AD-type 
symptoms, such as brain tumours, depression and infections). Patients with 
early stage dementia may require observation over a period of time to see if 
and how symptoms progress.  
 
A number of frameworks for the diagnosis of AD have been developed over 
the years, such as the NINCDS-ADRDA (National Institute of Neurological 
and Communicative Disorders and Stroke and Alzheimer¶s Diseases and 
Related Disorders Association), seeking to standardise diagnostics of AD and 
other dementias, bringing together neuropsychological testing as well as 
biomarker profiling, MRI and PET scanning (McKhann et al. 1984; Dubois et 
al. 2007).  
 
Treatments and prevention 
Since the fundamental cause of AD remains unclear, it is difficult to develop 
effective treatments. Knowing what aspects of the pathology of the condition 
are causes and which are consequences might allow the development of 
therapies which could actually prevent or cure the disease. As it is, currently 
available treatments target the symptoms of the disease, so while they may be 
effective in reducing day to day manifestations of the disorder, they do not 
modify the course of the disease. 
 
NICE approved treatments 
Four drugs are currently approved by the National Institute for Health and 
Care Excellence (NICE) for the treatment of AD: acetylcholine esterase (AChE) 
inhibitors (donezepil, galantimine and rivastigmine) are recommended for the 
management of symptoms in mild to moderate AD, while memantine can be 
used in the treatment of severe AD, as well as for moderate AD in those 
patients that cannot be treated using AChE inhibitors (National Institute for 
Health and Care Excellence 2011). The aim of all these treatments is to manage 
the cognitive, behavioural and psychological symptoms of the condition in an 
attempt to maintain function, enabling independence for as great a time as 
possible. Aside from drug treatments, patients with AD may be aided in a 
variety of ways, depending on severity and circumstances, e.g. social support, 
community dementia care, home nursing, respite care and residential care 
homes.  
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The three AChE inhibitors, all similar in terms of treatment and cost 
effectiveness, share a common mechanism of action: increasing levels of 
acetylcholine (ACh) at the sites of neurotransmission in the brain. Such 
treatments arose following observations of reduced ACh release, reduced 
choline uptake and loss of cholinergic neurons ȱ£Ȃȱǰȱ ȱ
lead to the development of the cholinergic theory of AD (Francis et al. 1999). If 
dysfunction in the AD brain does arise from deficiencies in ACh, inhibiting its 
degradation (e.g. using AChE inhibitors) should increase the available level of 
the neurotransmitter, and thus reduce the cognitive impairment seen. 
However, since the AChE inhibitor treatments only provide symptomatic 
relief without slowing the progression of the disease, it seems unlikely that 
they are targeting the fundamental cause of the condition, making it unlikely 
that ACh deficiency alone is the root cause of AD. 
 
Memantine is a medium affinity, voltage-dependent, non-competitive N-
methyl-D-aspartate (NMDA) receptor antagonist, which works by blocking 
the effects of the increased levels of glutamate seen in AD patients, which is 
thought to contribute to neuronal dysfunction. 
 
Clearly the devastating effects and huge global burden of AD makes finding 
new treatments imperative, and a vast number of clinical and pre-clinical 
trials are currently underway for a plethora of drugs targeting various aspects 
of AD.  
 
$ȕUHODWHGWreatments 
Unsurprisingly, given its predominance as one of the major pathological 
ȱȱǰȱ“?ȱȱȱȱȱ¢ȱȱ ȱȱȱȱ
ȱ ȱ ȱ ȱȱȱ ȱ¢ǯȱ ȱȱ ȱ ȱ ȱ“?ȱ
levels in the brain have been attempted: reducing its production; preventing 
its aggregation; or promoting its clearance.  
 
ȱ“?ȱȱȱȱȱȱȱȱȱȱȱȱ¢ȱ“?- 
ȱ ȱ “?-secretases (discussed in greater detail later), they seem logical 
tȱ ȱ ȱ ȱ ȱ“?ȱǯȱ ȱȱ ȱ ȱ ȱ ȱ ȱ
each has ȱȱȱǰȱ¢ȱȱȱ“?-secretase, which 
can lead to unacceptable side effects.  
 
 ȱ“?-secretase inhibitors that have reached clinical trials include LY450139 
and Semagacestat, but both trials were halted. Treatment with LY450139 did 
ȱȱȱȱ“?ȱǰȱȱȱȱȱȱȱ
was discontinued at phase II (Fleisher et al. 2008). Semagacestat reached phase 
III trials, but was stopped when the treatment group showed worsening 
cognitive functions relative to the placebo group (Samson 2010). There 
ȱȱȱȱȱȱ“?-ȱǰȱ ȱȱȱ“?ȱ
ȱ ȱȱ ȱ ¡ȱ ȱ ȱȱ ȱ ȱ£¢Ȃȱ
other target molecules (Ozudogru and Lippa 2012). 
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ȱ ȱ ȱȱ “?-secretase (BACE1) are expected to have less 
severe side effects. Knock-out animals lacking the ¢ȱȱȱ“?-
secretase (PSEN1 or PSEN2) fail to develop in to viable embryos, while gene 
knock-ȱȱ“?-secretase is well tolerated (Luo et al. 2001). Despite this, and 
despite promising results of BACE1 inhibitors in animal models (Fukumoto et 
al. 2010; Chang et al. 2011), very few “?-secretase targeted therapies have 
reached clinical trial. One promising result was obtained in the case of CTS-
21166, a well tolerated BACE1 inhibitor which passed phase I clinical trials in 
humans, eliciting a dose dependent decreaȱ ȱ ȱ“?ȱ , although 
little has been published on the molecule (Panza et al. 2009). Further research 
 ȱ ȱȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱȱ“?ȱ ȱ
therapy in humans, and whether this has any positive effect on AD symptoms 
and progression. 
 
ȱȱȱ“?ȱȱȱȱȱȱȱȱȱȱ
oȱ “?ȱ ȱ ȱ ǰȱ ȱ ȱ ȱ ȱ ȱ ¢ȱ ȱ ¢ȱ
plaques. Whether this is a valid strategy, given increasing evidence that 
ȱ¢ȱ¢ȱȱȱȂȱȱȱȱȱ  “?ȱ
remains to be determined. Two such therapies have reached clinical trials, 
following promising results in animal studies (McLaurin et al. 2006; Gervais et 
al. 2007). Tramiprosate was shown to significantly reduce amyloid burden in 
Tg2576 mice (APP Swedish mutation transgenic strain) (Gervais et al. 2007), 
and was well tolerated in human clinical trials. However, in phase III trials, 
cognitive assessments and MRI measures were unaffected in response to the 
treatment, the reasons for which remain unclear (Aisen et al. 2011). The other 
therapy, ELND005 (scyllo-inositol) was well tolerated in humans at lower 
doses, but ȱ¢ȱ ȱ ¢Ȃȱȱȱ“?ȱ and on AD patients 
remains to be determined (Salloway et al. 2011; Schenk et al. 2012).  
 
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ “?ȱ
immunisation. There are two broad strategies for this; active and passive 
immunisation. Active immunisation involves the introduction of antigens (e.g. 
¢ȱ “?ŚŘǰȱ ȱ ȱ ȱ ȱ ȱ Ǽǰȱ ȱ ȱ ȱ ¢ȱ ȱ
elicits its own immune response. The alternative to this is passive 
immunisation, where the antibodies themselves are introduced to the patient, 
ȱ ȱ  ȱ ȱ ¢Ȃȱ ǯȱ ȱ ȱ ¢ȱ
which these strategies work ȱ ȱ“? remains unclear, but may include 
prevention of aggregation or stimulation of phagocytosis by microglia (Schenk 
2002; Schenk et al. 2012). These approaches are generally trialled on animal 
ȱ ¡ȱ ȱ ȱ ȱ  ȱ ȱ ȱ ¡ȱ “?ȱ
production, and some promising findings have been reported, with reductions 
in neuropathological features, and even some improvements to cognitive 
ȱ ȱȱ ȱ“?ȱ ȱ  (Schenk et 
al. 1999; Janus et al. 2000; Morgan et al. 2000). The crossover from these animal 
models in to humans has been problematic, however. Notably, AN 1792 was 
approved for human trials following extensive testing on animal models, and 
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was found to be well tolerated in Phase I human trials. The Phase IIa trial 
however, featuring 300 patients receiving AN 1792, was halted after a number 
of patients (18 (6%)) developed meningoencephalitis (Orgogozo et al. 2003), 
drawing scepticism from the public and scientific community with regards to 
this approach. Despite this, there are a number of investigations of both active 
and passive immunisation ongoing, and time will tell whether an acceptable 
level of adverse effects can be maintained, and whether this can actually help 
patients suffering from AD (Schenk et al. 2012).  
 
ȱȱȱ¢ȱȱ¢ǰȱ“?ȱ the actual causative 
factor for AD development, so the need to modulate its production would be 
crucial. However, over recent years, this theory has increasingly been called in 
to question, at least partly due to the failure ȱ“?ȱȱ ǯȱ 
ǰȱ“?ȱȱȱ ȱȱȱ¡ȱȱ(Maltsev et al. 2011), so 
even if it is not the fundamental causative agent, reducing its presence early 
on in the disease process could help limit the damage seen in AD patients.  
 
Who to treat? 
One significant issue in attempting to combat AD is that of deciding who to 
treat. Currently therapies are given when patients present with symptoms of 
dementia and receive AD as a clinical diagnosis. However, it is thought that 
the damage which eventually manifests in this way has actually begun to 
occur much earlier, perhaps decades before any cognitive impairment is 
detected in the individual. Any treatment given at this time may simply come 
too late: neurons which have been lost cannot be replaced, and decimated 
neural connections cannot be repaired.  
 
As such it is imperative that treatments are given as early in the disease 
process as possible. At the very least, early diagnosis is crucial, but ideally 
high risk, pre-symptomatic individuals should be identified (e.g. through 
biomarker screening, scanning to detect early (pre-symptomatic) changes in 
the brain, and identification of those with high risk genetic profiles). It is 
possible that in the plethora of drugs which have failed to elicit sufficient 
responses in clinical trials, there are useful therapies which have been 
disregarded because they were applied to patients for whom it was already 
too late to address the damage caused by AD. Prevention, in such a condition, 
may be the only viable form of cure.  
 
It is interesting to note that aside from the prospect of an absolute cure, simply 
delaying the onset of the condition for a modest time period (1-2 years) could 
reduce the global case load and associated financial burden significantly 
(Brookmeyer et al. 2007). 
 
Prevention 
Longitudinal studies of individuals taking non-steroidal anti-inflammatory 
drugs (NSAIDs) for unrelated conditions, such as rheumatoid arthritis, reveal 
a lower incidence of AD when such medication is used before the typical age 
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of onset of AD (Breitner et al. 1994; Stewart et al. 1997). This has lead to trials 
treating AD patients with NSAIDs, but with disappointing results. It was 
demonstrated that when patients already diagnosed with AD are given such 
treatments, there is no improvement (or even a worsening) of symptoms 
(Aisen et al. 2003; Martin et al. 2008). Taken together, this suggests that before 
the symptoms of AD present, limiting inflammation can slow or prevent the 
development of AD, thus implying inflammation may play a key early role in 
AD pathogenesis. These drugs are relatively cheap, easily available and have 
demonstrably acceptable side effects, so may represent a promising strategy 
for reducing AD incidence in the future, if at risk individuals can be identified, 
and NSAIDs given before disease onset.  
 
Similarly, it has been shown that the use of statins, taken to reduce cholesterol, 
are associated with a decreased risk of AD (Zamrini et al. 2004). This may be 
an effect of the drugs themselves; there is some evidence that statins may lead 
ȱ ȱ ȱ ȱ ¡ȱ “?ȱ ¢ȱ ȱȱ ȱ ȱ
insulin-degrading enzyme from microglia (Tamboli et al. 2010). However, it is 
also possible that the effect is indirect, with the drugs simply lowering 
cholesterol, high levels of which are a known risk factor for AD (Kivipelto and 
Solomon 2006).  
 
Exposure to environmental risk factors for AD can also affect susceptibility. 
Age is by far the most significant environmental risk factor for late onset AD, 
with risk increasing dramatically as aging occurs. Other factors include 
educational status, head injury, exercise, hypertension, and vitamin intake 
(Dosunmu et al. 2007; Dangour et al. 2010; Pogge 2010), although what effect 
modifications of these risk exposures could have on public health remains to 
be determined (Dangour et al. 2010). 
 
 
1.3. AD pathological hallmarks 
 
AD is a highly heterogeneous condition, with the physical manifestations of 
the disorder showing considerable overlap with other types of dementia (e.g. 
ȱȱȱǼǯȱǰȱȱȃȱȄȱ
ǻ“?ȱȱȱau tangles) generally taken to be diagnostic of AD can also 
be present in other types of dementia, as well as in non-demented brains.  
 
One of the major changes seen in AD is at the gross level, with shrinkage of 
the brain apparent as a result of neuronal and synaptic losses particularly in 
the hippocampus, an area which is implicated in the formation of new 
memories, and is particularly affected in early AD (see Figure 1.1). 
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Figure 1.1 - Healthy vs. advanced AD brain  
  
Image to show the difference in gross brain volume between healthy (left) and AD 
affected (right) brains, taken from http://www.alz.org/braintour/healthy_vs_ 
alzheimers.asp. Large lesions apparent on the AD image are typical and indicative of 
neuronal cell death. 
 
On ȱȱǰȱ“?ȱȱȱau neurofibrillary tangles (NFTs) are two of 
the major characteristic features of AD. The structure and localisation of these 
is shown in figure 1.2.  
 
Figure 1.2 - Amyloid plaques and tau neurofibrillary tangles 
 
Image to show the differences in brain pathology in normal and AD affected brains, 
taken from http://www.brightfocus.org/alzheimers/about/understanding/plaques-
and-tangles.html. The image on the left depicts a region of healthy brain from an 
unaffected individual, featuring normally functioning neurons and no extracellular 
accumulations of protein. On the right, an AD affected brain is shown. Here the 
neurons contain clumps of hyperphosphorylated tau, and there is extracellular 
ȱȱ¢ȱȱȱȱ ȱȱ“?ȱȱ¢ȱǯ 
 
 8 
 
 
$ȕSODTXHV 
“? or amyloid plaques are extracellular accumulations of protein, which are 
ȱ ȱ ȱ ¢ȱ“?ȱ ǰȱalong with a multitude of other 
proteins and cell constituents, including apolipoprotein E (ApoE), clusterin (or 
ApoJ) and several components of the complement cascade (Liao et al. 2004). 
Activated glial cells and immune complexes are often found in the vicinity of 
“?ȱǰȱ ȱȱ ȱȱ (Eikelenboom et 
al. 2006).  
 
The A“?ȱ ȱ ȱ ȱ  ȱ ȱ ¢ȱ ȱ rotein (APP) is 
processed, which can follow either the amyloidogenic or non-amyloidogenic 
pathway, summarised in Figure 1.3, depending on which secretase enzyme is 
involved in the first of the sequential cleavage steps.   
 
Figure 1.3 - APP processing 
  
Schematic diagram of APP processing, adapted from Thinakaran 2008 (Thinakaran 
and Koo 2008). In the non-¢ȱ ¢ǰȱ“?-ȱȱ ȱȱ“?ȱ
ȱǰȱȱ“?ȱȱȱǯ ǰȱ“?ǰȱȱřȱȱ
AICD are generated. In the amyloidogenic  ¢ǰȱȱ¢ȱ“?- ȱ“?-secretase 
ȱȱȱȱȱ“?ǰȱȱ“?ȱȱǯ 
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Both APP processing pathways produce the amyloid precursor protein 
intracellular domain (AICD), which is thought to have important roles in 
transcriptional control, although the genes on which it exerts these effects are 
yet to be established (Chang and Suh 2010). It is the amyloidogenic pathway Ȯ 
with cleavagȱ ȱ ¢ȱ “?- ȱ “?-secretase - that generates the aggregation 
ȱ“?ȱǯȱȱȱȱȱȱ“?ȱǰȱȱ“?-secretase can 
cleave the protein at several different amino acid residues: “?-ŚŖȱȱ“?-42 
are the most common (~90% and <10% respectively), although shorter species 
have been reported (Selkoe and Wolfe 2007)ǯȱ “?-42 is particularly 
hydrophobic and prone to aggregation.  
 
Neurofibrillary tangles 
tau, the main component of neurofibrillary tangles, is a microtubule associated 
protein, which is involved in the stabilisation and regulation of microtubule 
bundles, crucial for cytoskeletal integrity and axonal transport (Roy et al. 
2005)ǯȱ Ȃȱ ȱ ȱ ȱ ȱ ¢ȱ ȱ ȱ ȱ  ȱ
phosphorylation and dephosphorylation. When this balance is breached, tau 
hyperphosphorylation can occur, disrupting its normal functions, and giving 
the molecule a propensity to form paired helical filaments. These are the 
insoluble, aggregation prone building blocks of neurofibrillary tangles which 
form within the cytoplasm of neuronal cells (Goedert et al. 1995). Tau is also 
implicated in a number of other neurodegenerative disorders, such as frontal 
temporal dementia (Neumann et al. 2009). This can be caused by mutations 
within the gene encoding tau, microtubule associated protein tau (MAPT) 
(Goedert and Jakes 2005), which leads to neuronal cell loss and consequent 
cognitive decline. The formation of amyloid plaques is generally thought to 
precede the formation of tau tangles -  both plaques and tangles are found to 
arise from mutations in APP, while mutations in tau generally only give rise 
to tangles (Lovestone 2000).    
 
It is not clear how either of these signature lesions relate to AD pathology, and 
whether they are early, causative events in the development of AD, or late 
stage consequences of the disease process.  Additional to these, inflammation 
of the brain, vascular involvement and cerebral amyloid angiopathy (CAA) 
are also often observed in AD brains compared to normal controls, but none of 
these are specific or necessary for a diagnosis of AD.  
 
1.4. Types of AD 
 
There are two general forms of AD, classified on the basis of the time of onset 
of symptoms - those showing symptoms before the age of 65 (generally 
between 50-65, but can be much earlier (Bird et al. 1996)) are classified as early 
onset, and account for about 5% of total AD cases. Late onset AD (LOAD), 
which constitutes around 95% of cases, shows the onset of symptoms after the 
age of 65. Although this distinction is often made, it is a rather arbitrary cut off 
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dividing a whole spectrum of ages of onset, likely due to differing 
contributions of genetic and environmental risk factors, in to two discrete 
categories. 
 
Early onset AD 
Early onset AD can be divided in to two groups - early onset familial 
(EOFAD) and early onset sporadic AD. The first, EOFAD is a monogenic 
disorder caused by rare mutations in one of three genes (PSEN1, PSEN2, or 
APP), inherited in a Mendelian fashion, which almost guarantee the onset of 
symptoms before the age of 65. All three of these genes are tightly linked to 
APP processing (PSEN1 and PSEN2 encode ȱ ȱ ȱ “?-secretase 
enzyme), which mutations then disrupt, ȱ ȱ ȱ ȱ “?ȱ ȱ
formation of amyloid plaques at an earlier age than is seen in LOAD. 
 
The first EOFAD causative mutation in APP was identified by Goate et al. in 
1991 (Goate et al. 1991). Multiple EOFAD affected families had mutations 
which showed linkage to chromosome 21. The variant, V717I was termed the 
London mutation (Goate et al. 1991). Subsequent to this, a large number of 
other causative mutations have been identified, including 24 in APP, 185 in 
PSEN1 and 14 in PSEN2 (Tanzi 2012). The majority are fully penetrant 
autosomal dominant mutations, with one APP recessive mutation reported to 
date (Tanzi 2012). Most of the mutations in APP alter the relative ratios of 
“?42Ǳ“?40. The Swedish mutation, notable as it is often used as a model for AD 
ȱȱǰȱȱȱȱȱȱ ȱȱ“?ȱȱȱ
APP (Lannfelt et al. 1994)ǰȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ“?ȱ
speciǰȱ ȱ ȱ ȱ ȱ ȱȂȱ ¢ȱ ȱ ȱ (Tanzi 
2012). There is also known to be an APP mutation (A673T) that is protective 
against both AD and cognitive decline in elderly AD unaffected individuals 
(Jonsson et al. 2012).  
 
Early onset sporadic AD is less easily defined. Individuals with this form of 
AD do not appear to follow the monogenic inheritance pattern typical of the 
familial form of AD but have an age at onset below 65 years. This may be due 
to complex interplay between different genetic and environmental risk factors, 
as for the late onset condition, or may be due to as yet undiscovered 
mutations, perhaps showing differing levels of penetrance, making it harder 
to track within families (Jin et al. 2012; Antonell et al. 2013). 
 
Late onset AD 
The vast majority of cases of AD are late onset (LOAD), with the onset of 
symptoms after the age of 65. LOAD is a complex disorder, caused by a 
combination of genetic and environmental risk factors, all of which alter risk 
for AD without alone being necessary or sufficient for the development of the 
disorder. Age is the most significant environmental risk factor for LOAD, and 
other factors which have been implicated in increasing or decreasing LOAD 
risk, affecting age of onset, or affecting disease progression include 
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educational status, head injury, hypertension, high cholesterol and vitamin 
intake (Dosunmu et al. 2007; Pogge 2010). 
 
1.5. Genetics of LOAD 
 
Since this thesis deals primarily with LOAD, LOAD shall simply be referred to 
as AD, and any mention of AD from this point forward refers to the late onset, 
complex disorder. 
 
Although the heritability of AD is estimated to be around 70%-80% (Gatz et al. 
2006), relatively little is understood about the genetics of the condition. None 
of the genes involved in EOFAD have been implicated in sporadic AD risk 
(Tanzi and Bertram 2005), and until recently, there was only one well 
established and replicated genetic risk factor for AD Ȯ ȱ “?Śȱ ȱ ȱ
Apolipoprotein E (APOE), which, due to its large effect size, was identified via 
linkage studies in the early 1990s (Pericak-Vance et al. 1991). 
 
ApoE is a 229 amino acid glycoprotein with three major isoforms, created by 
combinations of non-synonymous single nucleotide polymorphisms (SNPs) at 
 ȱȱȱ ȱȱǰȱ ȱȱȱ“?Řǰȱ“?řȱȱ“?Śȱ. The 
“?Śȱ ȱ ȱ ȱ ȱ  ȱ ȱ ȱ ȱ ȱ ǰȱ  ȱ ȱ ȱ
possession of a single copy at a 2-řȱȱȱǰȱȱ“?Śȱ£¢ȱȱ
ȱŗŘȱ ȱȱ ȱ ȱ ȱ ȱȱ“?Śȱǲȱ ȱ ȱ ȱ“?Řȱ
allele has a protective effect, and is associated with a decreased risk of AD 
(Farrer et al. 1997).   
 
The main site of ApoE expression is in the liver, with the brain second (Kim et 
al. 2009). Most of the expression in the brain is accounted for by astrocytes 
(Grehan et al. 2001), rather than neuronal cells, although these can be induced 
to express low levels of ApoE under certain conditions (Xu et al. 2006). Its 
normal biological function is not yet fully understood, so it is unknown 
 ȱȱȱȱȱȱȱ¢ȱȱ“?Śȱȱȱȱȱȱ
of neuroprotective function, the gain of neurotoxic function, or a combination 
of the two. There is evidence that the different ApoE isoforms may have 
differing effects on neuroinflammation (Kim et al. 2009)ǰȱ“?ȱȱȱȱ
brain (Reiman et al. 2009) ȱ“?ȱȱȱȱ (Deane et al. 2008), 
any of which could be related to an alteration in AD risk. The SNPs in APOE 
that generate the different protein isoforms have striking effects on the 
structure of the molecule (Mahley et al. 2006), so it is unsurprising that its 
function is affected; it is just yet to be elucidated how, and how this impacts 
on AD risk.  
 
 
 
 
 12 
1.6. Genome wide association studies  
 
Despite two decades of research trying to find new genetic variants involved 
in AD risk, no other loci could be definitively confirmed and replicated as 
genetic risk factors for AD, although over 500 genes were investigated 
(Bertram et al. 2007),  largely identified as being plausible biological 
candidates, based on what is known about the aetiology of the condition.  
 
The problem with looking at biological candidate genes is that one is entirely 
limited by prior knowledge of the condition, and when that knowledge is 
limited or incomplete, such as is the case for AD (and many other complex 
disorders), genes which are involved, but do not necessarily fit with current 
understanding are bound to be overlooked. Additionally, any genes which are 
discovered via this approach are unlikely to greatly further the understanding 
of the aetiology of the condition since they will fit with mechanisms and 
pathways which are already thought to be involved.  
 
In order to combat this, an unbiased method of searching for loci involved in 
disease risk was needed - a way of considering all genes in the human genome 
simultaneously, without any assumption as to which might be involved.  
 
This much needed method was provided by the advent of genome wide 
association studies (GWAS), which became possible as a number of crucial 
components came together concurrently. Firstly, the HapMap project 
(HapMap 2003) was formed - an international collaboration that sought to 
catalogue all common human variation in a number of different populations, 
and document the patterns of linkage disequilibrium (LD) therein. Secondly, 
technology was developed that allowed hundreds of thousands of SNPs to be 
genotyped simultaneously, and relatively affordably. These two factors meant 
a panel of tag SNPs could be devised which would capture the majority of 
variance across the whole genome of an individual. Finally, sample sets that 
were large enough to give GWAS sufficient power became available through 
collaboration between different research groups. 
 
Essentially, a GWAS is based on hundreds of thousands (or millions, with the 
most recent technology) of SNPs being genotyped in large numbers of cases 
and controls (generally several thousand). Variants which are significantly 
more common in one group than the other are said to be associated with the 
particular trait being considered Ȯ more common in controls, and the variant 
is associated with decreased risk, more common in cases, and the variant is 
associated with increased risk. Because of the vast numbers of simultaneous 
independent tests being conducted, the rate of false positives would be 
unacceptably high at the standard level of significance (p < 0.05), so a 
conservative Bonferroni correction is applied, making the level generally 
classed as reaching genome wide significance p < 5x10-8, and anything falling 
between 5x10-5 to 5x10-8 is said to show suggestive significance.  
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ȱȱȱȱȱ	ȱȃȄȱȱȱȱȱǰȱ
both within the same population, and in different populations, although 
population specific differences in LD  may mean that a SNP tagging a causal 
variant in one population may not do so in a different population, and rare 
causative variants may be population specific. 
 
1.7. AD GWAS 
 
Although there had previously been a number of GWAS in AD, they failed to 
detect any signals reaching genome wide significance, other than APOE (Coon 
et al. 2007; Grupe et al. 2007; Abraham et al. 2008; Beecham et al. 2009; 
Carrasquillo et al. 2009), and loci showing suggestive significance did not 
replicate well. This was likely due the relatively small numbers of case and 
control samples used, meaning studies were underpowered to discover 
variants of modest effect sizes. Furthermore, early genotyping chips did not 
have a very comprehensive coverage of the genome, since tag SNPs were at 
first selected based on distance, rather than LD, which could mean causal 
variants simply were not represented in these studies.  
 
In September 2009, the first two truly large scale GWAS for AD, using the 
latest genotyping technologies, were simultaneously published in a single 
edition of Nature Genetics (Harold et al. 2009; Lambert et al. 2009). The two 
studies together identified three independent signals reaching genome wide 
significance, bringing the first major advancement in our knowledge of AD 
genetics in over 15 years. Each study used a two stage approach to garner 
compelling evidence for the loci identified, taking any SNPs showing evidence 
of association in the first stage, and replicating these in a second, independent 
sample set. The sample numbers and SNPs genotyped by each study are 
summarised in Table 1.1. Each paper found two genome wide significant hits: 
CLU and PICALM in the Harold et al. study (Harold et al. 2009), and CLU and 
CR1 in the Lambert et al. paper (Lambert et al. 2009), with odds ratios and 
significance values summarised in Table 1.2. Since CLU was identified by both 
papers, replication for this locus was immediately available. In addition to 
this, PICALM, identified as significant by Harold et al. showed suggestive 
significance (OR = 0.88, p = 2.8x10-3) in Stage 1 of the Lambert et al. paper, and 
CR1, identified as significant by the Lambert et al. paper showed suggestive 
significance (OR = 1.17, p = 8.3×10ƺŜ) in Stage 1 of the Harold et al. paper. Since 
then, further replication for all three loci has been published (Carrasquillo et 
al. 2010; Corneveaux et al. 2010; Jun et al. 2010; Seshadri et al. 2010), and a 
number of other genes have also been found to be associated with AD, 
including BIN1 (Seshadri et al. 2010), ABCA7, the MS4A locus, EPHA1, CD33 
and CD2AP (Hollingworth et al. 2011; Naj et al. 2011).  The basic design and 
summary results for CLU, PICALM and CR1 in some of the replication GWAS 
are presented in Table 1.3. 
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Although each of these new findings has received replication in independent 
Caucasian sample groups, replication in other populations has been less 
successful (Jun et al. 2010; Lee et al. 2010; Li et al. 2011; Logue et al. 2011). 
Whether this stems from genuine aetiological differences across populations, 
or whether these studies have simply been underpowered, with insufficient 
sample sizes to detect associations of the expected magnitude remains to be 
elucidated.  
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Table 1.1 Ȯ Study design of the two major 2009 AD GWAS 
 
 
 
 
 
 
 
 
 
 
Information on the number of SNPs genotyped, genotyping platform used, and post QC sample numbers in the two major AD GWAS published in September 
2009 (Harold et al. 2009; Lambert et al. 2009). 
 
Table 1.2 Ȯ Main results of the two major 2009 AD GWAS 
Gene SNP Paper p-value OR (combined) 95% CI 
CLU rs11136000 Harold et al. 8.5x10-10 0.86 0.82-0.90 
Lambert et al. 7.5x10-9 0.86 0.81-0.90 
CR1 rs6656401 Lambert et al. 3.7x10-9 1.21 1.14-1.29 
PICALM rs3851179 Harold et al.  1.3x10-9 0.86 0.82-0.90 
Results from the two major 2009 AD GWAS, including p-values and ORs of the SNPs reaching genome wide significance (Harold et al. 2009; Lambert et al. 
2009). 
 
 
 
 
Study Stage SNPs 
genotyped 
Genotyping Platform Cases Controls Total 
Samples 
Harold et al. 
2009 
1 529,205 Illumina HumanHap550/300 
BeadChips 
3941 7848 11789 
2 2 Sequenom assays 2023 2340 4363 
Lambert et al. 
2009 
1 537,029 Illumina Human610-Quad 
BeadChips 
2032 5328 7360 
2 11 Taqman (Applied Biosystems) 
or Sequenom assays 
3978 3297 7275 
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Table 1.3 Ȯ CLU, PICALM and CR1 replication GWAS 
Study Part/Design Samples Genotyped Results 
Cornevaux 
et al. 2010 
Case-control 1019 Cases, 591 Controls (White - 
USA, UK, Netherlands) 
34 SNPs CLU Ȯ rs11136000 Ȯ OR 0.86, p = 0.040 
PICALM Ȯ rs541458 Ȯ OR 0.81, p = 0.01 
CR1 Ȯ rs6656401 Ȯ OR 1.28, p = 0.008 
Carrasquillo 
et al. 2010 
Case-control 1819 Cases, 2565 Controls (White Ȯ 
USA) 
3 SNPs CLU Ȯ rs11136000 Ȯ OR 0.82, p = 8.6x10-5 
PICALM Ȯ rs3851179 Ȯ OR 0.80, p = 1.3x10-5 
CR1 Ȯ rs3818361 Ȯ OR 1.15, p = 0.014 
Jun et al. 
2010 
Meta-analysis 5935 Cases, 7034 Controls (9 white 
northern European cohorts) 
 
17 SNPs CLU Ȯ rs11136000 Ȯ OR 0.91, p = 0.0007 
PICALM Ȯ rs3851179 Ȯ OR 0.89, p = 3.9x10-5 
CR1 Ȯ rs3818361 Ȯ OR 1.14, p = 6.1x10-5 
Meta-analysis 1135 Cases, 1135 Controls (5 cohorts 
including African American, Israeli-
Arab and Caribbean Hispanic) 
17 SNPs No significant associations 
Schjeide et 
al. 2011 
Combined 
case-control 
2868 Cases, 1386 Controls (USA 
family samples, German unrelated 
cases and controls) 
5 SNPs CLU Ȯ rs11136000 Ȯ OR 0.88, p = 0.04 
PICALM Ȯ rs541458 Ȯ OR 0.82, p = 0.01 
CR1 Ȯ rs6656401 Ȯ OR 1.33, p = 0.001 
Naj et al. 
2011 
Combined 
case-control 
11840 Cases, 10931 Controls (14 
cohorts of European ancestry) 
9 Loci CLU Ȯ rs1532278 Ȯ OR 0.89, p = 8.3x10-8 
PICALM Ȯ rs561655 Ȯ OR 0.87, p = 7.0x10-11 
CR1 Ȯ rs6701713 Ȯ OR 1.16, p = 4.6x10-10 
Study design and results for some of the GWAS replicating the associations between SNPs in CLU, PICALM and CR1 and AD (Carrasquillo et al. 2010; 
Corneveaux et al. 2010; Jun et al. 2010; Naj et al. 2011; Schjeide et al. 2011). 
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The new genes which have been identified as AD risk factors via GWAS are 
all involved in a small number of pathways (see figure 1.4), which include 
ȱȱ“?ȱǰȱȱimmune response, and cell membrane processes. 
This gives new insights in to the aetiology of the condition, which may in turn 
lead to new targets for treatments.  
 
Figure 1.4 Ȯ Pathways of AD GWAS genes 
  
Diagram to show the way in which the new AD candidate genes identified by GWAS 
relate to potential pathways in AD pathogenesis, adapted from Morgan 2011 (Morgan 
2011). 
 
For the past two decades, the amyloid cascade hypothesis has been the 
dominant theory of AD pathogenesis. The amyloid cascade hypothesis (Hardy 
and Higgins 1992) ȱȱȱȱȱ“?ȱȱȱ¢ȱȱȱ
in the pathogenesis of AD, and all other features of the disease (neurofibrillary 
tangle formation, neuroinflammation, vascular damage, neuronal cell death 
ǯǼȱ ȱ ¢ȱ ȱ ȱ ǯȱ ȱ ȱ ȱ “?ȱ ȱ ȱ ȱ
responsible for this has changed over the years since the hypothesis was first 
ǯȱ¢ǰȱȱ ȱȱȱȱ“?ȱȱ ȱȱȱ the 
neurotoxic effects, however, ȱ “?ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
cognitively normal individuals (Villemagne et al. 2008); plaque presence and 
cognitive decline do not correlate well (Terry et al. 1991); and treatments 
 ȱȱ“?ȱȱ ȱȱȱȱȱ ȱȱȱ ȱ
term symptomatic improvements (Holmes et al. 2008), this has become less 
popular than the theory that it may be pre-ǰȱ ȱȱȱ“?ȱ
that are the source of the problem (Ferreira et al. 2007), perhaps via disruption 
of synaptic signalling. Under this version of the amyloid cascade hypothesis, it 
ȱȱ ȱ ȱ“?ȱȱ ȱ ȱ ȱ ȱȱȂȱ ȱ ȱ
ȱ ȱ ȱ “?ȱ ȱ  ¢ȱ ȱ ǰȱ ȱ ȱ
damage (Maltsev et al. 2011).  
 
There are numerous strands of support for the theory; individuals with 
trisomy 21 (with an extra copy of the APP gene)ǰȱ ȱ ȱ “?ȱ
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production and often develop AD at a young age (Olson and Shaw 1969), and 
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ “?ȱ
production (Pimplikar 2009). “?ȱȱ ȱ  ȱ ȱ ȱ ¡ȱ ȱ
both in vivo and in vitro (Maltsev et al. 2011).  
 
Most of the evidence against the amyloid cascade hypothesis is related to the 
version of the hypothesis that postulates the plaques to be the harmful species, 
however, even the revised version of the theory cannot explain all aspects of 
the condition (Pimplikar 2009), and consequentially, a number of alternative 
hypotheses have been proposed over the years, each claiming a different 
primary cause of the condition. These hypothesised initial insults include tau 
hyperphosphorylation (Maccioni et al. 2010), decreased acetylcholine 
production (Francis et al. 1999), oxidative stress (Markesbery 1997), 
mitochondrial disregulation (Swerdlow and Khan 2004), neuroinflammation 
(Tan and Seshadri 2010; Zotova et al. 2010) and vascular damage (Marchesi 
2011).  
 
Each of these theories has its own relative strengths and weaknesses, but none 
can fully explain the entire catalogue of neurological features and symptoms 
in AD. It is hoped that the new AD associated genes will help to create a more 
unified theory of AD pathogenesis, which will eventually explain fully how 
the disease forms and what the causative agents are.  
 
1.8. New genes in AD 
 
The three most significant genes which were implicated in AD risk by the 
Lambert et al. and Harold et al. GWAS were CLU, CR1 and PICALM (Harold 
et al. 2009; Lambert et al. 2009). As these three genes are the main focus of this 
thesis, they will be discussed in detail later (see CLU, PICALM and CR1 
sections 1.9, 1.10 and 1.11 respectively). Below is an overview of what is 
currently known about the other newly identified GWAS genes, and a brief 
review of the ways in which they may contribute to AD risk, given previous 
theories of the condition, and the pathways implicated by the new AD 
associated genes. 
 
1.8.1. BIN1 
The gene encoding bridging integrator 1 (BIN1, also known as amphiphysin 
II), was first implicated in AD risk by the Harold et al. 2009 GWAS, where a 
suggestive association (p<10-6) was detected between two SNPs, rs744373 and 
rs7561528 ~30kb upstream of the gene and AD (Harold et al. 2009). In later 
studies with larger sample sizes, both SNPs have since reached genome wide 
significance (rs744373 p =1.59×10ƺŗŗ, OR 1.13 (95% CI 1.06Ȯ1.21) (Seshadri et al. 
2010); rs7561528 p = 5.2x10-14, OR 1.17 (95% CI 1.12-1.22) (Naj et al. 2011); 
rs7561528 p = 2.6x10-14, OR 1.17 (95% CI 1.12-1.21) (Hollingworth et al. 2011)).  
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The gene, situated on chromosome 2q14 is comprised of 20 exons, which are 
alternatively transcribed to give ~10 protein isoforms (Pruitt et al. 2007). The 
isoforms of the protein are differentially expressed between tissue types, with 
some displaying brain-specific expression, and show differences in subcellular 
localisation (Wechsler-Reya et al. 1997; DuHadaway et al. 2003). BIN1 has 
tumour suppressor gene activity, and has been linked to both breast and 
prostate cancers (Kuznetsova et al. 2007). Like PICALM, BIN1 is implicated in 
the process of clathrin mediated endocytosis (CME), facilitating the recycling 
of neurotransmitters and synaptic vesicles (SVs) which is important for 
ȱǯȱȱȱȱ¡ȱǰȱ ȱŗȂȱȱ¢ȱȱ
the recruitment of dynamin to the site of CME at the membrane, which is 
ȱȱȃȱȄȱȱȱ(Pant et al. 2009). 
 
1.8.2. ABCA7 
The gene encoding ABCA7 is situated on chromosome 19p13.3, spanning a 
region of around 25.5kb. It is a member of the ATP binding cassette (ABC) 
transporter gene super-family, with 49 documented ABC proteins, and 12 
ABCA sub-family members. Members of these families are involved in the 
active transport of a range of substances (e.g. ions, sugars, peptides) across 
cellular and organelle membranes (Vasiliou et al. 2009). ABCA7, along with 
other ABCA family members, is expressed in the brain, and features two 
ȱ ǰȱ ȱ ȱ ȱ ¡ȱ “?ȱ ǯȱ ȱ ȱ
function of ABCA7 is not completely understood, ABC transporters are 
thought to facilitate the uptake of glucose, amino acids and ions to the brain, 
as well as having lipid trafficking functions which may be relevant to AD 
pathology (Kim et al. 2008). Apolipoproteins A-I have been shown to be able 
to act as ligands for ABCA7, introducing the possibility that the transporter 
¢ȱȱȱȱ“?ȱȱ(Tanaka et al. 2011). 
 
The gene was first implicated in AD risk by a GWAS conducted by 
Hollingworth et al. in 2011. In this study, intronic SNP rs3764650, greatly 
surpassed the threshold for genome wide significance after replication and 
meta-analyses including data from a companion study (p = 5.0x10-21, OR 1.23 
(95% CI 1.17-1.28)) (Hollingworth et al. 2011; Naj et al. 2011). 
 
1.8.3. MS4A locus 
Several SNPs at the MS4A locus have been implicated in AD susceptibility by 
GWAS (Hollingworth et al. 2011; Naj et al. 2011). The MS4A gene region spans 
an area of around 800kb on chromosome 11q21, with 16 members of the MS4A 
family documented in this area to date, many encoding proteins with multiple 
isoforms (Liang and Tedder 2001). The SNPs implicating this region in AD 
risk fall within a block of high LD, making it difficult to pinpoint which of the 
many genes are involved, but implicating MS4A2, MS4A6A, MS4A4E and 
MS4A4A. MS4A6A, MS4A4E and MS4A4A are not well characterised, but 
homology in protein structure, and presence in a large gene cluster implies 
structural and functional similarities with MS4A1 and MS4A2 which have 
been experimentally characterised, and are thought to be involved in calcium 
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signalling via immunoglobulin receptor signalling complexes (Walshe et al. 
2008). Many of the MS4A genes have been shown to be expressed in the brain, 
and in cell types associated with immunity and neuroinflammation (Liang 
and Tedder 2001), which may suggest mechanisms by which the alteration in 
AD risk is invoked.  
 
This region was implicated in AD risk when two large GWAS published 
simultaneously in 2011 found several SNPs within the region reached genome 
wide significance. In a combined meta-analysis of data from both studies, 
three SNPs were found to have highly significant associations with AD 
(rs610932 - p = 1.2x10-16, OR 0.91 (95% CI 0.88-0.93); rs670139 - p = 1.1x10-10, OR 
1.08 (95% CI 1.06-1.11); rs4938933 - p = 8.2x10-12, OR 0.89 (95% CI 0.87-0.92)) 
(Hollingworth et al. 2011; Naj et al. 2011).  
 
1.8.4. EphA1 
The EphA1, or erythropoietin-producing human hepatocellular carcinoma 
gene spans a region of around 17.8kb on chromosome 7q34, featuring 18 exons 
which encode a 976 amino acid member of the receptor tyrosine kinase 
superfamily (Hirai et al. 1987; Maru et al. 1988). It was first implicated in AD 
risk by two GWAS published in 2011, where in the meta-analysis of data taken 
from each study, a SNP ~3kb upstream of the gene, rs11767557 reached 
genome wide significance (p = 6x10-10, OR 0.87 (95% CI 0.78-0.96) 
(Hollingworth et al. 2011; Naj et al. 2011), a finding which has subsequently 
been replicated (Carrasquillo et al. 2011).  
 
The product of the gene, which is expressed in multiple tissue types, is 
thought to be involved in cell-adhesion, cellular organisation and synaptic 
plasticity (Yamazaki et al. 2009; Hruska and Dalva 2012; Triplett and Feldheim 
2012). EphA1 is important in synapse development during embryogenesis 
(Hruska and Dalva 2012), which could suggest that underlying differences in 
neuronal circuitry dictated by differences in EphA1 during development may 
render the brain more or less able to cope with the changes associated with 
AD (Chen et al. 2012)ǯȱ ¢ǰȱ ȱ Ȃȱ ȱ ȱ ȱ ǰȱ
promoting maintenance of the synapse and synaptic plasticity could affect AD 
susceptibility (Chen et al. 2012).  
 
1.8.5. CD33 
The gene encoding CD33 or siglec-3, (sialic acid binding immunoglobulin-like 
lectin-3) is situated on chromosome 19q13.3, spanning a region of around 
14.9kb. CD33 is a transmembrane receptor for sialic acids, which is expressed 
in multipotent cells of the myeloid lineage, as well as in mature monocytes, 
macrophaghes, dendritic cells, basophiles and mast cells, with three isoforms 
validated to date (Andrews et al. 1983; Griffin et al. 1984; Valent and 
Bettelheim 1992; Yokoi et al. 2006). CD33 is thought to be involved in the 
¢Ȃȱȱǰȱȱ¢ȱȱȱ¢ȱ¢ȱ dampening any innate 
ȱ ȱ ȱ ¢ȱ ȱ ȃȄȱ (Crocker et al. 2007; Varki 2009). 
Siglec family members have also been shown to be implicated in the 
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endocytosis of various ligands (Biedermann et al. 2007; Tateno et al. 2007; 
Walter et al. 2008), although not via CME, which is emerging as a common 
factor between several AD risk genes (Tateno et al. 2007). Either of these 
processes could be linked to the aetiology of AD development.  
 
CD33 was first implicated in AD when in a study looking at families with 
multiple affected individuals, Bertram et al. found an association between a 
variant (rs3826656) ~3kb upstream of the gene and AD risk (p = 4x10-6), but 
which failed replication in an independent cohort (Bertram et al. 2008). In 
2011, two companion GWAS papers were published, with meta-analysis of the 
combined data revealing a genome wide significant association between SNP 
rs3865444 and AD (p = 1.6x10-9, OR 0.91 (95% CI 0.88-0.93)) (Hollingworth et 
al. 2011; Naj et al. 2011), a finding which has subsequently been replicated 
(Carrasquillo et al. 2011). 
 
1.8.6. CD2AP 
The gene CD2AP (CD2-associated protein) was implicated in AD when the 
SNP rs9349407, within intron one showed association with AD in the 
combined data of two large companion GWAS from 2011(p = 8.6x10-9, OR 1.11 
(95% CI 1.07-1.15) (Hollingworth et al. 2011; Naj et al. 2011). Although this 
effect has failed to replicate in other studies of Caucasian populations 
(Carrasquillo et al. 2011), meta-analysis including the initial data showed a 
strengthened association (p = 6.5x10-11).  
 
CD2AP is a 149.5kb gene with 18 exons, situated on chromosome 6p12. 
Although the gene is known to be expressed in the brain (Su et al. 2004), the 
function of CD2AP is not completely understood. It has roles in the immune 
system (stabilising interactions between T cells and antigen presenting cells 
(Dustin et al. 1998)), cellular structural organisation (anchoring various 
cellular components to the actin cytoskeleton), cell adhesion, endocytosis and 
apoptosis (Monzo et al. 2005). Links to innate and adaptive immunity, vesicle 
trafficking, endocytosis and synaptic plasticity may provide insights in to how 
the gene is related to AD pathology. Alternatively, the gene is implicated in 
renal disease, which commonly leads to hypertension and can cause 
ȱ ǰȱ ȱ ȱ Ȃȱ ȱ ȱȱ¢ȱ ȱ ȱ ȱ ǰȱ
altering susceptibility to known AD risk factors (Shih et al. 1999; 
Grunkemeyer et al. 2005).   
 
The following sections (1.9. CLU, 1.10. PICALM and 1.11. CR1) are largely 
based on chapters written for the book Genȱ ȱ ȱ £Ȃȱ
disease, published in 2013 by Springer New York (Morgan 2013). 
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1.9. CLU 
 
An Introduction to CLU 
CLU is one of the most robustly evidenced genetic risk factors for AD after 
“?Śǰȱȱȱȱȱȱȱȱȱȱ	ǯȱȱ
these were not the first time CLU had been implicated in AD, the GWAS 
evidence brought a new fervour to the investigation of how CLU could be 
mechanistically involved in the pathology of AD, and a drive to discover the 
specific genetic variations which convey the observed alteration in disease 
risk. 
 
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȃȄȱǰȱ ȱ ȱ ¢ȱ ȱ ȱ ȱ ȱ
wide variety of physiological functions, including lipid metabolism, 
complement inhibition, sperm maturation, DNA repair and cell cycle control. 
ȱ ȱ “?ȱ tabolism, neuroinflammation and apoptosis are all 
ȱ ȱ  ¢ȱ ȱ Ȃȱ ȱ ȱ ǰȱ ȱ ȱ
¡ȱ¢ǰȱȱȱȱ ȱȱȂȱȱȱȱ
is responsible for its relationship with AD risk.  
 
Clusterin ± genetics and regulation 
CLU is also known as apolipoprotein J (ApoJ); complement lysis inhibitor 
(CLI); sulfated glycoprotein 2 (SGP-2); testosterone-repressed prostate 
message 2 (TRPM-2); and secreted protein 40,40 (SP-40,40). This spectrum of 
nomenclaȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȃȱ ȱ ¢ȱ
functions and wide-spread expression, which lead to independent 
ȃ¢Ȅȱȱȱ¢ȱȱȱȱ¡ǯȱȱ ȱ¢ȱȱ
in 1983 in the fluid of the rete testis of rams (Blaschuk et al. 1983), with ApoJ 
(de Silva et al. 1990), CLI (Jenne and Tschopp 1989) and SP-40,40 (Kirszbaum 
et al. 1992) subsequently identified in human serum, eventually coming to be 
considered a single protein species - CLU.  
 
The CLU gene (NCBI - NG_027845.1, Ensembl - ENSG00000120885), 
comprising 9 exons, is situated on chromosome 8p21-p12, spanning a region 
of around 18kb (see Figure 1.5). There is a certain discrepancy between 
reported isoforms of CLU in different online databases and in the literature. 
NCBI lists three different transcripts for CLU, only one of which is said to be 
coding: 2877bp Isoform 1 (NM_001831.3, encoding NP_001822.3). Ensembl 
lists 21 transcripts, three of which are classed as coding (ENST00000316403 at 
3080bp, ENST00000523500 at 2381bp and the 2098bp ENST00000405140), all of 
which are said to give rise to a single protein isoform of 449aa - CCDS47832. 
Reporting at the 5th International CLU workshop, Trougakos et al. stated 
there were two alternatively spliced CLU transcripts, the main gene transcript 
(termed isoform two) corresponding to  the major, secreted, form of the CLU 
protein, and a second transcript, alternatively spliced to exclude exon two 
(Trougakos et al. 2009). Ling et al., in a recent paper investigating CLU 
isoforms and AD risk, reported the expression of two transcripts in the brain 
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(termed CLU1 and CLU2 (with CLU2 ȱȱȂȱȱ ǼǼǯȱ
These were identical in exons 2-9 but had different, untranslated, first exons 
and different proximal promoters, and the expression of CLU2 was 
consistently higher than CLU1 (Ling et al. 2012). The structure of these 
isoforms is shown in Figure 1.6. This view of CLU transcripts differing in exon 
one but sharing identical translated exons is supported elsewhere in the 
literature, where a putative third transcript has been suggested which shares 
exons 2-9 with CLU1 and CLU2 but has another, different exon one (Andersen 
et al. 2007; Rizzi and Bettuzzi 2010). Leskov et al. have also reported a 
transcript lacking exon two (Leskov et al. 2003). Because the main isoforms 
only vary in the first, untranslated exon, differences between them are thought 
to be regulatory rather than coding. Indeed, there is evidence that different 
isoforms are differentially regulated by various stimuli (Cochrane et al. 2007; 
Schepeler et al. 2007), which could well be explained by the presence of 
alternative promoter regions for different transcripts. 
 
Figure 1.5 - Genetic location of CLU 
 
Location of the CLU gene on chromosome 8p21-p12 and the transcripts of the gene 
according to RefSeq. Image taken from UCSC Genome Browser (Kent et al. 2002) 
(http://genome.ucsc.edu/). 
 
Figure 1.6 - CLU Isoforms 
 
The structure of the two most commonly reported and experimentally confirmed 
isoforms of CLU, adapted from Rizzi 2010 (Rizzi and Bettuzzi 2010).  Black boxes 
represent exons which are consistent between the two transcripts, while the gray 
boxes indicate the differing first exons.  The translation start codon resides in the 
second exon, meaning both transcripts are thought to give rise to identical proteins. 
 
Expression of CLU occurs in almost all mammalian tissues, with different 
levels of expression characteristic of specific tissue types. Expression within 
the brain is relatively high, along with the liver, testes and ovaries (de Silva et 
al. 1990). Within the brain, expression appears to be highest in astrocytes, 
which secrete CLU (Pasinetti et al. 1994; Saura et al. 2003). CLU is expressed at 
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low levels by neurons (Charnay et al. 2008), and shows regional variation in 
expression in different areas of the brain (Pasinetti et al. 1994). Morgan et al. 
demonstrated expression of CLU changes over the course of normal aging, 
with expression increasing in the corpus callosum and caudate-putamen (both 
white matter rich regions) and decreasing in interior and peripheral regions of 
the hilus (Morgan et al. 1999). Expression of CLU in mammals begins 
prenatally (around the 14th day of gestation in mice (Charnay et al. 2008)) and 
persists throughout adult life. 
 
Lymar et al. demonstrated in rats that in cell types which normally express 
CLU at low levels, the proximal 266bp or 311bp of the CLU promoter are 
sufficient to give maximal expression of reporter genes (Lymar et al. 2000). 
However, in cell types which normally express high CLU levels, in this case 
Sertoli cells, a region from -426 to -311 was also needed for maximal reporter 
gene expression (Lymar et al. 2000). The CLU promoter features a number of 
binding sites for various stress related transcription factors, indicative that the 
expression of CLU can be modulated in response to various stressors, and it 
ȱȱȱȱ¢ȱȱȱȱȱȱ¢ȱŗ“?ȱȱ
IL2 (Zwain et al. 1994)ǯȱȱ	“?ȱȱȱ ȱȱȱȱȱ-regulate CLU 
expression (Jin and Howe 1997)ǰȱ ȱȱȱȱ	“?ȱ ¢ȱ ȱ
exist within the promoter and first intron of the gene (Michel et al. 1995). A 
multitude of other molecules have been shown to be able to regulate CLU 
expression, including heat shock factors (Michel et al. 1997), c-myc (Thomas-
Tikhonenko et al. 2004), n-myc (Chayka et al. 2009)ǰȱ ȱ “κȱ(Li et al. 2002), 
members of the AP1 complex (Jin and Howe 1999), insulin-like growth factor-
1 and its receptor (Criswell et al. 2005) and H-ras (Kyprianou et al. 1991; Lund 
et al. 2006). 
 
CLU is also subject to epigenetic regulation. Nuutinen et al. showed that 
inhibiting histone deacetylase could induce CLU expression, while gene 
methylation and deacetylation silenced CLU expression in neuronal cell lines 
studied (Nuutinen et al. 2005). Lund et al. demonstrated that in H-ras 
transformed cells, which have decreased CLU expression, methylation levels 
at the clusterin gene were 20-40% higher than in non-transformed cells (Lund 
et al. 2006). The group identified a region -560 to -314 (relative to transcription 
start site) where methylation of CpG dinucleotides was significantly higher in 
the transformed cells, particularly between -385 and -376. No classical CpG 
island was found to be present within the CLU promoter, but there was one 
present 14.5kb upstream of the gene (Lund et al. 2006) which was shown to be 
hyper-methylated in H-ras transformed cell lines. This same region was also 
shown to have methylation levels two fold higher in the colon and small 
intestine (medium and low CLU expression respectively) compared to the 
testis (high CLU expression) (Lund et al. 2006). Hypo-methylation of the CLU 
promoter region had previously been demonstrated in cells with high overall 
levels of CLU expression (Rosemblit and Chen 1994). 
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Given CLUȂȱ ¡ȱ ¡ȱ attern and wide variety of postulated 
physiological roles, it is unsurprising such a range of molecules and 
mechanisms contribute to its regulation. 
 
Clusterin ± the protein 
There are two forms of CLU Ȯ the major form is secreted (sCLU), but there is 
also a nuclear isoform (nCLU). sCLU is thought to have largely pro-survival 
functions, while nCLU is pro-apoptotic, expressed in response to the presence 
of certain stressors.  
 
sCLU is a heavily glycosylated heterodimer, both subunits of which are 
encoded by the CLU gene. Post-translational processing of the full 449 amino 
acid pre-protein (49kDa) results in a protein with the mature structure shown 
in Figure 1.7. A 22 amino acid hydrophobic signal sequence at the N-terminus 
of the full translated protein directs the molecule to the endoplasmic 
reticulum, where the signal peptide is cleaved and removed. A second 
ȱ ȱ  ȱ ŘŖśȱ ȱ ŘŖŜȱ ȱ ȱ “?ȱ ȱ “?ȱ ǰȱ
which are subsequently bound together by five disulphide bridges 
(Kirszbaum et al. 1992). On transit from the endoplasmic reticulum to the 
Golgi apparatus, from which sCLU will be secreted, the protein undergoes 
heavy glycosylation, giving the molecule its final molecular weight of 70-
80kDa.  
 
Figure 1.7 - sCLU Protein Structure 
 
Structure of the mature sCLU protein with domains and glycosylation sites shown, 
adapted from Rizzi 2010 (Rizzi and Bettuzzi 2010). Other groups have speculated 
slightly different domains may be present, e.g. Jones 2002 postulated the presence of 
two coiled coil domains within the protein sequence (Jones and Jomary 2002). 
 
sCLU has been shown to be able to interact with a wide variety of molecules, 
ȱǰȱ“?ǰȱ ȱȱȱǰȱ ch has 
lead to it being implicated in a wide range of physiological processes. 
However, it has been speculated that rather than reflecting active involvement 
in these processes and genuine biological functions of CLU, interacting with 
such a range of molecules may rather reflect its capability to act as a 
chaperone (Humphreys et al. 1999).  
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Clusterin as a chaperone 
Chaperone molecules are important in managing the aggregation of proteins. 
Stressed proteins can become partially denatured and unfold, exposing 
hydrophobic regions which would normally be masked internally. The 
exposure of these hydrophobic regions confers a propensity to aggregate and 
precipitate, which if unchecked can have cytotoxic effects.  
 
It has been suggested that the structural and functional characteristics of CLU 
ȱȱȱȱȂȱȱȱȱȱȱȱ(Nuutinen et 
al. 2009). Since most of CLU is secreted, this chaperone activity would occur 
largely in the extracellular space, although it may be capable of acting as a 
nuclear chaperone in times of cellular stress, when the nCLU isoform of the 
protein (discussed later) is generated.  
 
ȱ ȱ “?-ȱ ȱ ȱ Ȃȱ ȱ ȱ ȱ typical of 
chaperone proteins (e.g. small heat shock proteins) (Law and Griswold 1994; 
Lakins et al. 2002), while the large disordered regions, or molten globule 
domains, represent flexible protein-protein interacting regions which allow 
CLU to interact with a low specificity to a range of target molecules (Bailey et 
al. 2001).  
 
Unlike some chaperones, CLU cannot itself facilitate the refolding of stressed 
proteins, but can stabilise them, preventing aggregation (Poon et al. 2000). It 
may also be capable of enabling the clearance of such molecules from the 
extracellular space via receptor mediated endocytosis (Nuutinen et al. 2009). 
The stable regions of CLU can specifically interact with targets such as 
megalin/low density lipoprotein-related protein 2 (LRP2, a cell surface 
receptor which facilitates the endocytosis of various ligands) (Zlokovic 1996).  
 
In addition to AD, CLU has been implicated in other disorders which feature 
protein aggregation as a prominent characteristic, including Creutzfeldt-Jakob 
disease, where it has been detected in prion clusters (Freixes et al. 2004), and 
in familial amyloidosis, where it has been linked to the prevention of 
lysozyme aggregation (Kumita et al. 2007). 
 
As well as acting as a chaperone, CLU is speculated to be involved in a host of 
ȱ ȱ ȱ¢ȱ ȱ ȱ ȱ ȱǰȱ ȱ“?ȱǰȱ
lipid trafficking and metabolism, neuroinflammation and apoptosis. 
¢ǰȱȂȱ¢ȱȱȱȱȱȱȱȱȱ
the blood brain barrier (BBB) may be relevant in AD pathology. 
 
nCLU 
The other form of clusterin, nCLU, is less well characterised. Reddy et al. first 
demonstrated the presence of a 43kDa protein, which they speculated was a 
non-secretary form of CLU (Reddy et al. 1996). The group identified a second, 
in frame, ATG codon within the third exon, 99 bases downstream of the ATG 
from which translation of sCLU begins in exon two. It is thought this arises 
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from a transcript where the first and third exons are joined by alternative 
splicing (Leskov et al. 2003), resulting in an mRNA lacking exon two, and thus 
the normal start codon. Ling et al. failed to find such a transcript in their 
recent investigation of CLU isoforms in the brain, however, they speculated 
that since its expression is associated with cell death, it would be transient and 
therefore not necessarily detectable in the context of high CLU1 and CLU2 
expression (Ling et al. 2012).  
 
The nCLU protein lacks the first 33aa of the pre-sCLU protein, the region 
which contains the hydrophobic signal sequence, meaning the protein is not 
targeted to the endoplasmic reticulum, and thus is not secreted. Three 
potential nuclear localisation signals exist in the nCLU protein sequence, but 
mutational analysis has indicated these are not necessary in establishing the 
cellular location of nCLU (Scaltriti et al. 2004). There is evidence that nCLU 
may exist in the cytoplasm as an inactive precursor molecule, with induction 
and translocation to the nucleus occurring in response to certain stressors (e.g. 
ionising radiation (Yang et al. 2000), or TGF-“?ȱ(Reddy et al. 1996) exposure). 
nCLU contains two coiled coil domains. The N-terminal coiled coil domain 
appears to be able to bind to the C-terminal one, suggesting the protein may 
be capable of oligomerisation. nCLU has been shown to be able to bind to Ku-
70 (Yang et al. 2000), an interaction which appears dependent on three crucial 
leucine residues within the C-terminal coiled coil domain (Leskov et al. 2003). 
ȱȱȱȱȱȱȱȂȱ-apoptotic functions. Ku-
70 is a crucial component of the double-strand DNA repair complex 
Ku70/Ku80. Binding of nCLU to Ku-70 could disrupt the repair complex, 
leading to a failure to repair damaged DNA, and ultimately apoptosis of the 
cell (Leskov et al. 2003). 
 
As CLU is expressed in virtually all tissues and shows a high degree of 
conservation across mammalian species (see Figure 1.7), it may be assumed 
that its role is one of fundamental importance biologically. However, despite 
this, and despitȱ Ȃȱ ȱ ȱ ȱ ȱ ȱ  ȱ ¢ȱ ȱ
physiological processes, experiments with CLU knockout mice have shown 
the absence of CLU is well tolerated, with mice developing and living 
normally (McLaughlin et al. 2000; Charnay et al. 2008). The lack of overt 
phenotype in CLU knockout mice may reflect the ability of other molecules to 
compensate for its absence. Other apolipoproteins may be able to fulfil some 
ȱ Ȃȱ ǰȱ ȱ ȱ  ȱȱ ȱ ȱ ȱ ȱ ȱ or 
ApoE deficiency in knockout mice (Anderson et al. 1998). McLaughlin et al. 
initiated myosin-induced autoimmune myocarditis in wild type and CLU 
knockout mice, and found a similar initiation of humoural and cell mediated 
inflammatory responses between the two. However, the severity of the 
inflammatory response was significantly increased, and significantly more 
cardiac tissue injury and long term impairment of cardiac function was 
observed in the CLU deficient animals (McLaughlin et al. 2000). These results 
suggest CLU may play a protective role against post-inflammatory 
destruction of tissue in autoimmune myocarditis (McLaughlin et al. 2000). 
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Imhof et al. induced ischemic cerebral injury in mice, which gave rise to long 
lasting expression of CLU in the astrocytes of wild type animals. CLU 
knockout mice displayed significantly slower tissue remodelling during 
recovery from such injury than did wild type mice (Imhof et al. 2006). Each of 
these findings of impaired recovery in CLU knockout animals implies a 
protective role of CLU, aiding in the recovery of tissues from various assaults. 
Impairment of such mechanisms could well contribute to the tissue damage 
and neuronal cell death observed in AD.  
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Figure 1.7 - Conservation in the CLU region 
 
Image to show genetic conservation across selected vertebrate species in CLU and the surrounding chromosomal region, taken from ECR browser 
(Ovcharenko et al. 2004) (http://ecrbrowser.dcode.org/). Blue Ȯ exons, pink Ȯ introns, yellow Ȯ untranslated regions, red Ȯ intergenic regions, green Ȯ repetitive 
DNA elements. The height of the graph is proportional to the level of conservation between human and that particular species (shown on right). 
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As well as being associated with AD, there are a number of other disorders 
CLU has been implicated in, often showing altered expression levels in the 
disease condition versus controls. Such conditions include atherosclerosis 
(Ishikawa et al. 1998), systemic lupus erythematosus (Newkirk et al. 1999), 
type 2 diabetes (Kujiraoka et al. 2006), heart disease/myocardial infarction 
(Vakeva et al. 1993; Poulakou et al. 2008), polycystic kidney disease (Harding 
et al. 1991) and rheumatoid arthritis (Devauchelle et al. 2004), many of which 
feature inflammatory or autoimmune aspects. Gao et al. speculated that AD 
ȱȂȱ ȱ ǻǼȱ¢ȱ ȱ ȱȱ ȱ ǰȱ ȱ
that many PD patients suffer from dementia, and Parkinsonian movements 
are often seen in AD patients (Gao et al. 2011). The group found that the same 
SNP within CLU that was associated with AD (rs11136000) was also 
ȱ ȱǰȱ ȱ ȱ ȱ ȱ ȱȱȂȱ ȱ ȱ
dementia risk, suggesting the two disorders do indeed share some common 
aetiological factors (Gao et al. 2011). 
 
With roles in both promoting cell survival and inducing apoptosis, it is 
unsurprising CLU has drawn extensive attention in relation to cancer 
development, progression and susceptibility treatment. Changes in CLU 
expression levels are seen in many cancers, including those of the prostate 
(Miyake et al. 2000), breast (Redondo et al. 2000), colon (Pucci et al. 2004) and 
bladder (Miyake et al. 2001). In general, CLU expression often appears to be 
decreased in naive cancer cells, with increased expression in cancers which 
have developed resistance to conventional treatments (Miyake et al. 2000; 
Cappelletti et al. 2008).  It has been speculated that up-regulation of CLU may 
be part of the mechanism by which breast cancer cells become resistant to anti-
oestrogen therapies, and thus down-regulation of CLU, in combination with 
conventional cancer treatments, may help combat the ability of tumours to 
evade the cytotoxicity of anti-cancer therapies. OGX-011 is an antisense 21 
base oligonucleotide targeted against the exon two region of CLU mRNA, 
which contains the translation start site (Chi et al. 2005). A number of studies 
have been conducted using OGX-011 in combination with usual cancer 
therapies, but while some have yielded promising results (So et al. 2005; 
Laskin et al. 2012), others have seen little effect beyond the expected response 
to the conventional treatments alone (Chia et al. 2009).  
 
Clusterin and AD 
In addition to the evidence from GWAS that CLU is involved in AD risk, a 
host of other research connects the gene/protein to the disorder. CLU was first 
implicated in AD back in 1990, when May et al. demonstrated expression of 
the gene in the hippocampus was significantly increased in AD when 
compared to healthy controls (May et al. 1990). CLU protein levels have also 
been shown to be higher in the frontal cortex and hippocampus of AD patients 
(Lidstrom et al. 1998). Early studies failed to find a link between AD and CLU 
levels in cerebrospinal fluid (CSF) (Harr et al. 1996), however, using newer 
techniques, it has subsequently been shown that CLU is significantly 
increased in the CSF of AD patients (Nilselid et al. 2006; Sihlbom et al. 2008; 
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Thambisetty et al. 2012) thereby possibly indicating its utility as a diagnostic 
biomarker. The protective allele of rs11136000 has been shown to be associated 
 ȱ ȱ ȱ ȱ ȱ ȱ ȃȱ Ȅȱ ǻşŘ-93 years at 
recruitment) (Mengel-From et al. 2010). Recently, plasma clusterin levels have 
been shown to be associated with brain atrophy both in AD (Mengel-From et 
al. 2010) and in mild cognitive impairment (MCI) (Thambisetty et al. 2012), the 
latter of which is indicative of an early role for CLU in the neurodegeneration 
seen in AD patients. CLU expression was also shown to be linked to disease 
severity (Thambisetty et al. 2010; Schrijvers et al. 2011) and clinical 
progression (Thambisetty et al. 2010) in AD patients. CLU expression has been 
shown to be increased in neurons as aging (a major risk factor for AD) occurs 
(Grassilli et al. 1992). Disregulation of epigenetic control may be central in 
conditions such as AD (Wang et al. 2008), and as discussed previously, CLU 
expression may be controlled largely by epigenetic mechanisms, again, linking 
CLU to potential pathogenic mechanisms in AD. CLU has been shown to be 
present in the amyloid plaques characteristic of AD (McGeer et al. 1992), but is 
absent from neurons containing neurofibrillary tangles (Giannakopoulos et al. 
1998). 
 
Contradictory findings have been reported with regards to the effect of APOE 
genotype on CLU expression levels. Harr et al. reported a significant decrease 
in CLU expression in the frontal lobes of AD patients with the APOE “?ŚȦ“?Śȱ
genotype (Harr et al. 1996). However, Bertrand et al. reported that the 
decreased APOE ¡ȱ ȱ “?ŚȦ“?Śȱ ȱ ȱ  ȱ ȱ ¢ȱ ȱ
increase in CLU expression, speculating that this may be some kind of 
compensatory mechanism, since the two apolipoproteins have overlapping 
functions (Bertrand et al. 1995). These apparently contradictory findings could 
be due to a variety of factors. It could reflect the inconsistent roles of different 
CLU isoforms, or varying effects of CLU at different stages of the disease, but 
it may simply reflect differences in experimental design.  
 
Although it has been overwhelmingly demonstrated that CLU is a genetic risk 
factor for AD, the exact nature of its relationship with AD, and how this 
alteration in risk is conveyed remains unclear.  
 
&OXVWHULQDQG$ȕ 
Despite a recent shift away from the amyloid cascade hypothesis, it has been 
the prevailing theory of AD pathogenesis for around two decades, and 
amyloid plaques constitute one of the two major pathogenic hallmarks of AD. 
With this in mind, the relationshiȱ ȱ¢ȱȱȱȱȱ“?ȱ
cannot be ignored.  
 
ȱȱȱ ȱȱȱȱȱȱ“?ǯȱȱȱȱȱ¢ȱ
plaques (McGeer et al. 1992)ǰȱȱȱȱȱȱ“?ȱȱȱȱȱ
CSF (Ghiso et al. 1993)ǰȱȱȱȱȱ ȱ“?-ŚŖȱȱ“?-42 in vitro 
(Matsubara et al. 1996). CLU and ApoE together have been shown to be 
ȱ ȱ ȱ “?ȱ ȱ ǰȱ ȱ ȱȱ ȱ ȱ
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ȱ“?ȱ ȱ ȱȱ(DeMattos et al. 2004). Recently, increased plasma 
CLU levels have been shown to be positively associated with the burden of 
ȱ “?ȱ ȱ ȱ ȱ ¡ȱ(Thambisetty et al. 2010). It has been 
ȱ ȱ ȱ¢ȱ ȱ ȱ ȱ ȱ ¢ȱ “?ȱȱ ȱ
recognition by the immune system, which could minimise the potentially 
harmful effects of invoking an immune response against protein clusters 
within the brain (Nuutinen et al. 2009). 
 
¢ȱ ȱȱȱȱ ȱ ȱ ȱ ȱ ȱȱȱ“?ȱ
solubility and aggregation, with some apparently contradictory findings. 
ȱȱȱȱȱȱȱ¢ȱȱ“?ǰȱȱs 
oligomerisation and inhibiting the formation of fibrillar structures (Oda et al. 
1994; Matsubara et al. 1996). However, DeMattos et al. demonstrated using a 
ȱ ȱ ȱ ȱ ȱ ¢ȱ ȱ “?ȱ ȱ ȱ ȱ
formation (DeMattos et al. 2002). It is thought the effect may be dependent on 
tȱ ȱ ȱ ȱ ȱ ȱ “?ȱ ǰȱ  ȱ  ȱ Ǳ“?ȱ ȱ
leading to a promotion of aggregation and plaque formation, and a high 
Ǳ“?ȱȱȱȱȱȱ¢ȱ (Yerbury et 
al. 2007).  
 
ȱȱȱȱȱȱ¢ȱȱȱȱȱȱȱ“?ȱȱ
the brain. The first way in which this could occur is via endocytosis. Hammad 
ȱǯȱȱȱ¡ȱȱȱȱ“?ȱȱȱȱ¢ȱǰȱ
ȱ ȱ ǰȱ ȱ ȱ ȱ “?ȱ ȱ ȱ ȱ ȱ  ȱȱ
lysosomal degradation (Hammad et al. 1997). It has also been shown that 
ȱ ȱ ȱ “?ȱ ȱ ȱ ¡ǰȱ ȱ ȱ ȱ
ȱ ¢ȱ ȱ ȱ ȱ ¢ȱ ȱ ȱ “?ȱ ȱ ¢ȱ ȱ
lines, although CLU is not itself necessary for this phagocytosis (Nuutinen et 
al. 2007)ǯȱ¢ȱȱ“?ȱȱ ȱȱȱȱȱȱ
“?ȱ ȱȱǰȱ¢ȱȱȱȱȱȱǯȱ¢ǰȱ
CLU may be able to faciȱ ȱȱ“?ȱȱ ȱȱȱȱ
(BBB). It has been demonstrated that CLU-“?ȱ ¡ȱ ȱ ȱ ȱ ȱ
(Zlokovic 1996). Bell et al. found that administering CLU-“?ŚŘȱ¡ȱȱ
mouse brains gave an almost two-fold increase in clearance rate across the 
ȱ ȱ ȱ “?ŚŘȱ ǰȱ ȱ ȱ ȱ  ȱ ȱ by antibodies 
against megalin (Bell et al. 2007). Interestingly, the known AD risk allele of 
APOEǰȱ “?Śǰȱ ȱ ȱ  ȱ ȱ ȱ ȱ ȱ ȱ “?ȱ ȱȱ ȱ
mechanism (Bell et al. 2007)ǯȱȱǰȱȱ¢ȱȱȱȱ“?ȱ
across the BBB, aided by CLU, represents an important means of reducing the 
ȱȱȱ“?ǰȱȱȱȱȱȱȱȱȱȱ¡ȱ
ȱȱ“?ǯ 
 
ȱ ǰȱ Ȃȱ ȱ  ȱ “?ȱ ȱ ¢ȱ ȱ ȱ ȱ ȱ ȱ
capacity to act as a chaperone. It interacts with a plethora of other molecules 
ȱ ȱ “?ȱ ȱ ȱ ¢ȱ ȱ ȱ ǰȱ ȱ ȱ ȱ ȱ
subject to intense scrutiny, perhaps without being directly relevant to AD 
development at all.  
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Clusterin, the cell cycle and apoptosis 
The symptomatic changes seen in AD occur as a result of the massive 
neuronal loss associated with the condition, although the cause of this loss 
remains to be elucidated. Regulators of the cell cycle and apoptosis could 
affect the way in which cells cope with stress, and thus mediate the extent of 
the neuronal destruction incurred when neurons are exposed to these 
unknown AD triggers. DNA damage and apoptotic features have been linked 
to AD for many years, with speculation that neurons in AD-affected regions 
may be in a struggle between apoptosis and repair (Cotman and Su 1996).  
 
The major, secreted, form of CLU is known to have largely pro-survival 
functions, which could be of great significance to AD pathology, since the 
¢ȱ ȱ ȱȱǯȱȱȱȂȱ-survival properties 
could affect the survival capacity of neurons, and thus affect how resilient a 
brain will be to AD type changes.  
 
Much research has been done on the effect of CLU on the cell cycle, but it is 
important to remember neurons are terminally differentiated, and thus post-
mitotic, therefore such effects are likely to be irrelevant to neuronal survival. 
However, it may be that Ȃȱȱȱȱȱ¢ȱȱ¢ȱȱ
neuronal survival. It has been demonstrated that CLU can increase the 
proliferation of primary astrocytes in culture (Shin et al. 2006; Shim et al. 
2009). Astrocytes in affected areas of AD brains have been shown to have up-
regulated CLU expression, which, if it causes similar proliferative effects in 
vivo as in vitro, could create a pro-survival feedback mechanism, supporting 
neuronal survival (Nuutinen et al. 2009). 
 
Clusterin and lipid metabolism 
Deregulation of processes involved in lipid metabolism and transport are 
increasingly being seen as potential causes of the pathogenic features seen in 
AD. It has long been observed that higher cholesterol levels in middle age are 
linked to an increased incidence of AD later in life, and that use of statins, 
which lower cholesterol, reduce AD risk (Jick et al. 2000). APOE, the longest 
established genetic risk factor for AD, is known to participate in lipid 
trafficking, and CLU has a similar role in this process, reflected in its 
ȱ ȱ ȱǯȱ ȱ“?Śȱ ȱ ȱ ȱ ȱ ȱ  ȱ ȱ ȱ ȱ
efficient at transporting cholesterol (Gong et al. 2002), which may indicate 
impaired lipid transport is of importance in the development of AD. 
 
The brain is an organ rich in insoluble lipids. In order to be transported 
between cells, these lipids must be solubilised, which is achieved via the 
binding of various proteins, forming lipoprotein particles. ApoE and ApoJ are 
two of the main cholesterol transporting molecules within the brain (Beffert et 
al. 1998). CLU has also been shown to be present in lipoprotein particles in the 
CSF (Suzuki et al. 2002).  
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ApoE and CLU are thought to be present in different lipoprotein particles, 
with ApoE-containing particles being larger, and with higher lipid content 
than CLU-containing ones. The types of lipid also differ, with approximately 
equal proportions of phospholipid and cholesterol in ApoE-containing 
particles, while CLU-containing particles have more phospholipid than 
cholesterol (DeMattos et al. 2001). 
 
Two studies have previously reported potential associations between 
polymorphisms within CLU and lipid levels (Nestlerode et al. 1999; Miwa et 
al. 2005), raising the interesting possibility that CLU could exert its effect on 
AD indirectly, affecting susceptibility to other AD risk factors such as 
cardiovascular disease and atherosclerosis (Yu and Tan 2012).  
 
Clusterin and neuroinflammation 
It has long been observed that neuroinflammation is a key characteristic of 
AD. Plaques are commonly surrounded by inflammatory and immune 
antigens, activated microglia, astrocytes and complement. What is becoming 
increasingly appreciated is that instead of being incidental bystanders in AD, 
inflammation and the immune response could be early, possibly causative 
processes in AD pathology, as discussed in section 1.2. AD in the clinic Ȯ
Prevention.  
 
There are several links between CLU and inflammation/immunity. CLU is 
important in the regulation of complement activation (Jenne and Tschopp 
1989), it can modulate the membrane attack complex (Kirszbaum et al. 1992) 
and can activate microglia (Xie et al. 2005). It can also regulate important 
ȱȱȱȱǰȱȱȱ“κȱ(Takase et al. 2008), and its 
own expression in astrocytes can be regulated by cytokines such as IL-ŗ“?ȱȱ
IL-2 (Zwain et al. 1994). As mentioned previously, CLU is thought to be able 
ȱȱ ȱ“?ȱȱȱȱȱ(Nuutinen et al. 2009).  
 
ȱȱȱȱȂȱȱȱȱȱȱ ȱ
the brain is protective against AD risk. CLU is clearly able to limit the immune 
response, directly (e.g. by preventing complement activation) and indirectly 
ǻǯǯȱ ¢ȱȱ“?ȱǼǰȱ ȱ ȱ¢ȱ ȱȂȱ ȱ ȱ
AD risk is via its involvement in inflammation and immune responses. 
 
Clusterin as a neuroprotective guardian 
¢ȱ ȱ Ȃȱ ȱ ȱ ȱ ¢ȱ neuroprotective role for the 
protein. Neurofibrillary tangle-free neurons which express CLU have been 
shown to be resistant to cell death (Giannakopoulos et al. 1998). CLU is up-
regulated following many types of brain injury, including pathogenic 
conditions such as AD, and experimental lesions (May et al. 1990), implying a 
protective role. It has already been discussed that following experimental 
induction of ischemic cerebral injury, CLU knockout mice showed impaired 
tissue remodelling and had delayed recovery when compared to wild type 
mice, again supporting a protective role for CLU when faced with tissue 
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damage (Imhof et al. 2006). Interestingly, this protection could stem from 
Ȃȱ -survival functions, reducing apoptotic cell death, from its lipid 
transporting capacity, since cellular damage requires lipids for repair and 
remodelling, or from its relationship with the immune response, limiting 
inflammation and modulating damage in this way.  
 

 ǰȱȂȱȱȱȱȱȱȱȱǯȱȱȱ
been shown to accumulate in dying neurons following seizures and neonatal 
hypoxic ischemia (a model for cerebral palsy), leading Han et al. to investigate 
the role of CLU in this cell death. The group found CLU knockout mice 
incurred around 50% less neuronal injury than WT mice following neonatal 
hypoxic ischemia, implying that CLU normally exacerbates cell death, a 
finding that was confirmed by CLU increasing cell death in response to 
oxygen/glucose starvation in vitro (Han et al. 2001). This was shown to be 
independent of caspase-3, a key protein in apoptosis (Han et al. 2001).  
 
Clusterin as a therapeutic target 
With an unequivocal role in AD, CLU must surely be considered as a potential 
target for therapeutic intervention. CLU based therapies are already under 
development for cancer (e.g. OGX-011). The major aim of these is to reduce 
levels of CLU, which has largely pro-survival properties, in the hope this will 
render cancer cells more susceptible to treatment. However, it is likely that in 
AD it is the pro-survival functions that would need to be enhanced, not 
diminished, so this approach is unlikely to be beneficial here.  
 
There has been some evidence of CLU based therapies having beneficial 
effects in treating atherosclerosis and peripheral neuropathies in animals 
(Navab et al. 2005; Dati et al. 2007), but AD presents the additional challenge 
of requiring a method of delivery that can traverse the blood brain barrier. 
ȱ ȱ ȱ ȱ  ȱ ȱ Ȃȱ ȱ ȱ ȱ ȱ ȱ
development of AD, it is difficult to know what aspect of its action to target, 
and how this would affect its other functions, perhaps leading to unacceptable 
side effects. The area is further complicated by the existence of different CLU 
isoforms with apparently opposing functions. Significant further research is 
needed in the area to explore the full therapeutic potential of CLU in AD. 
 
1.10. PICALM 
 
An introduction to PICALM 
The gene encoding phosphatidylinositol binding clathrin assembly protein 
(PICALM) has sometimes been overlooked by the scientific community, 
regarded as a homologue of the neuron specific Adaptor Protein 180 (AP180) 
with a more widespread expression but equivalent function. However, as 
increasing differences between the two proteins come to light, attention is 
turning to PICALM, whose roles in cancer, growth and development, 
haematopoiesis and now neurodegeneration make it a fascinating target for 
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¢ǯȱ ȱ ȱ Ȃȱ ȱ ȱ ȱ ȱ CME, an indispensible step in 
intracellular trafficking of proteins and lipids, to which other AD associated 
genes (namely BIN1) have also been linked. 
 
Despite speculation of late, it is yet to be determined how PICALM is 
mechanistically linked to AD risk, and what the genetic determinants 
underlying this relationship are.  
 
PICALM ± genetics and regulation 
The ubiquitously expressed PICALM gene (NCBI Gene ID - 8301, Ensembl - 
ENSG00000073921), whose protein product is also known as clathrin assembly 
lymphoid myeloid leukaemia protein (CALM), is a ~112kb gene situated on 
chromosome 11q14 (see Figure 1.8). It was first identified in 1996 when it was 
found to be involved in a rare but recurrent translocation (t(10;11)(p13;q14)), 
creating a PICALM/AF10 fusion gene in acute myeloid leukaemia and acute 
lymphoblastic leukaemia patients (Dreyling et al. 1996).  
 
Figure 1.8 Ȯ Genetic location of PICALM 
 
Location of PICALM on chromosome 11q14, with the gene transcripts according to 
RefSeq shown below. Image taken from the UCSC Genome Browser (Kent et al. 2002) 
(http://genome.ucsc.edu/). 
 
At least three protein isoforms of PICALM exist (Baig et al. 2010), and 
debatably more. The generally uncontested isoforms are the full length protein 
at 652aa and a shorter isoform of 610aa. In the literature, a 632aa isoform is 
also documented (Baig et al. 2010). ȱȱȱǻȱȱȂȱ
RefSeq), this 632aa isoform is not included, and instead a 645aa isoform and a 
551aa isoform are reported. The RefSeq transcripts that give rise to these 
isoforms are shown in the lower panel of Figure 1.8. Clearly the discrepancies 
between the database and literature are in need of resolution. Table 1.4 shows 
the isoforms of PICALM as per the online databases. Figure 1.9 shows the level 
of conservation in the PICALM region across multiple vertebrate species. 
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Table 1.4 Ȯ PICALM isoforms 
Isoform* Encoded Protein 
Length (aa) 
RefSeq Transcript 
ID 
RefSeq Protein 
ID 
Ensembl Transcript 
ID 
Ensembl 
Protein ID 
1 652 NM_007166.3 NP_009097.2 ENST00000393346 CCDS8272 
2 610 NM_001008660.2 NP_001008660.1 ENST00000532317 CCDS31653 
3 645 NM_001206946.1 NP_001193875.1 ENST00000526033 CCDS55784 
4 551 NM_001206947.1 NP_001193876.1 ENST00000528398 CCDS55783 
Isoforms of PICALM, as reported in online databases, RefSeq and Ensembl. 
*Numbered consistent with NCBI RefSeq.  
 
Figure 1.9 - Conservation in the PICALM region 
 
Genetic conservation across selected vertebrate species in PICALM and the surrounding chromosomal region, taken from ECR browser (Ovcharenko et al. 
2004) (http://ecrbrowser.dcode.org/). Blue Ȯ exons, pink Ȯ introns, yellow Ȯ untranslated regions, red Ȯ intergenic regions, green Ȯ repetitive DNA elements. 
Height of graph proportional to level of conservation between human and that particular species (shown on right). 
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PICALM is ubiquitously expressed, unlike its neuronal cousin, AP180. Recent 
research has suggested that PICALMȂȱ ȱ ȱ ȱ ¡ within the 
brain is in the endothelial cells of vessel walls, with weak labelling in neurons 
and glial cells (Baig et al. 2010). Xiao et al., when considering PICALM 
expression in the brains of APP/PS1 transgenic mice found neurons were the 
major site of expression in the hippocampus and cortex, with no labelling of 
PICALM in astrocytes or microglia (Xiao et al. 2012). Yao et al. found 
expression of PICALM in hippocampal and cerebella neurons, dispersed in 
and around synapses, particularly at the sites of clusters of SVs, while 
expression of AP180 was largely restricted to the pre-synaptic region (Yao et 
al. 2005).  
 
Schwartz et al. found that in the rat, PICALM expression began as early as the 
twelfth day of development, in undifferentiated embryonic stem cells, neural 
stem cells and in post mitotic neurons, implying a role in the development of 
the nervous system (Schwartz et al. 2010). Indeed, Bushlin et al. had 
previously provided evidence that PICALM and AP180 were involved in the 
normal development and growth of hippocampal neurons (Bushlin et al. 
2008)ǯȱ £Ȃȱȱȱȱȱȱ¡ȱȱȱȱȱȱ
isoforms of PICALM, and found expression of each, but following opposite 
trends. The long isoform increased in expression while the short isoform 
decreased in expression as the brain developed (between the twelfth and 
eighteenth days of gestation) (Schwartz et al. 2010). During this time there is a 
transition from neural progenitors being the predominant cell type to post-
mitotic neurons being most abundant. This may indicate two things. Firstly, 
that in these two cell types, PICALM plays differing roles, and secondly, that 
the two PICALM isoforms observed have themselves different roles, which 
should be considered when investigating the function of the protein. Only two 
transcripts were detected, despite the presence of a third PICALM protein 
with a higher molecular weight, speculated to be due to post translational 
modifications.  
 
PICALM - the protein 
The main function of PICALM appears to be in CME, a process which over 
expression of PICALM can inhibit (Tebar et al. 1999). CME allows the 
internalisation of surface bound ligands, such as proteins and lipids, 
facilitating their intracellular trafficking (Hollingworth et al. 2010). It has been 
reported to be involved in regulating the protein content of the cell membrane, 
managing the insertion and removal of receptors, which could be particularly 
important in neurons where it may provide a mechanism for modulating 
synaptic strength (Man et al. 2000; Wang and Linden 2000). It is also important 
in maintaining sustained neurotransmission, as CME is a mechanism for 
recycling SVs following neurotransmitter release (Jung and Haucke 2007). 
CME mainly traffics its cargo via clathrin coated vesicles (CCVs), which can 
transport molecules from the cell membrane to early endosomes, or from the 
trans golgi network to late endosomes (Nordstedt et al. 1993). These processes 
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are under tight regulation by a variety of factors, in order that transportation 
occurs efficiently and accurately. 
 
The clathrin coats of CCVs are formed from networks of clathrin triskelions, 
which consist of three clathrin heavy chains and three clathrin light chains 
(Wu and Yao 2009). The C-terminal region of PICALM can bind to the clathrin 
heavy chain, and to AP2, while the N-terminal region binds to 
phosphatidylinositol-4,5- bisphosphate, which is present in the plasma 
membrane, and thus PICALM may have a role in recruiting clathrin and AP2 
to the cell membrane (Ford et al. 2001).  It is the N-terminal, membrane 
binding, region of PICALM which shares the greatest homology with AP180 
(~82%) (Miller et al. 2011).  This is termed the ANTH (AP180 N-terminal 
homology) domain. 
 
Kim et al. showed that PICALM purified from rat livers was able to promote 
the assembly of clathrin triskelia into clathrin cages, a function it bears in 
common with AP180 (Kim and Kim 2000).  PICALM is able to interact with 
different sites of the clathrin heavy chain, allowing it to regulate the size and 
shape of the budding CCV by dictating the degree of curvature in the clathrin 
coat (Tebar et al. 1999). Meyerholz et al. demonstrated that knockdown of 
PICALM expression via RNA interference (RNAi) lead to an excess of 
particularly small vesicles forming, and the normally uniformly round 
vesicles showing a tendency to elongate and form tubular structures 
(Meyerholz et al. 2005). In Drosophila, deletion of an AP180/PICALM 
homologue was shown to lead to disruption of the normal localisation of 
clathrin in nerves, and reduced endocytosis of SVs (Zhang et al. 1998).  
 
Klebig et al. reported fit1 mice, with mutations in PICALM, showed a 
decreased lifespan and growth retardation, along with numerous 
haematopoietic abnormalities, manifesting in severe anaemia and a decreased 
white blood cell count (Klebig et al. 2003), suggesting potential roles for 
PICALM in growth, haematopoiesis and iron metabolism. There are a number 
of different fit1 mice, each with a different mutation within PICALM, and with 
phenotypic severity related to the severity of the mutations (Klebig et al. 2003).  
 
Suzuki et al. recently found similar results in their study investigating 
PICALM deficiency in murine development (Suzuki et al. 2012). While mice 
with heterozygote PICALM deficiency exhibited no discernable phenotype, 
the vast majority of homozygotes died between birth and weaning, with those 
that survived longer still having a shortened lifespan relative to wild type 
mice. PICALM deficient embryos were found to weigh just 74% of those with 
normal PICALM expression, and by 28days, they weighed just 30-40% of their 
wild type littermates, indicating PICALM is important for growth both in 
utero, and after birth. In PICALM deficient mice, there was evidence of cortical 
atrophy and enlargement of the ventricles, although the hippocampus 
appeared unchanged (Suzuki et al. 2012). The group also found an effect on 
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haematopoiesis Ȯ the mice were severely anaemic, with fewer red blood cells, 
and lower than normal haemoglobin levels (Suzuki et al. 2012).  
 
There is evidence that PICALM is important in early development and growth 
of neurons, since PICALM deficient cells have been shown to lack normal 
dendrite structures (Bushlin et al. 2008; Schwartz et al. 2010). Conversely, 
AP180 lacking cells develop normal dendrites but do not show normal axonal 
development (Schwartz et al. 2010). Neither of the genes appear to have an 
influence on the proliferation of neuronal progenitors, rather on their correct 
development and morphology (Schwartz et al. 2010). Whether this effect 
occurs as a result of the disruption of CME, or through some alternative 
mechanism, remains to be elucidated. 
 
Potential role in AD 
Since PICALM has been implicated in AD risk, a number of studies have been 
published which have looked for links between SNPs in PICALM and various 
aspects of the disease.  
 
Biffi et al. found significant associations between the GWAS SNP rs3851179 
and neuroimaging measures ascertained by MRI scan (Biffi et al. 2010). Both 
overall hippocampal volume and entorhinal cortex thickness were associated 
with the SNP. Indeed, this finding has been corroborated by a study in which 
Furney et al. found that the protective allele of the PICALM GWAS SNP was 
related to an increased thickness of the entorhinal cortex (Furney et al. 2010). 
 
A number of studies have looked for a relationship between PICALM SNPs 
and CSF biomarker levels. Schjeide et al. found that the risk allele of PICALM 
SNP rs541458 was associated with a dose dependent decrease in levels of CSF 
“?-42 (Schjeide et al. 2011), with homozygotes for the risk allele showing 
around a 20% reduction ȱȱ“?ŚŘȱǰȱ ȱ¢ȱȱȱȱ
a clue as to the pathogenic mechanism by which PICALM is linked to AD 
(Schjeide et al. 2011). Kauwe et al., however, failed to find any associations 
between PICALM ȱ ȱ ȱ ȱ ȱ “?-42 (Kauwe et al. 2011), and 
although there was some suggestion of an association between PICALM SNPs 
and levels of tau in the CSF, this was not strong enough to withstand 
correction for multiple testing (Kauwe et al. 2011). Kok et al. reported that 
rs3851179 was significantly associated with plaque load in post-mortem 
brains, with the allele associated with a lower risk of AD also emerging as 
protective against amyloid plaques (Kok et al. 2011). There is some evidence 
that the SNP rs3851179 may also be associated with cognitive function. 
Mengel-From et al. found the protective allele of the SNP was associated with 
ȱȱȱȱȱȃȱȄȱǻşŘ-93 years of age at the time of 
enrolment), but in male subjects only (Mengel-From et al. 2010). 
 
Disruption to the endocytic pathway has been reported as one of the earliest 
detectable changes in AD, preceding the initiation of plaque deposition 
(Cataldo et al. 2000). Whilst there is no evidence that PICALM is present in 
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plaques and tangles (Baig et al. 2010), there is some evidence that PICALM 
expression is increased in the frontal cortex in AD (Baig et al. 2010). It was 
ȱȱȱȱȱȱȱȱȱȱȱ“?ǰȱȱȱȱ
case, there would also be an increase in expression expected in the temporal 
cortex, which was not observed (Baig et al. 2010). Thomas et al. reported an 
approximately 2.4 fold increase in PICALM expression (along with increases 
in other CME related proteins, clathrin and dynamin) in the cortex of mice 
expressing the Swedish mutation form of human APP compared to wild type 
littermates (Thomas et al. 2011). In contrast to this, it has been shown that 
PICALM can be cleaved and degraded by calpain, a protease which is 
elevated and activated in AD brains, and has been shown to be able to block 
CME (Kim and Kim 2001; Rudinskiy et al. 2009). 
 
Disruption to APP processing  
Jun et al., in their meta-analysis (see Table 1.3), found that when data was 
adjusted for the presence of at least one APOE “?Śȱ ǰȱ ȱ ȱ ȱ
association between PICALM SNPs and AD was greatly reduced (Jun et al. 
2010). PICALM  ȱȱȱȱȱȱ¢ȱȱ“?Śȱȱȱǰȱ
leading to the speculation that APOE and PICALM may interact 
synergistically (Jun et al. 2010). It is worth noting that other groups seeking 
epistatic interactions between PICALM and ApoE have failed to detect an 
effect (Belbin et al. 2011; Lambert et al. 2011). However, if there is a genuine 
interaction between the genes, it suggests they both participate in a common 
pathway that contributes to the development of AD. Since there is compelling 
ȱȱȱȱȱ ȱȱȱ“?ȱȱȱǰȱȱ
could constitute said pathway. As mentioned above, Schjeide et al. found a 
link between PICALM SNPs and leȱȱ“?ŚŘȱȱ (Schjeide et al. 2011), 
while Kok et al. demonstrated a link between PICALM SNPs and plaque load 
(Kok et al. 2011). Both of these findings strengthen the evidence that 
PICALMȂȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ  ȱ “?ȱ
metabolism. Some of the evidence linking PICALM to APP processing and the 
ȱȱ“?ȱȱȱ ǯȱ 
 
ȱ ȱ ȱ “?ǰȱ ȱ ¢ȱ ȱ ȱ ȱ ȱ  ȱ “?- ȱ “?-
secretases, is reliant on the endocytic pathway and internalisation of APP (Koo 
and Squazzo 1994; Vetrivel and Thinakaran 2006). There is evidence that APP 
is subject to CME (Nordstedt et al. 1993), immediately linking the protein 
mechanistically with PICALM. Mutational analysis of the cytoplasmic domain 
of APP, thought to contain an internalisation signal (Chen et al. 1990), leads to 
ȱ¢ȱȱȱǰȱȱ¢ǰȱȱ“?ȱ 
(Koo and Squazzo 1994). A number of other studies have also demonstrated 
ȱ ¢ȱ ȱ ȱ “?ȱ ȱ ȱ  ȱ (Carey et al. 
2005; Cirrito et al. 2008; Xiao et al. 2012), while the converse is also true, with 
ȱ ȱ ȱ ¢ȱ ȱ “?ȱ ȱ(Grbovic et al. 2003; 
Cirrito et al. 2008; Xiao et al. 2012).  
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Alterations in PICALM which affect endocytosis may affect the subcellular 
distribution of APP, or the secretase enzymes that process it, potentially 
ȱ ȱ ȱ ȱ “?ȱ  (Miller et al. 2011), but while 
¢ȱ¢ȱȱ¢ȱ ȱ ȱȱȱȱ“?ȱoduction, 
Ȃȱȱȱȱȱȱǯȱ 
 
Xiao et al. looked at the relationship between PICALM, APP processing and 
plaque pathogenesis in a cell culture model of APP processing (neuroblastoma 
cells over expressing APP) and in APP transgenic mice (Xiao et al. 2012). In the 
cell line, the group found prior to the initiation of endocytosis, APP was 
largely confined to the cell membrane, and PICALM to cytosolic vesicles, but 
once endocytosis was initiated, APP and PICALM co-localised to intracellular 
vesicles. Similarly, in APP/PS1 transgenic mice, PICALM expression was 
detected in neurons, co-localising with APP in the hippocampus and cortex 
(Xiao et al. 2012). As mentioned above, the group were able to show in both 
their in vitro and in vivo systems that altering levels of PICALM would alter 
Aȱǰȱȱ“?ȱȱȱǰȱȱȱȱ ȱȱȱ
partly specific, since uptake of transferrin, also subject to CME, remained 
unchanged (Xiao et al. 2012). When the group altered the expression of 
PICALM in six month old mice, and investigated the effects on the brain four 
months later, they found that decreasing PICALM expression (by ~50% in the 
Ǽȱȱȱȱȱȱȱ“?ȱȱȱǰȱȱ
caused a trend towards non-amyloidogenic APP processing, while increasing 
PICALM expressioȱ ȱȱ“?ǰȱ ȱ ȱ ȱ ȱ ȱ  ȱ
amyloidogenic APP processing. Levels of full length APP were consistent 
regardless of treatment, indicating that while PICALM affects processing of 
APP, it does not affect its production (Xiao et al. 2012). A failure to co-
immunoprecipitate PICALM and APP may indicate that any interaction 
between the two is either weak or indirect. The study also reported an effect of 
ȱ¡ȱȱ“?ȱȱȱȱ ȱǰȱ ȱȱ
expression leading to a decreased plaque load, and vice versa, likely due to the 
ȱ ȱ“?ȱ  (Xiao et al. 2012). Wu et al., however, found that while 
ȱȱ ȱȱŗŞŖȱ¡ȱȱȱȱȱ“?ǰȱȱ
down of PICALM did not, suggesting it may not have a direct role in the 
ȱȱ“? (Wu et al. 2009). This could potentially have been due to the 
use of a cell line expressing the Swedish mutant form of APP, which may be 
processed differently to the wild type form (Wu et al. 2009; Xiao et al. 2012).  
 
Treusch et al. recently conducted a comprehensive study investigating 
ȱ ȱ “?ȱ ¡¢ȱ ȱ ¢, and found twelve yeast genes notably 
affected “?ȱ ¡¢ and had clear human homologues. Three of these were 
involved in CME, including YAP1802, the yeast homologue of human 
PICALM (Treusch et al. 2011). Following up on this finding, the group 
investigated the C.elegans homologue of yeast YAP1802 and human PICALM; 
unc-11. Wild type C.elegans have five glutamatergic neurons in their tails, but 
when modified to express “?ǰȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ǰȱ
with only 25% of worms having five intact neurons by day seven. 
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Simultaneous expression of unc-11 (the PICALM homologue) was shown to 
increase the number of C.elegans which had five intact neurons (Treusch et al. 
2011)ǯȱ ȱ ȱ ¢ȱ ȱ ȱ ¡ȱ ȱ ȱ “?ȱ ȱ ȱ
cortical rat neurons, and found those containing a lentivirus engineered for 
PICALM ¡ȱ  ȱ ¢ȱ ȱ ȱ ȱ ȱ ȱ ¢ȱ “? 
(Treusch et al. 2011). This group thus provided three separate lines of 
evidence, in three separate model systems, that PICALM is able to modulate 
“?ȱ ¡¢ǯȱ ȱ  ȱ ȱ ȱ ȱ ¢ȱ ȱ ȱ ȱ ȱ ȱ
ȱ“?ȱȱǰȱ ǰȱȱ¢ǰȱȱȱȱ“?ȱȱ ȱ
detected in cells expressing YAP1802ǰȱ ȱ ȱ¢ǯȱ“?ȱ ȱ ȱ
to affect the distribution of clathrin, decreasing the size of clathrin foci at cell 
membranes, but increasing the number and intensity of these (Xiao et al. 
2012), an effect which may be linked to PICALM, given its proposed ability to 
recruit clathrin to the cell membrane (Ford et al. 2001) .  
 
It has also been commented that since Ȃs expression in the brain may 
be predominantly in the endothelial cells of vessel walls, it is perfectly situated 
ȱ ȱ ȱ ȱ ȱ ȱ ȱ “?ȱ oss the blood brain barrier (Baig et al. 
2010). This is consistent with the finding of Schjeide et al. that the risk allele of 
PICALM ȱ śŚŗŚśŞȱ  ȱ ȱ ȱ ȱ ȱ ȱ “?ȱ ȱ ǰȱ
perhaps implying the AD risk associated allelȱȱȱȱȱ“?ȱȱ
the brain to the CSF (Schjeide et al. 2011). 
 
APP independent links with AD 
Although there is strong evidence PICALM may play a role in APP 
metabolism and transport, APP is just one of a wide range of molecules which 
are subject to CME. Because APP has been so intrinsically linked to AD 
historically, it is easy to see why such efforts have been made to characterise 
its relationship with PICALM. However, we are a long way from knowing all 
of the molecules with which PICALM interacts and affects, so it is impossible 
to say which might be involved in the development of AD, and how that 
involvement comes about.  
 
Perturbations of endocytosis could easily upset the homeostasis of any type of 
cell, but even more so for neurons, which must continually recycle receptors 
and neurotransmitters to maintain long term signalling and function (Jung 
and Haucke 2007).  
 
A number of molecules other than APP display disrupted endocytosis when 
expression levels of PICALM are altered. The GluR2 subunit of the AMPA 
receptor shows a small but significant increase in its cell surface levels when 
PICALM expression is repressed using RNAi (Harel et al. 2011). This had 
¢ȱ ȱ ȱ ȱ ȱ ȱ “?ȱ ȱ ȱ Ȃȱ ȱ ȱ
endocytosis, decreasing surface AMPA receptor presence, and leading to 
signalling abnormalities and structural changes in neurons (Hsieh et al. 2006). 
RNAi knockdown of PICALM also affects the endocytosis of EGFR (Huang et 
al. 2004) and R-SNARE proteins (Harel et al. 2008; Koo et al. 2011; Miller et al. 
 44 
2011). Changes in PICALM expression levels can also alter the intracellular 
distribution of many other molecules, such as AP1, mannose-6-phosphate 
receptor, and transferrin (Meyerholz et al. 2005).  
 
As mentioned above, several studies have been published investigating the 
relationship between PICALM and SNARE proteins (soluble N-
ethylmaleimide-sensitive-factor attachment protein receptor). The SNAREs 
are a family of proteins, all containing the conserved 60-70 amino acid SNARE 
motif. They are generally membrane bound, tetramer complexes which are 
key in mediating the fusion of vesicles, organelles and membranes. There are 
multiple SNARE proteins in mammalian cells and in order for trafficking to 
occur accurately, it is imperative that the correct SNARE proteins are present 
both in the vesicle and the organelle membrane to which it needs to fuse 
(Miller et al. 2011). As there are a finite number of combinations of SNARE 
proteins, given the complexity of the sorting task, it is thought regulation of 
the localisation of the specific SNARE proteins is important in the regulation 
of the transport process as a whole. They are also crucial in mediating 
neurotransmitter release, allowing fusion of SVs with pre-synaptic 
membranes to facilitate signalling, thought to be important in memory 
formation (Yao 2004). Efficient recycling and sorting of SNAREs with high 
accuracy is crucial to ensure prolonged neurotransmitter release is possible. It 
was unclear how these SNARE proteins are endocytosed and sorted with such 
specificity, but it has recently reported that PICALM may be a key player in 
these processes (Koo et al. 2011).   
 
Harel et al. first reported a link between R-SNARE protein VAMP2 (vesicle 
associated membrane protein 2, also known as synaptobrevin 2), the most 
abundant synaptic vesicle protein (Koo et al. 2011), and PICALM when they 
demonstrated that over expression of PICALM lead to a reduction in surface 
VAMP2 by around 20%, while PICALM knockdown using siRNA increased 
the presence of surface VAMP2 by around 30% (Harel et al. 2008). They did 
not find co-localisation of the two molecules, leading to speculation that any 
interaction must be weak or indirect (Harel et al. 2008), although later studies 
have indicated that PICALM and VAMP2 (as well as VAMP3 and VAMP8) do 
physically interact via the N-terminal region of the SNARE motif in VAMP2 
and the ANTH domain common to both PICALM and AP180 (Koo et al. 2011; 
Miller et al. 2011). Koo et al. similarly reported a link between PICALM 
expression and surface VAMP2 Ȯ again, suppression of PICALM (and AP180) 
expression was shown to lead to an increase in VAMP2 present at the 
neuronal surface, indicative that it is failing to be retrieved and recycled 
effectively; an effect which seemed specific to VAMP2, since other SV proteins 
were unaffected (Koo et al. 2011). The effect was more pronounced when both 
PICALM and AP180 expression were suppressed, perhaps suggesting 
overlapping functionality in this context (Koo et al. 2011). Miller et al. found 
the interaction was strongest between PICALM and VAMP8, which is 
consistent with its higher rate of internalisation (Miller et al. 2011). VAMP8 
and VAMP3 are thought to be important in the fusion of endocytic vesicles 
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 ȱ ȱ Ȃȱ ȱ ȱ ȱ ¢ȱ ǰȱ  ȱ Řȱ ȱ
involved in the rapid fusion and recycling of SVs with the plasma membrane 
(Antonin et al. 2000; Miller et al. 2011). Knockdown of PICALM was found to 
cause surface accumulation of all three of the highly related SNARE proteins 
considered (Miller et al. 2011). The group found PICALM can bind 
simultaneously to both VAMP8 (and so presumably VAMP2 and 3) and its 
other established binding partner, phosphatidylinositol-4,5-bisphosphate 
(Miller et al. 2011).  
  
These studies have provided compelling evidence that PICALM is involved in 
the endocytosis of at least three SNARE proteins, VAMP2, VAMP3 and 
VAMP8. Could disrupted endocytosis of these molecules be the underlying 
ȱȱȂȱȱȱȱǵȱȱȱtion 
of such molecules is pivotal in ensuring accurate transport of cargoes about 
the cell, and in facilitating neurotransmitter release.  
 
As already discussed, alterations in PICALM expression levels can upset the 
intracellular distribution of a variety of molecules, which could be due to 
deficiencies in PICALM mediated SNARE endocytosis leading to incorrect 
localisation of SNAREs, disrupting normal transportation, which could 
contribute to AD pathogenesis. 
 
Disruption of neurotransmitter release and normal synaptic function could 
also play a major role in the degeneration seen in AD. It has been observed 
that AD brains have fewer synapses than controls; that synaptic density 
actually correlates better with cognitive decline in AD patients than does 
plaque burden; and that synaptic dysfunction may begin in the AD brain at an 
early stage, even before the loss of synapses and neurons occurs (Fitzjohn et 
al. 2001; Masliah et al. 2001; Yao 2004). Schoch et al. studied the fusion of SVs 
with the pre-synaptic membrane in VAMP2 knockout mice, and found there 
was roughly a tenfold decrease in spontaneous and sucrose stimulated fusion 
in the absence of VAMP2, and a 100-fold decrease in Ca2+ stimulated fusion 
(Schoch et al. 2001). This highlights the importance of VAMP2 in facilitating 
neurotransmitter release. If PICALM is a major player in determining the 
endocytosis of VAMP2, as appears to be the case, genetic changes which alter 
its function or regulation could affect VAMP2, interfering with normal 
neurotransmitter release, disruption of which could result in failed 
communication between neurons, leading to issues with learning and 
memory, as are seen in AD (Yao 2004). The strongest phenotype in Fit1 mice is 
seen when there are ȱȱ ȱȂȱ
ȱȱ Ȯ the 
very domain underlying its interaction with the SNARE proteins (Klebig et al. 
2003), perhaps indicative that it is the disruption of the PICALM/VAMP2 
interaction that so disrupts normal development and function (Miller et al. 
2011). Synaptic dysfunction could also underlie the observed relationship 
between PICALM and cognitive ability (Mengel-From et al. 2010).  
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1.11. CR1 
 
An introduction to CR1 
Complement Component (3b/4b) Receptor 1 (CR1) is a single chain type I 
transmembrane glycoprotein. Its main roles are in the regulation of the 
complement cascade, and in transporting opsonised immune complexes for 
removal from the circulatory system. It has been extensively studied due to its 
known genetic polymorphisms, different protein allotypes, and its significant 
number of disease associations, largely with autoimmune, infectious and 
inflammatory conditions. Variations within the CR1 protein also form the 
basis of the Knops blood group system. When CR1 was first implicated in AD 
risk by the 2009 GWAS published by Lambert et al., attention turned to its 
possible role in neurodegeneration (Lambert et al. 2009). Neuroinflammation 
has long been implicated in AD, often regarded as a harmless bystander. 
However, the identification of multiple genetic risk factors for AD that are 
related to immunity and inflammation may suggest inflammation plays a 
more sinister role in the neurodegenerative process, which genetic variation in 
CR1 ȱȱȱ ǯȱȱȂȱ ȱȱ“?ȱȱȱȱ
emerged as a potential explanation for why genetic variation in CR1 affects 
AD risk.  
 
CR1 ± genetics and regulation 
The gene encoding CR1 (also known as CD35) is located on chromosome 1q32 
(see Figure 1.10), amidst a cluster of complement related genes, often termed 
the regulators of complement activation (RCA) gene cluster, whose protein 
products belong to the RCA family. The genes surrounding CR1 are shown in 
Figure 1.11. The pattern of conservation at the region of the CR1 gene across 
various mammalian species is displayed in Figure 1.12. 
 
Figure 1.10 Ȯ Genetic location of CR1 
 
Location of the CR1 gene on chromosome 1q32 (above) and transcripts (blue tracks) of 
the gene according to RefSeq (below) Ȯ F allele is upper transcript, S allele below. 
Image taken from the UCSC Genome Browser (Kent et al. 2002) 
(http://genome.ucsc.edu/). 
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Figure 1.11 Ȯ Genetic neighbours of CR1 
 
Locations of CR1Ȃȱ genetic neighbours on chromosome 1, all members of the RCA gene cluster, taken from the NCBI website 
(http://www.ncbi.nlm.nih.gov/gene/1191). Chromosomal co-ordinates listed at the top of the figure, with genes and orientations displayed below. 
 
Figure 1.12 Ȯ Conservation in the CR1 gene region 
 
Image to show genetic conservation across selected vertebrate species in CR1, taken from the ECR browser (Ovcharenko et al. 2004) 
(http://ecrbrowser.dcode.org/). Blue Ȯ exons, pink Ȯ introns, yellow Ȯ untranslated regions, red Ȯ intergenic regions, green Ȯ repetitive DNA elements. Height 
of graph proportional to level of conservation between human and that particular species (shown on right). 
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CR1 was first identified as a membrane bound protein on the surface of 
erythrocytes, and is widely expressed on a number of blood cells, including 
neutrophils, eosinophils, monocytes, macrophages, B-lymphocytes and a sub-
population of CD4-positive T cells. Aside from these peripheral blood cells, 
CR1 is also expressed on lymph node follicular dendritic cells, Langerhan cells 
in the skin and glomerula podocytes (Yoon and Fearon 1985; Liu and Niu 
2009; Crehan et al. 2012). Expression of CR1 has also been reported on human 
astrocytes (Gasque et al. 1996) and neurons (Zanjani et al. 2005; Hollingworth 
et al. 2010), although elsewhere CR1 was not detected on these cells, and it 
was stated that CR1 expression in the brain was likely to be low, and 
potentially restricted to the phagocytic Kolmer cells of the choroid plexus 
(Singhrao et al. 1999). In addition to the membrane confined versions of the 
protein, a soluble form of CR1 (sCR1) exists at low levels (~30ng/ml) in the 
blood (Yoon and Fearon 1985), as well as a form of the protein found in urine, 
thought to be derived from vesicles from glomerula podocytes (Pascual et al. 
1994). 
 
The level of expression of CR1 varies between different cell types, and indeed 
shows vast variation in the figures reported in the literature, depending on the 
method of detection used (Moulds 2010). Expression levels of CR1 on 
erythrocytes show huge variation between healthy individuals (up to ten fold 
in Caucasians), an affect which is largely due to different expression level 
alleles associated with a Hind III restriction fragment length polymorphism 
(RFLP) site (Wilson et al. 1986). Although erythrocytes generally have lower 
expression levels than other cell types (e.g. leukocytes, with between 10,000 
and 30,000 molecules per cell (Moulds 2010), B cells and monocytes with 
around 20,000-40,000 molecules per cell (Krych-Goldberg and Atkinson 2001), 
and resting neutrophils, with around 5,000 molecules per cell, which can 
increase up to ten fold when stimulated (Fearon and Collins 1983)), because of 
their relative abundance in the circulation, the majority (>85%) of CR1 in the 
circulatory system is erythrocyte bound CR1 (E-CR1) (Moulds 2010). 
 
Due to the different expression levels of CR1, Kim et al. (Kim et al. 1999) 
sought to identify the regulatory elements which may control this expression 
within the promoter of the CR1 geneǯȱ¢ȱȱȱȱȱǅŘȱśȂȱȱȱ
gene, and found no evidence of a typical TATA type promoter sequence, but 
did find a CAAT-box type sequence (TCAAAA, which had previously been 
shown to be capable of acting as a CAAT-box (Kunz et al. 1989)), which was 
observed around position -54 to -ŚşǯȱȱśȂȱȱȱ ȱȱȱȱ
contain a GC-rich region, particularly high in CpG dinucleotides (Kim et al. 
1999).  
 
As well as variation in expression in CR1 across different cell types, there is 
variation in the glycosylation levels of CR1, such that the molecular weight of 
CR1 can differ by around 6kDa between erythrocytes and neutrophils or T 
cells (Wong 1990; Crehan et al. 2012). Between different cell types on which 
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CR1 is expressed, its function varies, perhaps partially dependent on these 
different glycosylation patterns, and not all of the roles of CR1 have been fully 
elucidated yet.  
 
CR1 ± protein structure and function 
CR1 is a single chain type I transmembrane glycoprotein. Four protein 
allotypes of CR1 exist, with varying molecular weights, showing codominant 
inheritance. The four alleles, termed CR1-A (sometimes referred to as the F 
allele), CR1-B (sometimes referred to as the S allele), CR1-C and CR1-D encode 
proteins of 190kDa, 220kDa, 160kDa and 250kDa respectively. The F/S allele 
naming system of the two most common isoforms, CR1-A and CR1-B, is a 
reflection of their motility in gel electrophoresis (Fast and Slow moving). In all 
populations, CR1-C and CR1-D are rare, perhaps indicative of a selective 
advantage of the two intermediately sized isoforms. CR1-A and CR1-B have 
frequencies of approximately 0.87 and 0.11 in Caucasian individuals (Crehan 
et al. 2012), frequencies which are relatively consistent across populations 
studied (see table 1.5 for population frequencies in different ethnic groups, 
and for a summary of the characteristics of the four different protein 
allotypes).  
 
Table 1.5 Ȯ CR1 isoform properties 
Allele Protein Size 
(non-reducing) 
(kDa) 
SCR 
Number 
LHR 
Number 
Frequency 
(Caucasian) 
Frequency 
(African 
American) 
CR1-C 160 23 3 Rare Rare 
CR1-A (F) 190 30 4 0.87 0.82 
CR1-B (S) 220 37 5 0.11 0.11 
CR1-D 250 44 6 Rare Rare 
ȱȱŗȂȱȱȱ¢ǰȱȱȱȱȱǯ (Crehan et 
al. 2012) and Krych-Goldberg and Atkinson (Krych-Goldberg and Atkinson 2001). 
Numbers of short consensus repeats (SCRs) and long homologous repeats (LHRs) are 
given for each allele. 
 
The CR1 protein has four main structural domains: a 41aa signal peptide; the 
extracellular domain; a 25aa transmembrane domain; and a 43aa cytoplasmic 
domain (Klickstein et al. 1987). The differences between the four CR1 allotypes 
lie within the extracellular domain, which is comprised of multiple short 
consensus repeats (SCRs), also known as complement control protein repeats 
(CCPs) or sushi domains. This type of motif is common to the extracellular 
regions of the RCA protein family, with varying numbers of SCRs in different 
proteins, ranging from ȱȱȱŗȂȱȱȱśśǰȱȱŚŚȱȱȱ
longest isoform of CR1. The 59-72aa SCRs have four common conserved 
cysteine residues, responsible for the formation of two disulphide bridges, and 
one conserved tryptophan, with looser conservation in the rest of the repeat, 
although a core of hydrophobic residues is also common to all SCRs 
(Klickstein et al. 1987; Crehan et al. 2012). The disulphide bridges flank an 
ȱ ǰȱ ȱ“?-pleated sheets, and connecting loops (Liu and 
Niu 2009). In CR1, unlike in the other RCA family members, the SCRs are 
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grouped in to long homologous repeats (LHRs). Each LHR is comprised of 
seven SCRs, with every eighth SCR being highly homologous (such that SCR 
1, 8, 15; 2, 9, 16 etc. are 65 - 100% identical) (Klickstein et al. 1987). The two 
ȱ¡ȱȱȱȂȱȱȱȱȱȱȱȱ
LHR structures. SCRs are also found in other, non-complement related 
proteins, indicating that although they can play a major role in the formation 
and function of complement related proteins, they are not restricted to this 
role (Klickstein et al. 1988). 
 
It is thought that the differences in the alleles arose from unequal crossover 
events during replication, that lead to deletions or duplications of the highly 
repetitive section of DNA encoding the LHR, such that the size difference 
between the alleles is equivalent to one LHR; around 18kb at the genetic level, 
and 1.4kb at the transcript level (Holers et al. 1987; Wong et al. 1989; Bettens et 
al. 2012). It is speculated that the crossover events resulting in the 
creation/deletion of the highly homologous LHRs occurred relatively recently 
in our evolutionary history, while duplication of the SCRs, which show looser 
conservation and are found throughout the RCA family, as well as other, non-
complement related proteins, arose through much older genetic events 
(Holers et al. 1987).  
 
The series of duplications and subsequent divergence has brought about the 
structure of the human CR1 protein Ȯ a large, multifunctional molecule. The 
LHR regions which define the different isoforms of CR1 encode a binding site 
for complement component C3b/C4b, sometimes termed site 2, so the larger 
isoforms have more copies of this binding site (one in CR1-C, two in CR1-A, 
three in CR1-B and four in CR1-D), the specificity of which is conferred by the 
NH2 terminal SCRs of LHR-B and C in the F allele  (Klickstein et al. 1988). 
Each isoform also includes a C4b binding site in LHR-A, sometimes termed 
site 1 (again, with specificity conferred by the NH2 terminal SCRs) and an 
additional active site in the centre of LHR-D (site 3), which is responsible for 
ȱȂȱ¢ȱȱȱȱ-binding lectin and complement protein 
C1q (Tas et al. 1999; Ghiran et al. 2000).  
 
A diagram of the structures of the two most common isoforms (CR1-A and 
CR1-B) is provided in Figure 1.13ǰȱ ȱ ȱ ȱ ȱ ŗȂȱ
binding sites.  
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Figure 1.13 Ȯ CR1 common protein isoforms 
Structure of the two most common CR1 isoforms, CR1-A (the F allele) above, and 
CR1-B (the S-allele) below. The active sites highlighted show the SCRs involved in the 
interaction between CR1 and its various binding partners. Adapted from figures in 
Crehan et al. (Crehan et al. 2012) and Liu and Niu (Liu and Niu 2009). 
 
According to information assimilated in Krych-	ȱȱȂȱŘŖŖŗȱ
paper (Krych-Goldberg and Atkinson 2001), site 1, in LHR-A, binds to C4b, 
weakly to C3b, has low cofactor activity for factor 1 mediated cleavage of C3b 
and C4b and has high decay accelerating activity for C3 convertases (Krych et 
al. 1994; Krych-Goldberg et al. 1999). Conversely, site 2, in LHR-B and C (in 
the F allele, with an additional LHR giving an additional copy of site 2 in the S 
allele) binds relatively strongly to C3b, more weakly to C4b (although affinity 
is comparable to that of site 1), has high cofactor activity for factor 1 mediated 
cleavage of C3b and C4b and has low decay accelerating activity for C3 
convertases (Krych et al. 1994; Krych et al. 1998; Krych-Goldberg et al. 1999). 
 
CR1 is the main receptor for complement components C3b (an inflammatory 
protein activated in AD (Bertram and Tanzi 2010)) and C4b, and is an 
important regulator of the classical and alternate complement cascades. C3b 
and C4b are thought to have arisen through a gene duplication event, and 
share around 29% homology (Krych-Goldberg and Atkinson 2001). It is 
thought the interaction between the two complement proteins and CR1 occurs 
through a highly conserved region of 27 amino acids proximal to the amino 
ȱȱȱȱ“?-chain (Taniguchi-Sidle and Isenman 1994).  
 
ȱ ¢¢ǰȱ ŗȂȱ ȱ ȱ ȱ in the transportation of opsonised 
immune complexes. Immune complexes present in the circulatory system 
which have activated complement are bound by C3b and C4b, for which CR1 
has multiple binding sites. C3b/C3b and C3b/C4b complexes are produced 
when the alternative and classical pathways (respectively) are activated.  
Although individually, each CR1 binding site has a low affinity for its target 
molecule (Arnaout et al. 1983), collectively, the presence of multiple CR1 
molecules, each with multiple ligand binding sites, allows interaction with 
complexes containing multiple C3b and C4b molecules to occur relatively 
strongly as the sites can act synergistically (Krych-Goldberg and Atkinson 
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2001). This synergistic binding facilitates the transportation of immune 
complexes from the circulation to the liver and spleen, where they can be 
removed and degraded by fixed macrophages (Krych-Goldberg and Atkinson 
2001), eliminating the factor that triggered the complement response initially.  
 
Since different isoforms of the CR1 protein have different numbers of C3b 
binding sites, it has been postulated that the different isoforms may show 
differences in their capacity to clear immune complexes efficiently, with 
individuals in possession of smaller CR1 isoforms (fewer C3b binding sites) 
postulated to be worse at this clearance. Wong et al. demonstrated different 
allotypes of CR1, with different numbers of active sites varied up to 100 fold 
in their capacity to bind dimeric C3b (Wong and Farrell 1991).  
 
CR1 can act as a versatile inhibitor of the complement cascade, dampening 
immune responses. It is able to impair the function of C3 and C5 convertases, 
which feature in both the classical and alternative complement pathways, via 
its decay accelerating activity (Krych-Goldberg and Atkinson 2001). It can also 
act as a cofactor for Factor 1, facilitating the irreversible cleavage and 
inactivation of C3b and C4b (Krych-Goldberg and Atkinson 2001). 
 
As mentioned before, the function of CR1 differs between the different cell 
types on which it is expressed. E-CR1 is by far the most extensively studied, 
but other roles on other cell types have also been identified. 
 
On B-cells, CR1 is involved in proliferation and differentiation (Fingeroth et al. 
1989). When B-cell surface CR1 is bound by ligands, it appears to prevent B-
cell proliferation (Jozsi et al. 2002). This is suggested as a mechanism by which 
CR1 is involved in autoimmune disorders (Khera and Das 2009). 
 
On neutrophils and monocytes, particularly when these cells are activated 
(e.g. by cytokines), CR1 mediates phagocytosis (Wright and Silverstein 1982), 
and can stimulate the release of interleukins, indicating another mechanism by 
which CR1 may help mediate the immune response (Bacle et al. 1990). The 
role of CR1 expressed on T cells remains unclear (Khera and Das 2009). 
 
sCR1 
It was first discovered in 1985 by Yoon et al. that there existed a soluble form 
of CR1, termed sCR1, free in circulation, as well as the membrane confined 
forms of the protein (Yoon and Fearon 1985).  sCR1 is present in serum at low 
concentrations, and plasma and serum levels of sCR1 are identical, indicating 
the protein is not lost during the clotting process (Pascual et al. 1993). sCR1 
has been shown to be derived from the proteolytic cleavage of leukocyte 
membrane CR1, either during its transition through the golgi apparatus or at 
the cell membrane itself, giving a form of the protein which is around 5kDa 
smaller and lacks the intracellular domain of the complete protein (Danielsson 
et al. 1994; Hamer et al. 1998). 
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sCR1 is a potent local inhibitor of the classical, lectin and alternative 
complement pathways (Ramaglia et al. 2008). Its mechanism of action appears 
to be two-fold: firstly, it aids in the dissociation of C3 convertases, and 
secondly, it targets C3b and C4b for degradation, preventing excessive 
activation of the complement cascade. Ramaglia et al. looked at the effect of 
sCR1 treatment on rats with mechanical peripheral nerve crush injuries 
(Ramaglia et al. 2008). The group found that complement activation in the 
damaged nerve was almost completely inhibited by sCR1 treatment; 
deposition of the membrane attack complex was inhibited, as were deposition 
of C4c (an activation product of the classical complement pathway) and C3c 
(an activation product common to all complement pathways). The affected 
nerves were protected from axonal loss and myelin breakdown in the early 
stages following the trauma, demonstrating the protective capacity of the 
molecule, however, the effects were relatively short lived, with nerve damage 
becoming apparent around 7 days after the initial assault (Ramaglia et al. 
2008). Whether this phenomenon is relevant to AD pathology remains to be 
established. Indeed, at present it is unclear whether sCR1 is even present in 
the brain, and what effects it may have if it is.  
 
CR1 polymorphisms 
There are three types of well documented variation associated with CR1. The 
first of these is the structural polymorphism generating the different protein 
isoforms, as discussed above. Secondly, there are polymorphisms that alter the 
expression level of E-CR1. As mentioned previously, the number of CR1 
molecules per erythrocyte can vary 10-fold among healthy individuals, and 
one reason for this is the high (H) and low (L) expression alleles, which are 
associated with a Hind III RFLP site within intron 27 of the gene (reportedly 
due to a SNP, T520C (Liu and Niu 2009)), but the causative genetic basis of the 
differing expression remains unknown (Weis et al. 1987; Cockburn and Rowe 
2006). Different levels of expression of different allotypes of the protein have 
been observed on the erythrocytes of heterozygote donors (Dykman et al. 
1983; Wong et al. 1983), indicating that the variance stems from some genetic 
factor within those alleles, and not from some trans-acting genetic or global 
regulatory mechanism. It has also been demonstrated that the variance does 
ȱȱȱ¢ȱ ȱȱřȂȱȱǰȱȱȱ
of the gene (Cockburn and Rowe 2006). 
 
The RFLP site generates two fragments of different lengths Ȯ a 6.9kb fragment 
linked to the low expression (or L) allele, and a 7.4kb fragment linked to the 
high expression (or H) allele (Liu and Niu 2009). According to Krych-
Goldberg and Atkinson, LL homozygotes typically display ~100 CR1 
molecules per erythrocyte; for HH homozygotes, this figure is ~1000; while 
heterozygotes show an intermediate number (Krych-Goldberg and Atkinson 
2001). Liu and Niu, however, reported these figures to be <200 per erythrocyte 
for LL homoxygotes, with HH genotype individuals possessing erythrocytes 
with 3-4 times more than this, and again, heterozygotes being in between the 
two (Liu and Niu 2009). It is likely that the discrepancies between the figures 
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reported are largely due to methodological differences. The frequencies of the 
alleles are reported to be 0.73 for the H allele and 0.27 for the L allele (Krych-
Goldberg and Atkinson 2001) in Caucasians, and 0.51 and 0.49 in Indian 
subjects (Katyal et al. 2003): both populations in which there is an association 
between the RFLP site and expression (Xiang et al. 1999; Katyal et al. 2003). 
The RFLP site is not associated with expression levels of the protein in African 
populations (Xiang et al. 1999; Rowe et al. 2002). 
 
It is proposed that polymorphisms linked to the RFLP site may affect the 
stability of CR1 (Liu and Niu 2009), with L allele polymorphisms producing a 
protein more prone to degradation, and therefore resulting in a reduced 
quantity of the protein reaching the cell membrane of erythrocytes (Crehan et 
al. 2012).  
 
The biological consequence of the lower levels of expression is that there are 
fewer CR1 molecules available to fulfil E-ŗȂȱȱ¢ȱǯȱ
Individuals with low expression levels are poorer at removing complement 
opsonised immune complexes from the circulatory system than are high 
expressing individuals (Gibson and Waxman 1994; Crehan et al. 2012). 
Complement activation in such individuals is likely to be consistently higher 
than for high expressing individuals, since immune complexes, bound by C3b 
and C4b will persist for longer in the circulation. 
 
Expression levels below ~100/cell, are termed the Helgeson phenotype 
(Moulds et al. 1992) (also referred to in the literature as Hegelson (Krych-
Goldberg and Atkinson 2001)), and are not associated with any overt disease 
phenotype (Krych-Goldberg and Atkinson 2001), in fact, it has been 
implicated in protection from severe malaria (Cockburn et al. 2004). 
 
The final group of polymorphisms associated with the CR1 locus are those 
that comprise the Knops blood group system. The antibodies which are 
formed against antigens in this system were previously classed as HTLA 
(high-titre, low avidity) antibodies, but as research progressed it became 
apparent that a group of these HTLA antibodies, sharing similar specificities 
and molecular origins actually belong to a discrete group Ȯ termed the Knops 
blood group system, the 22nd blood group system to be recognised by the ISBT 
(International Society of Blood Transfusion) Committee on Terminology for 
Red Cell Surface Antigens (Daniels et al. 1995). The antibodies themselves, 
raised against the Knops antigens are not regarded as clinically significant, as 
they do not cause adverse reactions following blood transfusions, or create 
haemolytic disease in babies (Moulds 2010).  
 
The Knops blood group antigens are named Kna and Knb; McCa and McCb; S11 
and S12 (also known as Sla and Vil); and S13, Yka and KCAM (previously 
known as KAM). Back in 1991, two groups (Moulds et al. 1991; Rao et al. 1991) 
identified the CR1 protein as the origin of the Knops blood group antigens, 
Kna, McCa and S11/Sla, and subsequently the other antigens of the system have 
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been attributed to the same protein. The molecular basis giving rise to the 
antigens at the genetic level have been identified, with 8 of the 9 antigens 
arising as a result of mutations in exon 29 (SCR 25), and Yka attributed to a 
SNP within exon 26 (SCR 22), both in LHR-D of CR1 (Moulds et al. 2001; 
Veldhuisen et al. 2011). Most of the antigens are generated by a single 
polymorphism, but S13 appears to be a conformational epitope which is 
formed by the combination of changes at amino acid positions 1601 and 1610 
(Moulds et al. 2002). There are also a postulated S14 and S15, which are not yet 
officially recognised (Moulds et al. 2002; Covas et al. 2007). All the antigens 
occur in exposed parts of the CR1 protein, where they are accessible by 
antibodies. Table 1.6 shows the properties of the different Knops blood group 
antigens, including ISBT number, molecular basis and frequency in Caucasian 
populations.  
 
Table 1.6 Ȯ Properties of the Knops Blood Group System 
Antigen 
ISBT 
Number Nucleotide* 
Amino 
Acid SNP 
Frequency 
(Caucasian) % 
Kna KN1 4681G 1561V 
rs41274768 
98 
Knb KN2 4681A 1561M 4.5 
McCa KN3 4768A 1590K 
rs17047660 
100 
McCb KN6 4768G 1590E 0 
S11/Sla KN4 4801A 1601R 
rs17047661 
100 
S12/Vil KN7 4801G 1601G 0 
S13 + 
 
       - 
KN8+ 4801A, 
4828T 
1601R, 
1610S rs17047661, 
rs4844609 
100 
KN8- 4801A, 
4828A 
1601R, 
1610T 
0 
Yka    + 
         - 
KN5+ 4223C 1408T 
rs6691117 
92 
KN5- 4223T 1408M 8 
KCAM + 
              - 
KN9+ 4843A 1615I 
rs3737002 
95 
KN9- 4843G 1615V 5 
Information about the Knops blood group Antigens, adapted from Moulds (Moulds 
2010) and Veldhuisen et al. (Veldhuisen et al. 2011). 
*Numbered from translation start site 
 
Ethnic differences in the frequencies of Knops antigens have long been 
recognised, with some showing vastly different frequencies between 
Caucasian and African populations (e.g. McCb is virtually absent in 
Caucasians but is found in around 50% of West Africans) (Moulds 2010). It is 
widely thought that this variance is due to differing selective pressures in 
different geographical regions. CR1 has numerous disease associations 
(discussed in further detail below), including certain polymorphisms within 
the gene conferring protection from conditions such as malaria and 
M.tuberculosis infection. Knops antigens associated with such a selective 
advantage are likely to have become significantly more frequent in African 
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populations, where such diseases are a serious threat to health, rather than in 
regions where these are not endemic.  
 
While the molecular basis of all the known Knops antigens has now been 
established, there are multiple other known polymorphisms within the CR1 
gene, suggesting the possibility that more, as yet undiscovered Knops 
antigens exist (Moulds 2010). 
 
CR1 ± Other Disease Associations 
CR1 is largely involved in autoimmune and inflammatory disorders, as well 
as infectious diseases such as malaria and HIV. sCR1 has been linked to renal 
and hepatic failure, multiple cancers of the blood (Pascual et al. 1993) as well 
as SLE (Khera and Das 2009). 
 
It has been postulated that CR1 may play a role in preventing the 
ȱȱȱȃȄȱȱȱȱ¢ȱ-cells, a mechanism 
which if disturbed, could lead to the development of autoimmune disorders 
(Khera and Das 2009).  
 
Acquired reduction in E-CR1 levels is observed in patients with systemic 
lupus erythematosis (SLE) (Walport et al. 1987; Kumar et al. 1995), rheumatoid 
arthritis (Kumar et al. 1994) and insulin dependent diabetes mellitus (Ruuska 
et al. 1992), and decreased CR1 expression correlates with disease severity in 
HIV patients (Jouvin et al. 1987). 
 
CR1 is known to be associated with rosetting behaviour in P.falciparum 
malaria, facilitating the invasion of erythrocytes, and thus spreading the 
infection within an individual (Rowe et al. 1997). Low E-CR1 expression levels 
appear to be protective against severe malaria (Cockburn et al. 2004). Infection 
of monocytes and macrophages by M. tuberculosis and a variety of Leishmania 
species is also thought to be linked to or mediated by CR1 on the surface of 
these cells (Moulds 2010). 
 
More recently, the SNPs rs6656401 and rs3818361, implicated in AD, have also 
been linked to susceptibility to depression (Hamilton et al. 2012). 
 
CR1 and AD 
Since CR1 was first implicated in AD risk, numerous studies have been 
conducted seeking links between SNPs within the gene and various aspects of 
AD.  Two independent studies seeking potential links between CR1 SNPs and 
levels of ȱ ȱ ǻ“?ȱ ȱ au) failed to detect any significant 
associations (Kauwe et al. 2011; Schjeide et al. 2011). Brouwers et al. however, 
did find some evidence for an association between CR1 SNPs and levels of 
“?1-42 (Brouwers et al. 2012). 
 
When looking for a relationship between CR1 SNP rs6656401 and cognitive 
function in extremely old individuals (92-93 at age of intake), Mengel-From 
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found no significant association (Mengel-From et al. 2010). They did however 
find a suggestive association between the GWAS risk allele and poorer 
cognitive performance, in male subjects only (Mengel-From et al. 2010).  
 
Kok et al. found some evidence that CR1 rs1408077 may be linked to plaque 
load in the brain, since the CC genotype was found to be more likely than the 
AA genotype to have sparse senile plaques, rather than no senile plaques (OR 
2.1 (95% CI 1.01-4.43) p=0.048) (Kok et al. 2011). This is strengthened by reports 
from Chibnik et al., who found that the risk allele of SNP rs6656401 was 
associated with AD pathological traits (mainly neuritic amyloid plaque load, 
as well as diffuse plaque load, although not with neurofibrillary tangles) 
(Chibnik et al. 2011). Additionally, each risk allele at the SNP was linked to 
increased cognitive decline, both generally, and specifically with episodic and 
semantic memory, perceptual speed and visuospatial ability (Chibnik et al. 
2011). This is in agreement with the tentative link between memory and CR1 
risk SNPs observed by Mengel-From et al. (Mengel-From et al. 2010).  
 
Furthermore, Keenan et al. identified a coding SNP, rs4844609, within LHR-D 
of CR1 ǻȱȱȱ ȱŜŜśŜŚŖŗȱǻȂȱŗǼǼȱ ȱ ȱȱ ȱȱ
in episodic memory, accompanied by increased AD neuropathological 
features, and that the effect showed an interaction with APOE genotype 
(Keenan et al. 2012). 
 
Biffi et al. reported an association between CR1 SNP rs1408077 and entorhinal 
cortex thickness (p=0.03) (Biffi et al. 2010). However, when Furney et al. 
conducted a similar study investigating the effect of AD risk genes on various 
neuroimaging measures, no associations between CR1 SNPs and any of the 
parameters they considered were detected (including entorhinal cortex 
thickness) (Furney et al. 2010). This inconsistency highlights the requirement 
for further studies of sufficient power to detect what aspects of AD are 
affected by CR1 genotype. 
 
CR1 DQG$ȕ 
Given the evidence for links between CR1 ¢ȱ ȱ ȱ “?ȱ  
(Brouwers et al. 2012), as well as brain plaque load (Chibnik et al. 2011; Kok et 
al. 2011; Keenan et al. 2012), it may be that the relationship between CR1 and 
ȱȱȱȱ“?ȱȱȱǯȱ 
 
ȱ ȱ ȱ ȱ ¢ȱ “?ǰȱ arly oligomeric forms, in AD 
affected brains (Rogers et al. 1992), and complement opsonins (such as C3b) 
ȱȱ ȱ“?ȱ ȱ ȱ¢ȱ ȱ  (Bradt et al. 1998; 
Rogers et al. 2006). 
 
CR1 ¢ȱȱ“?ȱȱȱȱǰȱȱ¢ǰȱȱȱ
of “?ȱ ȱȱȱǻǯǯȱ¢ȱȱ¢ (Brouwers et al. 2012)), 
ȱ¢ȱǻȱ“?ȱȱȱ¢ (Rogers et al. 2006)). 
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It has already been discussed that a major function of E-CR1 is in the removal 
ȱȱȱ¡ȱȱȱ¢ȱ¢ǰȱȱ“?ǰȱȱ
by complement component C3b, constitutes one such complex that can be 
removed in this way (Rogers et al. 2006). Individual differences in the CR1 
protein, either in its structure or expression levels, could therefore render 
individuals more or less capable of conducting such clearance (Rogers et al. 
2006).  
 
It has been suggested that the different alleles of CR1 may affect this process, 
with smaller isoforms in possession of fewer C3b binding sites perhaps being 
less efficient at this clearance. However, this is inconsistent with Brouwers et 
ǯȂȱding that the longer, S allele of CR1 is linked to an increased risk of AD 
(Brouwers et al. 2012). According to the above hypothesis, this longer form 
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ “?ȱ ȱ ȱ
peripheral blood, and would be expected, therefore, to be linked to a reduced 
risk of AD (Brouwers et al. 2012)ǯȱ ȱ ȱ ȱȱȱ ȱ ȃȱ
Ȅȱ ¢ǰȱ ȱ ȱ ȱ ȱ CR1Ȃȱ ȱ  ȱ ȱ ȱ t 
¢ȱȱȱȱȱ ȱ“?ȱǯ 
 
CR1 and neuroinflammation 
CR1 is involved in the regulation of the complement cascade on many levels, 
mainly acting to reduce activation of complement by a variety of mechanisms, 
so could prevent damage due to inflammation in the brain occurring. Larger 
forms of CR1, with increased numbers of active sites, would be expected to be 
more efficient at reducing complement activation, and would therefore be 
protective. However, this is contradicted by the findings of Brouwers et al. 
that the larger S allele of CR1 was associated with increased AD risk 
(Brouwers et al. 2012). 
 
There is evidence from mouse models, however, that inhibiting complement 
activation actually increases plaque deposition and neurodegeneration, while 
increasing complement C3 reduces plaque load, suggesting complement 
activation might actually be protective (Wyss-Coray et al. 2002), which is 
ȱ ȱ ȱ ȱ ǯȂȱ ǯȱ ¢ǰȱ ȱ ȱȱ“?ȱ ȱ
the brain relies on its opsonisation with C3b, and longer CR1 isoforms limit 
the availability of active C3b, the brainȂȱ ¢ȱ ȱ ȱ “?ȱ ȱ ȱ
compromised, exposing it to greater damage than do the shorter isoforms 
(Brouwers et al. 2012). 
 
ȱȱǯȂȱȱȱȱȱ ȱ
-D of CR1 is linked to increased 
AD pathology and cognitive decline perhaps suggests an alternative 
mechanism for the relationship between CR1 and AD (Keenan et al. 2012). 
LHR-ȱ ȱ ȱ ȱ ȱ ȱ ŗȂȱ ȱ  ȱ ŗȱ ȱ
mannan-ȱǰȱȱȱȱȱȱŗȂȱȱ ȱȱ
of these that mediates its relationship with AD risk. Although little is known 
about mannan-binding lectin in relation to AD, C1q has been shown to be 
present at high levels in AD brains relative to controls, particularly in areas 
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with a high predominance of pathological hallmarks (Yasojima et al. 1999). 
ŗȱ ȱ ȱ ȱ  ȱ ȱ ȱ  ȱ ȱ “?ȱ ȱ ¢ȱ  
(Fonseca et al. 2004), and when knocked out in transgenic animals, is shown to 
ȱȱȱ“?ǰȱȱȱ (Fonseca et al. 2011). 
 
Because inflammation in the brain is so closel¢ȱȱȱ“?ǰȱȱȱ
exact relationship between CR1 and AD Ȯ whether effects are exerted directly 
ȱ“?ǰȱ ȱ-on effects on inflammation, or whether CR1Ȃȱȱ
ȱ ȱǰȱȱȱ“?ȱȮ will take extensive further research. 
 
CR1 and Brain Structure 
A final intriguing possibility is raised by a study in which Bralten et al. 
reported an association between CR1 genotype and entorhinal cortex volume 
in young, healthy adults (Bralten et al. 2011), using high resolution MRI 
technology to assess brain structures. In the discovery cohort, there was an 
association between CR1 genotype at SNP rs6656401 and gray matter volume 
in both the hippocampus and entorhinal cortex, with carriers of the risky A 
allele displaying lower gray matter volume in these regions. Although the 
hippocampal finding was not replicated in the second cohort, the entorhinal 
cortex volume link was replicated, with evidence that the effect may be dose 
dependent. Exploratory analysis of other brain regions found evidence the 
link between CR1 genotype and brain structure may extend into areas such as 
the amygdala, anterior medial temporal lobe and collateral sulcus, although 
further study will be necessary to confirm these suggestive findings (Bralten et 
al. 2011).  
 
The research suggests that variance in CR1 at the genetic level affects the 
structure of the brain, even in young healthy adults, perhaps making carriers 
of the risk allele more susceptible to AD in later life. As mentioned above, Biffi 
et al. (Biffi et al. 2010) reported an association between CR1 genotype and 
entorhinal cortex thickness in AD and MCI patients, in agreement with the 
ȱȱ ȱ ¢ǯȱ ȱ ȱ ȱȱ ȱ ǯȂȱ ǰȱ ǰȱȱ
the effect seen by Biffi et al. was an alȱ ȃȱ Ȅȱ ȱ ȱ ȱ
phenomenon which arose in these patients much earlier in their lives.  
 
APOE genotype has also been shown to have an effect on brain structure in 
young, ¢ȱǰȱ ȱ“?Śȱȱȱ ȱȱȱ
cortex thickness (Shaw et al. 2007). It was speculated that a smaller entorhinal 
cortex volume could leave individuals more prone to displaying symptoms of 
cognitive decline, while those with larger brain volumes may have an inherent 
resistance to neurodegenerative processes. It is a fascinating concept that 
perhaps rather than being mechanistically involved in AD per se, CR1 risk 
alleles may contribute to the formation of a neural environment more 
susceptible to the changes which bring about AD, while the protective alleles 
may contribute to the formation of brain structures more able to withstand the 
assaults of the disease.  
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1.12. Finding Causal Variants 
 
ȱ ȱ ¢ȱ ȱ ȱ ȱ ȱ ȱ ȱ 	ȱ ȃȄȱ ȱ ȱ
themselves the causative variants, but rather are tagging a variant or variants 
that are causal. All of the studies that have been conducted investigating the 
GWAS hits and various aspects of AD pathology are forced to use surrogate 
SNPs, since the true causative functional variants underlying the GWAS 
signals are not yet known, and this could undermine attempts disentangle AD 
aetiology. Knowing the true functional variant or variants underlying the 
association would not only give increased power to these types of study, but it 
could also give valuable insight into how this involvement in AD risk might 
come about. For example, if the causative variants lie in regulatory regions, 
the alteration in AD risk may stem from under or over expression of the gene, 
while non-synonymous coding changes could alter the biochemical properties 
of the protein molecule. 
 
Finding the causal variant(s), however, may not prove to be simple. There is 
currently debate over two competing hypotheses Ȯ the common disease, 
common variant hypothesis (CD/CV), and a hypothesis centred on rare SNPs 
being the ȱ ȱ ȱ ¢ȱ 	ȱ ȃȄǯȱ ȱ ȱ ȱ
variants (>5% minor allele frequency (MAF)), with a small effect on disease 
risk (ORs ~1.2) that GWAS were designed to detect. It would be expected that 
if the functional variants behind GWAS associations were common, they 
should be relatively easy to identify, since their high MAF would allow them 
to be seen by sequencing a small number of cases and controls. Yet, despite 
hundreds of disease associated loci being found by GWAS for various 
complex disorders, almost no causative variants responsible for these 
association signals have been found. This lends support to the hypothesis that 
rare variants (MAF <5%) with greater odds ratios may be the true variants 
underlying GWAS hits, an effect which has been ȱ ȃ¢ȱ
Ȅȱ (Goldstein 2009), and occurs when, by chance, more rare 
causative variants are associated with one allele of the common tag SNP than 
the other. If this is found to be correct in AD genetics, it could go some way to 
explainȱ ȱ ȃȱ ¢Ȅ(Manolio et al. 2009) of the condition, 
since the ORs of the rare variants could be significantly higher than those of 
the common SNPs with which they are linked (Wang et al. 2010).  
 
Several groups have attempted to pinpoint the true causative variants 
underlying the observed GWAS signals within CLU, PICALM and CR1, and 
the findings of some of these studies are reported below. 
 
CLU 
All the common variants  at the CLU locus which have been found to be 
associated with AD fall within the same ~13.4kb LD block, which is entirely 
contained within the boundaries of CLU. Figure 1.14 shows the pattern of LD 
in the CLU area, and indicates the location of the original GWAS SNPs. This 
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provides compelling evidence that CLU itself is the source of the association 
with AD, particularly given its strong biological candidacy.  
 
The CLU SNP rs11136000 which has been reported so extensively to be 
associated with AD risk is intronic, and is not thought to have an effect on the 
function of the gene.  
 
In 1996, far before the association of the CLU gene and AD had been 
highlighted by GWAS, Tycko et al. conducted a study to discover 
polymorphisms within CLU and test these for association with AD, based on 
functional evidence implicating CLU in AD risk. Seven variants were 
discovered within the gene, including two non-synonymous changes, but 
none showed association with the disease in their sample set (Tycko et al. 
1996).  
 
Harold et al. made initial attempts to discover the underlying causal variants 
by looking for SNPs showing strong linkage disequilibrium (LD) with the 
GWAS SNP, and potentially functional variants within the gene from 
publically available data. The synonymous SNP rs7982 in exon 5 was found to 
be in strong LD with rs11136000 and showed a similarly significant 
association with AD (Harold et al. 2009). As no amino acid change is evoked 
by the polymorphism, it was speculated that the activity of a splicing 
enhancer signal could be affected by the variant, although no bioinformatics 
or experimental evidence for this was provided (Harold et al. 2009).  
 
To search for common coding variants that might explain the association 
signal with rs11136000, Guerreiro et al. sequenced the entire coding region of 
CLU in 495 cases and 330 controls, and exon 5, or exons 5 and 6, were 
sequenced in additional samples. The group found 24 variants in total, and the 
14 of those which occurred in more than one individual were tested for 
association with AD, but no significant associations were detected, although 
there was suggestive significance (uncorrected p=0.04) for rs3216167, a SNP 
which had previously been reported to be associated with cholesterol levels in 
serum (Miwa et al. 2005; Guerreiro et al. 2010). The non-synonymous variants 
found were also assessed in terms of likely functionality using bioinformatics 
tools, and several were deemed likely to be deleterious. However, such 
analyses should be interpreted with an element of caution since predicted 
effects are not always reliable, and even seemingly severe mutations can have 
little phenotypic effect. The study identified a nonsense mutation, which 
would be expected to obliterate the expression of CLU from that allele, yet the 
subject in which it was discovered was a 69 year old healthy control 
(Guerreiro et al. 2010).  
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Figure 1.14 - Linkage disequilibrium around GWAS SNPs in CLU 
 
Pattern of linkage 
disequilibrium (LD) at the CLU 
locus. Data from HapMap 
(HapMap 2003) release #28, 
image created using Haploview 
(Barrett et al. 2005). LD values 
are shown as r2. SNPs which 
were found to be significantly 
associated with AD in the 
Harold et al. and Lambert et al. 
GWAS are highlighted in red 
(rs11136000 - Harold et al. 
OR=0.86, p=8.5x10-10; Lambert 
et al. OR=0.86, p=7.5x10-9. 
rs9331888 - Lambert et al. 
OR=1.16, p=4x10-8. rs2279590 - 
Lambert et al. OR=0.86, 
p=8.9x10-9) (Harold et al. 2009; 
Lambert et al. 2009). 
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18 variants were detected in CLU by Ferrari et al. who sequenced the coding 
region of the gene in 342 AD patients and 277 controls (Ferrari et al. 2012). The 
18 variants included 10 missense mutations, 6 synonymous changes, a 
nonsense mutation and an intronic SNP. When analysed in silico, several of the 
changes were predicted to be damaging to the structure of the protein (Q15R, 
S16R, R234H, P286S, M302V, R338Q, N369H and T428M). Three variants (the 
nonsense mutation, E14X; Q15R and P265S) were found only in cases and not 
controls in this study (Ferrari et al. 2012), although the nonsense mutation had 
previously been reported by Guerreiro et al., as discussed above (Guerreiro et 
al. 2010). 
 
Bettens et al. conducted a comprehensive screen for rare variants in CLU, se-
quencing all coding regions in 1930 individuals (cases and controls). Exons 5-
Şǰȱ ȱȱȂȱ“?ȱǰȱ ȱȱȱȱȱȱ¡ȱȱ
rare variants in AD patients compared to controls, including a number of 
predicted deleterious changes, and so were sequenced in up to 2755 further 
samples (Bettens et al. 2012). Association was seen between rs11136000 and 
AD, which persisted even when these rare coding variants were excluded 
from analysis. This indicates that the association of the common and rare 
SNPs with AD are independent of each other, and the GWAS signal cannot be 
explained by these rare variants (Bettens et al. 2012). It remains, therefore, to 
be established what is, or are, the underlying variants generating this 
association. 
 
It is noteworthy that these studies have all focussed on coding variants; 
sequencing exonic regions alone. Variants outside of these areas may affect 
regulation or expression of the gene, but would have been missed by the 
studies published to date, and could play a major part in the involvement of 
CLU in AD risk, although their functional consequences would be even more 
difficult to establish. 
 
PICALM 
Although the gene PICALM is often said to be associated with AD, the SNP 
which first implicated the gene in AD risk (rs3851179) actually resides 88.5kb 
śȂȱ ȱ ǯȱ ȱ ŗǯŗś shows the chromosomal location of PICALM, the 
SNP rs3851179, and the other genes which are in the vicinity. The nearest 
genetic feature to rs3851179 is the pseudogene, farnesyltransferase, CAAX 
box, alpha pseudogene 1 (FNTAP1). The active form of this gene, on 
ȱ Şǰȱ ȱ ȱ “?-subunit of CAAX geranylgeranyltransferase 
and CAAX farnesyltransferase. Another related pseudogene resides on 
chromosome 13. rs3851179 actually falls approximately equidistant between 
PICALM and EED (embryonic ectoderm development), a gene which encodes 
a member of the Polycomb-group family, involved in maintaining 
transcriptional repression of genes across generations. Despite the two genes 
being almost the same distance from the original SNP found to be associated 
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with AD, PICALM presents a stronger biological candidate for involvement in 
AD pathogenesis than EED, and indeed, other SNPs close to and within 
PICALM have subsequently been shown to associate with AD risk, so it is 
unlikely EED could be the true source of the association despite its equivalent 
proximity. 
 
Figure 1.15 Ȯ PICALMȂȱȱ 
 
Locations of genes near to rs3851179 on chromosome 11 and relative distances to 
these, adapted from the NCBI website (http://www.ncbi.nlm.nih.gov/gene/8301). 
Chromosomal coordinates given above, with genes and orientations demonstrated 
with arrows.  
 
Figure 1.16 shows the LD block surrounding rs3851179, as well as the pattern 
of LD within the PICALM gene itself. The rs3851179 SNP is contained within a 
tight LD block of around 28kb, and is therefore not in strong LD with SNPs 
within PICALM. Harold et al. (Harold et al. 2009) however, did state that the 
SNP rs541458 which resides just 8kb from PICALM is in LD with rs3851179, 
and showed that this SNP was indeed strongly associated with AD with the 
genotyping of additional samples (as discussed above). 
 
Harold et al. made some preliminary attempts to establish the actual causative 
variants, looking at potentially functional SNPs at the PICALM  locus (in 
putative transcription factor binding sites and synonymous exonic SNPs 
which could affect splicing regulation), but found these to be more weakly 
associated with AD, and so unlikely to be altering AD risk themselves (Harold 
et al. 2009). 
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Figure 1.16 - Linkage disequilibrium around rs3851179 and the PICALM gene 
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Patterns of linkage disequilibrium (LD) surrounding rs3851179 and the PICALM gene. 
Data from HapMap (HapMap 2003) release #28, images created using Haploview 
(Barrett et al. 2005). LD values are shown as r2. A. LD in the full region, including 
PICALM, the ~28kb LD block within which the GWAS SNP rs3851179 falls, and the 
intervening region. B. LD shown within PICALM alone. C. Pattern of LD immediately 
surrounding the GWAS SNP rs3851179, showing the boundaries of the ~28kb LD 
block, with the location of rs3851179 highlighted in red (OR=0.86, p=1.3 x 10-9 (Harold 
et al. 2009)). 
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Uncovering the actual causative variants underlying altered AD risk could 
give vital clues as to how PICALM is aetiologically involved in AD risk. 
Schnetz-Boutaud et al. sequenced the coding region of PICALM in 48 cases 
and 48 controls in the quest for causal variation, but failed to discover any 
novel variants (Schnetz-Boutaud et al. 2012). They did, however, comment 
that synonymous SNP rs592297, in LD with GWAS SNP rs3851179, falls 
within a potential exonic splicing enhancer site within exon 5 of the gene, 
which could affect the splicing, and thus expression and function of PICALM. 
Whether this does indeed affect the splicing of the gene, and how this relates 
to AD remains to be determined. Ferrari et al. also sequenced the coding 
region of PICALM, this time in 342 LOAD and 277 control subjects (Ferrari et 
al. 2012). 16 variants (3 synonymous (Q174Q, T586T and A590A); 2 missense 
(A411P, H465R); and 11 non-coding) were detected within PICALM, however, 
all were found in both cases and controls, and none of the variants were likely 
to be damaging when assessed with in silico prediction programs, so it is 
unlikely these are relevant to AD pathology. 
 
ȱ ȱȱ ȱȱȱȱȱ ȱśȂȱȱȱ ȱǰȱ ȱȱ
been speculated that the association with AD could be due to variants 
affecting regulation of gene expression (Sleegers et al. 2010), rather than being 
coding changes altering protein structure or function. 
 
CR1 
Both of the SNPs identified as significant GWAS hits by Lambert et al. 
(Lambert et al. 2009) fall within a ~127kb block of LD which is entirely 
encompassed by the CR1 gene, as shown in figure 1.17, strongly implying that 
the true causative variants underlying the signal reside within this large gene 
itself.
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Figure 1.17 Ȯ Linkage disequilibrium around CR1 GWAS SNPs 
 
Pattern of linkage disequilibrium (LD) at the CR1 locus. Data from HapMap (HapMap 2003) release #28, image created using Haploview (Barrett et al. 2005). 
LD values are shown as r2. Locations of the SNPs which were found to be significantly associated with AD in the Lambert et al. (Lambert et al. 2009) GWAS 
combined data set are highlighted by red arrows (rs6656401 OR=1.21 (95% CI 1.14-1.29), p-value of 3.5x10-9; rs3818361 OR=1.19 (95% CI 1.11-1.26), p-value of 
8.9 x10-8). 
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Brouwers et al. sought to fine map the association observed between AD and 
the CR1 SNPs from the Lambert et al. GWAS, looking at 26 SNPs spanning the 
CR1 ǰȱȱȱȱȱȱȂs repetitive regions, which were able 
to capture an estimated 87% of the total genetic variability at the locus 
(Brouwers et al. 2012). The SNPs associated with AD in the GWAS (rs6656401 
and rs9818361) were not genotyped as part of this study as they fall within 
CR1Ȃȱ ȱ Ȧǯȱ  ȱ ȱ ȱ ǻŚŞŚŚŜŗŖȱ ȱ ŗŚŖŞŖŝŝ) 
however, in strong LD with each other, and the SNPs from the GWAS, 
showed significant allelic association with AD risk in the Flanders-Belgian 
cohort of 1883 individuals. The strongest association was seen in APOE “?Śȱ
allele carriers. The group, as well as analysing the variants singly, combined 
their analyses to consider haplotypes, grouping the SNPs in to five LD blocks. 
Only the fourth LD block (spanning a region of around 130kb, including 
almost the entire gene, excepting the first and last exons) showed association 
with AD risk, again, strongest in the APOE “?Śȱ ǯȱ 	ȱ ȱ ȱ
links between Cŗȱȱ“?ȱȦǰȱthe group also considered 
ȱȱȱȱȱ¢ȱ ȱȱȱȱȱǻ“?1-42, total tau 
and ptau181) in CSF. The SNPs associated with AD (rs4844610 and rs1408077) 
did not show any association with any of the tested biomarkers, however 
there was evidence that the minor alleles of four other SNPs (rs646817, 
rs1746659, rs11803956 and rs12034383), all within the same LD block, were 
associated with increased CSF lȱȱ“?1-42 (Brouwers et al. 2012).  
 
As discussed previously, the group also used a multiplex amplicon 
quantification (MAQ) technique to allow them to distinguish the different 
alleles encoding the CR1 protein isoforms. Quantification of LCR1 copy 
number allowed the inference of the F- and S- allele genotypes (with one and 
two copies of this LCR respectively), with the caveat that S allele homozygotes 
would appear with the same LCR1 copy number as CR1-D/F allele 
heterozygotes. It was found that those with three copies of LCR1 (i.e. F- and S- 
allele heterozygotes) had around a 30% increase in AD risk than those with 
only two copies of LCR1 (i.e. F- allele homozygotes). This CNV was found to 
be in LD with the two SNPs (rs4844610 and rs1408077) which were also found 
to be associated with AD risk, suggesting the two actually represent a single 
common signal of association. The LCR1 CNV association with AD, but not 
the two SNP associations, were replicated in an independent French cohort 
(n=2003), with a meta-analysis of both data sets strengthening the evidence 
that the CNV is a genuine AD risk factor. The inconsistency of the SNP 
associations in contrast to the strength and replicability of the CNV 
association may suggest that the CNV itself is the underlying source of the 
association signal (Brouwers et al. 2012). It may be that the various SNPs at the 
CR1 locus which have shown association with AD have actually been tagging 
this CNV with which they are in LD.  
 
Ferrari et al. ȱ ŗȂȱ ȱ ȱ ȱ řŚŘȱ ȱ ȱ ȱ Řŝŝȱ
controls, and identified a total of 65 variants (39 missense, 15 synonymous 
ǰȱ şȱ ȱ ȱ Řȱ ȱ ȱ řȂȱ Ǽ (Ferrari et al. 2012). Six of these 
 70 
variants were both found only in cases, not controls, and were predicted to be 
probably or possibly damaging to the pȂȱ ȱ ȱ in silico 
prediction programs (P110T, I127T, K113E, T1349I, L172M and G2109S). 
Further work is needed to establish whether these variants do in fact affect 
protein function, and how this in turn impacts on susceptibility to AD. 
 
Next generation sequencing 
Next generation sequencing (NGS) technologies allow an unprecedented way 
to characterise and catalogue all genetic variation within a given locus. A 
number of different NGS methods are currently available (Metzker 2010), and 
more are in the pipeline, leading to fierce competition in terms of cost, 
throughput and quality of data, driving these methods to become increasingly 
affordable and efficient. The majority of investigative studies looking for 
causative variants underling GWAS signals so far have relied on costly and 
time consuming Sanger sequencing. This has meant that only small regions, 
usually the protein coding exons of the genes have been included by most 
studies. The capacity of NGS technologies to produce millions or billions of 
short sequencing reads in a single run means that these constraints no longer 
apply. While we are still some way from having whole genome sequencing of 
individuals affordable in a practical way to researchers, methods of target 
enrichment allow already identified genetic regions to be deep resequenced, 
and all genetic variation at that locus within a sample to be detected.  
 
Target enrichment 
Target enrichment methods enable the filtering out of regions of interest from 
genomic DNA as a whole. A number of different techniques can be used to 
achieve this, from traditional and long range PCR to a number of 
commercially available strategies, each with its own relative strengths and 
weaknesses. There are various important parameters to consider when 
assessing the performance of target enrichment methods. These include how 
much of the region of interest is able to be targeted by the enrichment strategy, 
and the proportion of sequencing reads which can be mapped back to the 
region of interest (specificity), which is important since off target reads reduce 
the capacity for the production of usable data. The depth of coverage across 
the region of interest, and the uniformity of this coverage are important when 
it comes to calling variants. Around 10-20x coverage is generally seen as 
necessary for confident SNP calls; less than this, and variants may not pass QC 
filters; significantly more than this can be a waste of resources and sequencing 
capacity. Sensitivity in this context is the proportion of the region of interest 
for which sequence data is obtained. Also of importance when comparing 
different methods are the cost of reagents and any specialist equipment 
required, throughput, ease of use, and timescale of processing.  
 
At the time of the design of this experiment, two of the major commercially 
ȱ ȱȱȱ ȱȂȱȱ ǻǼȱ ȱ
ȱ¢ǰȱȱȂȱǻ	Ǽȱ¢ȱȱ¢ȱǯȱ
The NG method works by the synthesis of oligonucleotides complimentary to 
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the genomic region of interest directly on to an array, to which the prepared 
genomic library can then be hybridised, while the SS method uses biotinylated 
RNA baits, again, complimentary to the genomic region of interest, which 
hybridise with target sequences in solution, and can then be pulled out using 
streptavidin coated beads. With each method captured DNA undergoes an 
amplification step prior to sequencing.  
 
A number of papers were available which sought to compare the two methods 
on a number of different parameters. Practically, SS is faster, requires less in 
the way of specialist equipment and has lower DNA requirements than its 
array based counterpart (Mamanova et al. 2010; Teer et al. 2010). In terms of 
ǰȱ Ȃȱ ȱ  ȱ ȱ at, due to the stringent repeat 
masker (discussed in greater detail in section 2.4) used in the generation of 
target regions for bait design, often less of the region of interest is targeted by 
this method when compared to NG, which uses its own, seemingly less 
conservative, repeat masking software. As a result of this, often a lower 
percentage of the region of interest is able to be sequenced using SS (Teer et al. 
2010; Hedges et al. 2011; Kiialainen et al. 2011). However, SS has been 
consistently found to have a higher proportion of reads mapping to the region 
of interest (Teer et al. 2010; Hedges et al. 2011; Kiialainen et al. 2011), 
indicating it is more specific than the NG method. In one study, SS was found 
to have an inferior read depth when compared to NG (Teer et al. 2010), but in 
two others (Hedges et al. 2011; Kiialainen et al. 2011), the depth of coverage 
was found to be greater when SS was used. SS was also found to give a greater 
level of consistency between samples than NG, demonstrating a greater 
¢ȱ  ȱ Ȃȱ  (Hedges et al. 2011; Kiialainen et al. 
2011). When sequenced regions are compared like for like, SS libraries have 
been shown to yield more SNP calls compared to NG, and these have been 
found generally to be more accurate (Kiialainen et al. 2011). For these reasons, 
SS was chosen for this project due to its cost efficiency and overall strengths in 
terms of specificity, coverage and reproducibility. 
 
Simply finding variants within a known associated locus, however, is 
insufficient. Countless SNPs exist within any given individual, harmful, 
protective and benign, and the effects of these are not easy to deduce. There 
are a plethora of bioinformatics tools available to predict the functions of 
variants, but these are never flawless, so functional characterisation is a must 
when determining whether any discovered variant is causative. Furthermore, 
a cautious attitude must be adopted since even when the effect of the variant 
on the gene or protein is known, the effect in vivo may not be clear Ȯ as shown 
by the non-sense mutation detected by Guerreiro et al., which may have been 
assumed to be strongly linked to the condition, had that subject not have been 
a healthy control (Guerreiro et al. 2010).  
 
The beauty of deep resequencing is that it offers an almost unparalleled 
opportunity to elucidate and begin to understand the true causative genetic 
basis of complex disorders, such as AD, at the very base level. This kind of 
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knowledge is likely, in time, to bring a better fundamental understanding of 
the aetiology of such conditions, which in turn could lead to huge progress in 
terms of diagnosis, treatment, and ultimately cures for some of these 
devastating conditions that are proving such a challenge to public health in 
modern society.  
 
1.13. Project Statement 
With the aim of detecting and cataloguing rare variation at the loci implicated 
in AD risk by the first two major AD GWAS (Harold et al. 2009; Lambert et al. 
2009)ǰȱ ȱ 	ȱ ȱ  ȱ ǰȱ ȱ Ȃȱ S system to 
specifically target the CLU, PICALM and CR1 loci. This enrichment was 
designed to capture the whole locus, rather than just the coding regions on 
which previous studies had been based, since exonic sequencing alone has so 
far not yielded many answers as to the causative variants underlying GWAS 
signals. A number of different types of analysis software for NGS data were 
utilised, enabling an assessment of the relative strengths and weaknesses of 
each, and the development of a definitive pipeline using the best tools tested 
(Chapter 3). Once variants within the region were detected, Sanger sequencing 
was used to validate the methodology and highlight some issues arising from 
indels and mononucleotide repeats when using NGS technologies (Chapter 4). 
The exonic variants detected in the three genes were prioritised for further 
analysis as there are more reliable tools for assessing coding variants 
functionally, and it provided a modest number to focus on, minimising the 
necessary correction for multiple tests needed when testing for association. 
Various bioinformatic resources were utilised to assess likely functionality of 
the exonic variants, which were also tested for association with AD in a large 
ȱǰȱȱ ȱȱȱȱȱȱȂȱ
likely contribution to AD pathogenesis, and highlighting those warranting 
further, functional investigation (Chapter 5). As for the exonic variants, the 
non-coding variants found were also assessed using bioinformatic resources 
and association testing in the imputed data set where evidence from the tools 
used suggested functional consequences (Chapter 6).  
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2. Methods 
 
Sequencing Project One 
 
2.1. Patient Demographics and Sample Preparation 
 
96 A£Ȃȱdisease (AD) samples were obtained from two UK centres Ȯ 
The University of Nottingham Brain Bank and Manchester Brain Bank (48.4% 
female, 51.6% male; mean age at onset 70.4 years; standard deviation 11.8; 
range 56-87. APOE ǲȱ “?Řȱ- śǯŝƖǲȱ “?řȱ- ŜřǯśƖǲȱ “?Śȱ- 30.8%). Both of these 
resources comprise part of the £ȂȱȱȱǻARUK) brain bank, 
which has been used in such projects as the GWAS that first implicated CLU 
and PICALM in AD risk (Harold et al. 2009). Cases with age of clinical onset 
over 56 and a confirmed or probable AD diagnosis, based on NINCDS-
ADRDA classification, were recruited. All subjects gave informed consent to 
be included in the study, which was granted approval by the local ethics 
committee.  
 
High quality, undegraded genomic DNA was required for the next generation 
sequencing (NGS) project. DNA was prepared from brain tissue samples, 
using a phenol chloroform based extraction procedure. Approximately 0.5cm3 
of brain tissue was manually chopped on dry ice, to prevent the tissue from 
thawing. This was ȱȱǻǅŗŞȱǰȱȱȱřŞŖǰȱśŖŴǼȱ
with 500µl AL lysis buffer and 50µl proteinase K (both Qiagen). Next, 500µl of 
refrigerated phenol chloroform was added to the sample (Sigma), which was 
mixed by inverting before being subjected to centrifugation for 5 minutes at 
13,000rpm. The top phase of the resultant sample was then removed to a clean 
eppendorf, and the addition of phenol chloroform, mixing and centrifugation 
was repeated. The top phase of this was removed, and had 3M sodium acetate 
(pH 5.2) added to it in a 1:9 ratio of sodium acetate to sample. Chilled 100% 
ethanol was then added, at an equal volume to the sample, to precipitate out 
the DNA. Following centrifugation at 13,000rpm for 15 minutes, a wash was 
performed using 200µl 70% ethanol, before another centrifugation step, this 
time for 10 minutes (13,000rpm). The remaining ethanol was then discarded 
and the pellet air dried, before resuspension in 100µl AE buffer (Qiagen), 
ȱ ȱ śŖŴȱ ȱ ȱ ǯȱ ȱ p spectrophotometer was used to 
assess the concentration and purity of the extracted DNA. The samples were 
assessed for degradation using gel electrophoresis (1% agarose gel). An 
example gel is shown in figure 2.1.  
 
Quantification of the 96 DNA samples was conducted using the Quant-iTTM 
dsDNA Broad Range Assay Kit from Invitrogen, following standard 
Ȃȱ ǰȱ  ȱ ȱ ȱ ȱ ȱ ǯȱ ȱ  ȱ
conducted such that samples of similar concentration were grouped together 
(see Appendix section 2.1 for sample pools). For each pool of 12, 600ng of 
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DNA per sample were combined, giving an overall DNA quantity of 7.2µg per 
pool. 
 
Figure 2.1 Ȯ Quality control of DNA samples for NGS 
 
Representative gel from phenol chloroform DNA extractions, ȱ ȱ “λ
ȱ
ladder (sizes of marker in bp shown). Samples 1-4 and 6 show successful extractions 
with minimal degradation, exactly as needed for NGS experiments. Sample 5 shows a 
significant amount of degradation, and would not have been accepted in to the 
project. The extraction of sample 7 failed. 
 
2.2. Power 
 
The predominant aim of this study was to discover novel rare single 
nucleotide polymorphisms (SNPs), so it was important to ensure a sufficient 
sample size was used to give adequate power to do this. Typically, common 
SNPs are viewed as having a minor allele frequency (MAF) greater than 0.05, 
while rare SNPs have MAFs between 0.01 and 0.05. Anything below 0.01 is 
very rare. The following equation was used for power calculations, where n is 
the number of chromosomes:  
 
n = [log(1-power)] / [log(1-MAF)]  
 
Table 2.1 shows the power this study had to detect SNPs of various MAFs, 
given a sample size of 96. It was calculated that the study had 80% power to 
detect SNPs with a MAF down to ~0.85%, thus this study had sufficient power 
to fulfil its aim to discover rare novel SNPs. 
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Table 2.1 Ȯ Power Calculations 
MAF Power (%) 
0.001 17.5 
0.005 61.8 
0.01 85.5 
0.02 97.9 
0.03 99.7 
0.04 ~100 
0.05 ~100 
0.10 ~100 
0.20 ~100 
0.30 ~100 
0.40 ~100 
0.50 ~100 
Table to show the power this study has to detect SNPs of varying MAFs based on a 
sample size of 96 individuals, or 192 alleles. 
 
2.3. Defining Regions to Sequence 
 
The UCSC genome browser (Kent et al. 2002) was used to obtain the basic 
coordinates for the genes of interest (CLU, PICALM and CR1). These 
coordinates were then expanded to encompass any areas of notable 
conservation across vertebrate species, assessed by eye using ECR browser 
(Ovcharenko et al. 2004), since evolutionary constraint may suggest functional 
regions of DNA, such as gene regulatory elements.  
 
In addition to the three genes, a fourth region was targeted in the study; the 
area in which SNP rs3851179 (the PICALM GWAS SNP) is located. To 
visualise the pattern of linkage disequilibrium (LD) in the region, Haploview 
(Barrett et al. 2005) was used, with SNP genotype data downloaded from 
HapMap (HapMap 2003) (on 05.11.2010). A region of 500kb surrounding the 
GWAS SNP was downloaded, to ensure no variants in strong LD with the 
GWAS SNP would be missed (since it is unlikely anything exceeding this 
distance would be in LD with the variant). When defining LD blocks, an r2 of 
ŖǯŞȱ ȱ ȱȱ ȱȱȱ ǻȱȱ ȱȂǼǯȱ¢ȱȱ ȱȱ
MAF lower than 0.01 were excluded (default 0.05), and all other Haploview 
settings were left as default. The entire LD block was targeted (~29kb). 
 
An additional 150bp was added on either side of the final genomic 
coordinates to be sequenced, ensuring that the ends of the region of interest 
would be covered by the full 5x tiling used in the bait design (see below). The 
coordinates and sizes of the genes/regions targeted are given in table 2.2. 
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Table 2.2 Ȯ Target regions for NGS 
Gene Coordinates (hg19) Size (kb) 
CLU 8:27450849-27475277 24.43 
CR1 1:207667495-207816719 149.22 
PICALM 11:85665237-85783519 118.28 
rs3851179 LD block 11:85840998-85870094 29.10 
Total: 321.03 
Coordinates and sizes of the regions targeted by SureSelect baits for the first 
sequencing project. 
 
2.4. Enrichment and Sequencing 
 
$JLOHQW¶V6XUH6HOHFW 
Ȃȱ (SS) system was the chosen method of target enrichment 
for the project, given its reported benefits over other commercially available 
target enrichment methods available at the time of study design (see 
Introduction section 1.12. Finding causal variants Ȯ Target enrichment) 
(Mamanova et al. 2010). SS is a method of target enrichment utilising a 
solution based hybridisation approach, whereby 120 base biotinylated RNA 
ȃȄǰȱ ¢ȱ ȱ ȱȱȱȱ ȱ ȱȱȱ
hybridised with the desired targets in a library of fragmented whole genomic 
DNA. Using streptavidin coated beads, these baits and their bound 
complimentary DNA can be extracted from the noise of whole genomic DNA 
using a magnetised system. This process is summarised in Figure 2.2.  
 
Once the genomic regions to be sequenced had been defined, the SS baits 
could be designed using AgiȂȱ ȱ ¢ȱ  
(https://earray.chem.agilent.com/earray/). In this, a number of different 
parameters can be specified, such as the sequencing platform to be used (in 
this case, Illumina single end short read), and the genomic coordinates (in 
hg19) of the regions of interest specified, in order for baits to be designed 
against them. Agilent specify a set of optimised parameters, and for the most 
part our study design adhered to these, however, instead of the default 2x 
tiling, we opted for 5x tiling (see figure 2.3), as it was hoped this would give a 
better enrichment of the target region, and was recommended by an Agilent 
eArray specialist (personal correspondence).  
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Figure 2.2 Ȯ SureSelect method of target enrichment 
 
Schematic diagram to show the processes involved in the SureSelect method of target 
ǰȱȱȱȂȱȱȱŗǯŘǯ 
 
Figure 2.3 Ȯ SureSelect bait design with 2x and 5x tiling 
 
Genomic DNA represented by black bar, 120mer baits represented by gray bars. 
Arrow indicates a specific position in the region of interest. Under 2x tiling, each bait 
overlaps by 50% (60bp), meaning any given position in the target region is covered by 
two baits. For 5x tiling, the baits overlap by 24 bases, resulting in any given position in 
the DNA being represented by 5 baits. 
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As default in eArray, a repeat masker is used in the design of SS baits 
(Repeatmasker.org (Smit 1996-2010), which is based on the RepBase (Jurka et 
al. 2005) library of repeats). This is the same repeat masker upon which the 
UCSC Genome BrowserȂȱȱȱȱǯȱȱȱȱȱ
the proportion of the region of interest that would be not be targeted by baits 
due to this repeat masking software, repeatmasker.org (Smit 1996-2010) was 
used. The gene sequences for the regions of interest were uploaded to this 
website, and submitted to the program for analysis, using its default settings 
(on 11.01.11).  
 
When the SS baits were designed with the repeat masker on, the proportion of 
each of the genes that would not be targeted by baits seemed very high, 
leading to questions as to whether the repeat masker used by eArray was 
overly conservative. Using repeatmasker.org the percentage of each gene that 
would not be targeted by baits were the repeat masker used was quantified, 
and was 34% for CLU, 48% for CR1, 34% for PICALM and 42% for the 
rs3851179 LD block. This would have meant that between a third and half of 
each gene we were aiming to acquire complete sequence data on would not 
even have been targeted. Figure 2.4 shows the .bed file results of the CLU bait 
design procȱ  ȱ ȱ ȱ Ȃȱ ȱ ǰȱ ȱ  ȱ ȱ
without the repeat masker enabled in the design process (the other genes, and 
the rs3851179 LD block showed similar results). It was therefore decided that 
the repeat masker would not be utilised in the design of the baits for this 
project, the hope being that only truly repetitive regions would fail to be 
sequenced, giving an obvious drop out in coverage at these regions, and this 
would be less in reality than with the repeat masker utilised. 
The process of enrichment was outsourced to Source Bioscience 
(http://www.sourcebioscience.com/) for financial and practical regions, and 
 ȱȱ¢ȱǰȱ ȱȂȱȱǯ 
 
Figure 2.4 Ȯ CLU bait design with and without repeat masker 
 
The upper panel shows Ȃ bait design conducted using the repeat masker, while 
the lower panel shows the targeted region when the repeat masker is not utilised. 
Genomic coordinates are shown at the top of each panel, with targeted region 
indicated with tȱȱȃȄȱǯȱȱȱȱȱȱȱ ȱ
in blue, while the lower region of each panel shows the locations of repeat regions 
according to RepeatMasker.org (Smit 1996-2010). 
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Illumina GaIIX Sequencing by Synthesis 
Ȃȱ 	ȱ  ȱ ȱ ȱ ȱ ȱ ȱ NGS to be utilised by the 
project, based on practical and financial reasoning, in combination with 
Illumina being one of the major players in NGS technologies at the time, 
offering many widely used and well respected platforms (Metzker 2010).  
 
Ȃȱȱȱȱȱȱȱȱ¢ȱ synthesis 
method. The initial stage involves solid-phase amplification of single DNA 
molecules (in our case, fragments of DNA from loci of interest) via bridge 
amplification, generating 100-200 million molecular clusters of DNA, each of a 
single template DNA fragment. The free ends generated can then be 
hybridised with universal sequencing primers to enable NGS to be performed. 
The actual sequencing is conducted using a four-colour cyclic reversible 
termination method, with total internal reflection fluorescence imaging 
facilitated by two lasers allowing the distinction of the different colours, each 
associated with a different base. The fluorescently labelled bases, with 
ȱřȂȱǰȱȱȱ¢ǰȱȱȱ¢ȱȱȱ
the template adds a single specific modified base in each cycle. The base is 
then imaged, and unbound nucleotides are washed away, before the 
fluorescent dye and terminating group attached to the nucleotide are cleaved, 
leaving a base which can then be added to in subsequent cycles. These 
processes are depicted in figure 2.5.  
 
Ȃȱ  ǰȱ ȱ ǻȱ ȱ ȱ ȱ ȱ
Variation) was used to convert the images read by the machine into intensity 
scores and base calls with quality scores. 
 
The sequencing was conducted by Source Bioscience, following standard 
Ȃȱǯȱ 
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Figure 2.5 Ȯ Ȃȱȱ¢ȱ¢ȱ 
 
  
Ȃȱ ȱ¢ȱ ¢ȱǯȱȱȱ  ȱ ȱȱȱ
step, used to create clusters of template molecules. Panel B shows the four-colour 
cyclic reversible termination method used to obtain sequence information. 
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2.5. Data Analysis 
 
Data files for each pool were received from Source Biosciences in zipped .fastq 
format, which contains the nucleotide sequence and ASCII coded quality score 
for each of the sequencing reads produced. These files were processed along a 
pipeline comprised of various bioinformatic tools, designed to assess the 
quality of raw reads, align the data, assess the quality of the alignment and 
call variants. At the time, the pipeline was experimental, so several different 
software packages were utilised for many of the stages, but based on the data 
here presented, this has since been refined to a definitive pipeline (which is 
presented in the Section 3.4 - Defining the Pipeline).  
 
An initial assessment of the quality of the data was performed using the 
program FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), which analyses 
data (in Sam, Bam or FastQ format) for a number of parameters (e.g. read 
quality, GC content and over represented sequences), which may be indicative 
of issues with the data as a whole, such as poor quality of reads or systematic 
biases. 
 
Example command to run FastQC: 
 
$ ./fastqc  1_NoIndex_L001_R1.fastq.gz 
Where 1_NoIndex_L001_R1.fastq.gz is the zipped fastq file containing the 
data from the first lane of the flow cell used, i.e. pool 1 samples. 
 
Alignment 
Alignment is the process by which the millions (or billions) of short 
sequencing reads generated by NGS technologies are mapped to a reference 
sequence. It is typically the first stage in processing NGS data, on a pathway 
which will eventually lead to the identification of variant sites. There are a 
plethora of programs available to conduct this function, each with individual 
strengths and weaknesses in terms of speed, sensitivity and accuracy. For our 
project, two alignment programs were selected, MOSAIK (highly user 
friendly, and had been used by the 1000 genomes project) and BFAST (which 
was the best performing alignment algorithm in a comparison of programs 
from a previous NGS study conducted within our laboratory (data 
unpublished)).  
 
MOSAIK 
MOSAIK (http://code.google.com/p/mosaik-aligner/) produces gapped 
alignments based on the Smith-Waterman algorithm. The multistage program 
is intuitive to use, with a comprehensive user guide and sensibly chosen 
default values to minimise the necessary amount of user input. It is 
multithreaded, so can run simultaneously on multiple processors, speeding 
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up the process of alignment, and is suitable for use with a number of 
sequencing technologies. 
 
The following steps are needed to generate alignments: 
 
MosaikBuild: This module converts various types of input files to a binary 
format (.dat), allowing efficient data processing. Both the reference and the 
sequencing reads need to be processed in this way, with the sequence 
technology (-st) used to generate the data being specified for the reads.  
 
MosaikJump: MOSAIK uses a hashing strategy, comparing reference and read 
hashes to compute alignments. Creating and utilising a hash map of a 
mammalian genome, such as the human one, would be prohibitively memory 
intensive; therefore MosaikJump is used to create a Jump Database (-j). This is 
ȱȱȃȄȱȱȃ¢Ȅȱ ǰȱ ȱ ȱȱȱȱȱ
conventional hash map, but in a much more efficient format, allowing for 
faster and less computationally intensive mapping. The selected hash size (-
hs) used requires a trade off between the greater speed provided by larger 
ǰȱ ȱ ȱ ȱ ¢ȱ ȱ ¢ȱ ȱ ǯȱ Ȃȱ
manual recommends a hash size of 15 as a good compromise between the two. 
 
MosaikAligner: This component performs the pairwise alignment between the 
short sequencing reads (converted to a hashed format) and the reference file 
ǻȱȱȱ ȱǼǯȱȃ
Ȅȱ ȱȱȱȱȱȱ
are clustered, and any clusters above the user defined alignment candidate 
threshold (-act) are submitted for analysis by the Smith-Waterman algorithm 
and filtered to generate the final alignment file. Several parameters can be 
altered at this stage to tailor the output of the alignment software or the 
running speed. This includes, the maximum number of mismatches allowed (-
mm) between the read and the reference, which is set as default to 4. Two 
parameters can be specified which reduce the time taken to perform the 
alignment. The maximum hash positions (-mhp) can be set (-mhp 100 
recommended by manual), which means only 100 random potential hash 
matches are stored within the program, speeding up alignment with little cost 
to alignment accuracy. As mentioned above, the alignment candidate 
threshold (-act) can also be set, defining the minimum cluster size to be 
submitted to the Smith-Waterman algorithm, again speeding up alignment 
without compromising accuracy (manual suggests Ȯact 20). The number of 
processors (-p) available to conduct the analysis can also be specified, 
allowing full utilisation of the available computational resources. 
 
MosaikText: This utility allows the conversion of the alignment .dat file to the 
more universally accepted .bam format, allowing the output to be used with 
other data analysis and handling software. 
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Example commands to run Mosaik: 
 
Convert reference file to .dat format: 
$ MosaikBuild ±fr 
Homo_sapiens.GRCh37.59.dna.toplevel.chr_only.valid.fa ±oa 
HG19_ref.dat  
Where -fr is the reference file to which alignment will be conducted 
(Homo_sapiens.etc.valid.fa), and -oa specifies the name of the output file. 
 
Convert sequencing reads to .dat format (run for each sequence file): 
$ MosaikBuild ±q 1_NoIndex_L001_R1.fastq.gz ±out 
sample1.dat ±st illumina 
Where Ȯq is the input file to be aligned and Ȯst specifies the sequencing 
technology used. 
 
Create Jump Database: 
$ MosaikJump ±ia HG19_ref.dat ±out HG19_jump ±hs 15 
 
Align reads with MosaikAlign (run for each sequence file): 
$ MosaikAligner ±in sample1.dat ±out sample1_aligned.dat 
±ia HG19_ref.dat ±hs 15 ±mm 4 ±mhp 100 ±act 20 ±j 
HG19_jump ±p8 
 
Convert .dat to .bam: 
$ MosaikText ±in sample1_aligned.dat ±bam 
sample1_aligned.bam 
 
BFAST 
BFAST (BLAT-like Fast Accurate Search Tool) (Homer et al. 2009) aims to 
provide a fast alignment program, without compromising on accuracy. Again, 
the program has multiple stages, with capability for multithreaded processing, 
allowing the full utilisation of available computational resources, and the 
benefits of increased speed which comes with this. The program works by 
creating indexes of the desired reference sequence, allowing the rapid 
generation of candidate alignment locations (CALs), with gapped local 
alignment then occurring according to a gapped Smith-Waterman algorithm, 
facilitating the selection of optimal alignments based on user specified 
parameters. This allows customisation of speed, sensitivity, and accuracy, 
depending on the needs of the user. 
 
The following steps are needed to generate the alignment: 
 
bfast fasta2brg: Generates a compressed binary version of the reference 
genome from a specified FASTA file. The only required inputs are the 
reference file (-f) and specification of ȮA 0 to indicate that the reads are not 
coded in colour space (-A 1 specifies colour space). 
 
bfast index: Creates indexes of the reference file (-f) and stores these in a 
compressed binary format. The command Ȯm specifies the mask to use for this 
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index. The masks are strings of 1 and 0 which specify where mismatches are 
ȃ Ȅȱȱȱ ȱȱȱȱǰȱȱ¢ȱȱȱ
the sequencing technology and read length used. Figure 2.6 shows the indexes 
recommended for Illumina reads with a length less that 40bp. The command 
should be run 10 times, once for each of the masks, with the index number 
each time being specified by the -i command (-i 1 for first index, -i 2 for 
second, etc.). Lookup time is minimised via the incorporation of a hash into 
the index, the size of which is specified by -w (14 is recommended for short 
Illumina reads). Specifying the available number of processers (-n) allows the 
program to make full utilisation of the available resources. 
 
Figure 2.6 Ȯ Indexes for BFAST alignment of reads <40bp 
 
Indexes for BFAST indexing step when using Illumina data with a read length less 
than 40bp. 
 
bfast match: Searches the produced set of reference indexes for CALs for a set 
of reads (-r, with additional command Ȯz if file is zipped).  
 
bfast localalign: Uses a Smith-Waterman algorithm to perform a local 
alignment of each read to the reference sequence, and assign each a quality 
score, based on the list of CALs, allowing for mismatches and gaps. Because 
this stage can be time consuming, it can be specified that reads with an 
excessive number of CALs be disregarded (-M 500 tells the program to ignore 
any reads with more than 500 CALs). 
 
bfast postprocess: Converts the file format to an output format which can be 
taken forward to use with other programs, in our case, the .sam format, which 
can easily be converted to the more universally accepted .bam format. This 
stage of processing can also be used to filter the alignments. 
 
Example commands to run BFAST: 
 
Make BFAST reference file: 
$ bfast fasta2brg ±f 
Homo_sapiens.GRCh37.59.dna.toplevel.chr_only.valid.fa ±A 
0 
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Index reference file: 
$ bfast index 
Homo_sapiens.GRCh37.59.dna.toplevel.chr_only.valid.fa ±m 
111111111111111111 ±w 14 ±i 1 ±n 8  
 
Find CALs: 
$ bfast match ±f 
Homo_sapiens.GRCh37.59.dna.toplevel.chr_only.valid.fa ±r 
1_NoIndex_L001_R1.fastq.gz ±z ±A 0 ±n 8 > Sample1_CAL 
 
Run local alignment: 
$ bfast localalign ±f 
Homo_sapiens.GRCh37.59.dna.toplevel.chr_only.valid.fa ±m 
Sample1_CAL ±A 0 ±M 500 ±n 8 > Sample1_aligned.baf 
 
Prioritise final alignments with bfast postprocess: 
$ bfast postprocess ±f 
Homo_sapiens.GRCh37.59.dna.toplevel.chr_only.valid.fa ±I 
Sample1_aligned.baf ±A 0 ±n 8 > Sample1.sam 
 
Data Manipulation and Analysis 
 
Samtools 
Samtools (Li et al. 2009) is arguably one of the most crucial pieces of software 
when dealing with NGS data. The majority of downstream analysis programs 
for NGS data require that aligned files are sorted (by position) and indexed 
before use. Samtools allows you to do this. It also enables the splitting of files 
from whole genomic alignments in to sections of interest to facilitate further 
analysis in a gene specific way. It can also be used to visualise and obtain basic 
statistics on data, and to convert between commonly used data formats such 
as SAM (Sequence Alignment/Map) and BAM (a binary form of SAM files). 
Samtools can be used for variant calling, however, it was not utilised in this 
way for this project, as our pooled sequencing data required programs 
specifically designed to handle variant calling in data where multiple 
inȂȱ¢ȱ ȱǯȱ 
 
After the completion of data alignment, Samtools was used to sort and index 
the data, then divide it in to regions of interest.  Example commands to do this 
are given below: 
 
$ samtools sort sample1_aligned.bam 
sample1_aligned_sorted.bam 
Where sample1_aligned.bam is the input file, and 
sample1_aligned_sorted.bam is the sorted output file. 
 
$ samtools index sample1_aligned_sorted.bam 
This creates a .bai index file specific to that bam file. This allows the retrieval 
of reads in any given region quickly and efficiently. 
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$ samtools view sample1_aligned_sorted.bam 8:27450349-
27475777 -bo CLU_1.bam 
Where 8:27450349-27475777 are the genomic coordinates for CLU, and -bo 
specifies that the output file should be in .bam format. This creates a file of all 
the aligned data within the CLU locus. Coordinates for the other regions were 
1:207666995-207817219 for CR1, 11:85664737-85784019 for PICALM and 
11:85840498-85870594 for the rs3851179 LD block. These coordinates include 
the targeted region, plus 500bp either side, to ensure the maximum amount of 
useful data were included in analyses. 
 
The alignment from BFAST was outputted in .sam, not .bam format, therefore 
it was necessary to convert to .bam before these steps could be performed: 
 
$ samtools view -S sample1_bfast.sam -bo 
sample1_bfast.bam 
Where -S identifies the input file is in .sam format, and -bo specifies that the 
output file should be in .bam format.  
 
The split files for each of the gene regions were also sorted and indexed before 
utilisation in other programs (as above).  
 
SamStat  
SamStat (Lassmann et al. 2011) is a program that gives statistics on mapped 
NGS data files, allowing the quality of reads and alignments to be assessed, 
and any major issues or abnormalities within the data set to be identified. 
Usage is very simple:  
 
$ samstat CLU_1.bam CLU_2.bam ...  
 
The output includes information on base quality distribution, read lengths, 
mapping quality, nucleotide composition and di-nucleotide over-
representation.  
 
Integrative Genomics Viewer (IGV) 
IGV (Robinson et al. 2011) is a simple and intuitive high-performance data 
visualisation package from the Broad Institute. It can be used for a variety of 
different types of data, including NGS and array-based data, and enables the 
researchȱȱȃȄȱȱȱȱȱǰȱȱȱ ȱȱȱȱ
the single base pair level. It is a Java program which can be installed on 
Windows, Linux or Mac. Usage is very simple - the desired file is opened 
within the program (in our case, indexed .bam files) and coordinates can be 
specified to focus on the regions of interest.  
 
Variant Calling 
In this project, the main aim of the study was the detection of variant sites 
within the sequenced regions. A wide range of variant calling software exists, 
both commercial and freeware, and each with its own relative strengths and 
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weaknesses in speed and accuracy. For individual sequencing data, the 
genome analysis toolkit (GATK) (McKenna et al. 2010) is emerging as the 
ȃȱ Ȅȱ ȱȱ ǰȱ ȱ ȱȱ ǻȱ ȱ ȱȱ Ǽȱ
was not applicable to pooled sequencing data. Two methods were used for 
variant calling in our data, both specifically designed with pooled sequencing 
designs in mind Ȯ Syzygy and CRISP. 
 
Syzygy 
Syzygy (Rivas et al. 2011) is a piece of software developed at the Broad 
Institute for the identification of variants in either pooled or individual 
sequencing data. In addition to simple identification of variants, it offers 
information on a number of other parameters, such as estimation of allele 
frequencies, power evaluation, single and group-wise marker association 
testing and basic annotation of detected variants. 
 
Syzygy requires a number of input files, additional to the aligned sequencing 
data. A dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) file containing known 
variants within the region was downloaded from the Tables section of the 
UCSC genome browser (Kent et al. 2002). A separate reference file for each 
chromosome was needed (for CLU, CR1 and PICALM; chromosomes 8, 1 and 
11 respectively), which again was downloaded from UCSC. For each gene, a 
manually created tab delimited .pif and .tgf file was also required, following 
the format shown in figure 2.7. The .pif file provides Syzygy with information 
on the pools/samples being analysed, while the .tgf file contains information 
on the targeted region. 
 
Figure 2.7 Ȯ ȱȱ¢£¢¢Ȃȱǯȱȱǯȱȱ 
 
 
The format for the .pif file is shown in the top panel. This gives Syzygy information on 
the pooling design used, firstly specifying the names and location of the .bam files, 
giving the phenotype (in our case, irrelevant, as only case samples were utilised), 
along with the number of individuals (12) and chromosomes (24) per pool. Below is 
the format for the .tgf file. This gives Syzygy information on the regions which have 
been sequenced (including gene/feature name, chromosomal coordinates, size, and 
which genome build these numbers refer to).  
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Example command to use Syzygy:  
 
$ syzygy --pif CLU.pif --tgf CLU.tgf --outputdir ./ --ref 
chr8.fa --hg19 --dbsnp CLU.dbsnp --power  
 
CRISP 
CRISP (or Comprehensive Read analysis for Identification of SNVs (and short 
indels) from Pooled sequencing data) (Bansal 2010) is a program designed for 
the identification of both common and rare variants from at least two pools of 
sequencing data, although at least five pools are recommended for optimal 
results. The principle of the program is centred around the concept of 
comparing variant distribution across multiple sequencing pools to 
distinguish genuine rare variants from sequencing errors. For common variant 
identification, individual base quality scores are utilised to evaluate the 
likelihood of observing that number of non-reference base calls due to 
sequencing errors alone. Rare variants are assessed by contingency table, 
comparing the distribution of variant calls across DNA pools, which also 
reduces the number of false positive variant calls occurring due to sequence 
context. A diagrammatical explanation of this concept is presented in figure 
2.8, taken from Bansal 2010 (Bansal 2010). The program also takes in to 
account the size of the pool used, and any biases in the distribution of reads 
on the forward and reverse strands.  
 
Figure 2.8 Ȯ Detection of rare variants using CRISP 
 
Each box represents a sequencing pool, with the dots representing individual 
sequencing calls (white Ȯ reference, black Ȯ alternative). In scenario A, all alternative 
calls occur within a single pool. The p-value for the contingency table here would be 
0.02, indicating it is likely that this data did not arise from random chance alone, and a 
variant should be called. In scenario B, although there are the same number of 
alternative calls in the second pool, there are also alternative calls in other pools. The 
p-value for the contingency table in this instance would be 0.24, suggesting that this 
could have arisen through sequencing errors alone, and therefore should not be 
identified as a potential variant. Image taken from Bansal 2010 (Bansal 2010). 
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During the project, several different releases of CRISP were utilised for variant 
calling (v5, release 071812 and release 082412). The usage instructions below 
and the variants presented in this document pertain to the 082412 release of 
CRISP. 
 
Example command to run CRISP: 
 
$ ./CRISP_092412 ±-bam CLU_1.bam --bam CLU_2.bam --bam 
CLU_3.bam --bam CLU_4.bam --bam CLU_5.bam --bam CLU_6.bam 
--bam CLU_7.bam --bam CLU_8.bam --ref 
Homo_sapiens.GRCh37.59.dna.toplevel.chr_only.valid.fa --
poolsize 24 --VCF CLU_variantcalls.vcf --qvoffset 33 --
regions 8:27450849-27475277 > CLU_variantcalls.log 
The poolsize specified is the haploid number of genomes per pool; in our case 
12 individuals = 24 haploid genomes. The command qvoffset specifies the 
quality value offset to be used in analysis, which should be 33 for data 
encoded in Sanger format, such as ours. This instructs the program how the 
quality scores of the data are coded, which varies across different sequencing 
platforms. Other commands can be incorporated to customise the algorithm, 
including altering the p-value thresholds for reporting SNPs, adjusting 
minimum base and minimum mapping quality. These options were left at 
their default settings. 
 
Coverage Calculations 
Average coverage for each of the regions of interest was calculated using the 
total reads aligned to the region (as outputted by SamStat) and the following 
equation: 
 
Average coverage = (number of reads * read length) / size of region (bp) 
 
This gave the average coverage for the region per pool, which could then be 
divided by 12 (i.e. the number of individuals in the sample) to calculate 
average coverage for the region per individual.  
 
% On Target 
The percentage of reads mapped to the target region was calculated for each 
pool, and an average for the whole experiment established, again using 
SamStat to obtain information on the number of reads which map to the target 
region, using the following equation: 
 
% on target = (number of reads on target / total number of reads generated) * 
100 
 
Enrichment factor calculations 
To assess the efficiency of the enrichment, enrichment factor calculations were 
performed, using the equation below: 
 
 
 
 
 
90 
Enrichment factor = average depth of coverage at region of interest (ROI)/ 
average depth of coverage across the rest of the genome 
 
Where: 
 
Average depth of coverage at ROI = reads mapping to ROI * read length (bp) / 
size of all ROIs (bp) 
 
Average depth of coverage across the rest of the genome = reads mapping to 
rest of genome * read length (bp) / size of genome (taken to be ~3,200,000,000 
bp) 
 
Ts/Tv Ratios 
Each SNP identified by CRISP was classified as a transition (A/G, T/C) or a 
transversion (A/C, A/T, G/C, G/T), and the ratio of transition to transverstions 
(Ts/Tv ratio) was calculated by dividing the number of transitions by the 
number of transversions. This was calculated separately for exonic and non-
exonic variants. 
 
Variant Effect Predictor 
Basic annotation of the polymorphisms called in the NGS data was conducted 
using EnsembȂȱȱȱȱǻǼȱ(McLaren et al. 2010) (accessed 
November 2011), which provided information on where the variants lie in 
relation to the major transcripts of each gene and whether these were novel or 
had been documented in dbSNP. Additional information can be included for 
coding variants (e.g. position of affected amino acid in protein sequence, 
whether the variant is synonymous or non-synonymous, and SIFT/PolyPhen 
predictions of functional consequences for missense SNPs).  
 
The web based version of the program was utilised, ensuring the most up to 
date versions of the databases are interrogated, as the standalone perl script 
version relies on downloading datasets, which will quickly become dated.  
 
Uploading variants for assessment is simple, requiring a .vcf file of 
SNPs/indels of interest, such as the one generated by CRISP. The output file is 
typically a text document which can then be opened in Microsoft Excel on 
Windows or LibreCalc on Linux operating systems.  
 
The VEP gives the relative position of the variants compared to all of the 
transcripts Ensembl has in its database for that region. Many of these 
transcripts are not known and confirmed protein coding transcripts, so for 
each of the genes, the main transcripts of interest were identified, and data for 
these alone was utilised in further analysis. The selected transcripts were 
ENST00000316403 for CLU, ENST00000393346 for PICALM, and 
ENST00000400960 plus ENST00000367049 for CR1 (encoding the F and S 
isoforms respectively).  
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Uploading ȱ ȱ ȱȂȱ ȱ ȱ  (Kent et al. 2002) 
was another way in which the variants detected could be put in context of the 
genes. This required the data to be in .bed format (a tab delimited format, with 
column one indicating the chromosome, and columns two and three 
specifying the start and end coordinates of the variant (for a SNP, these 
numbers will be the same)). Once the custom track is uploaded, navigating to 
the region of interest displays the variants where they fall within the gene.  
 
Tabix and the 1000 Genomes Project 
In order to obtain the most accurate and up to date frequency estimates from 
the 1000 genomes project data, a combination of Tabix and an in-house 
compiled perl script were used. The perl script is given in Appendix 2.2 
(written by former colleague, Hui Shi).  
 
The required input files are named Filename1 and Filename2. Filename1 gives 
details on the sample IDs and the population to which they belong. This is 
consistent for all genes and was obtained from the 1000 genomes project data 
site (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/). The second 
file, specified by filename2 is different for each gene, containing genotype 
information for a particular region. This was obtained using Tabix (example 
command shown below): 
 
$ ./tabix -hf 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521
/ALL.chr8.phase1_integrated_calls_20101123.snps_indels_sv
s.genotypes.vcf.gz 8:27450849-27475277 > CLU_Tabix_Out 
Where -hf specifies the location of the data of interest in the 1000genomes data 
ftp site, and the coordinates of interest are specified, pulling down the data for 
that region. Data for the four regions were obtained 04.01.2012. 
 
To run the script (example command): 
 
$ perl.pl  
(The input files are specified within the perl script itself) 
 
The output file can then be searched for coordinates of interest, and will give 
frequencies of variants at those positions for the four major 1000 genomes 
populations (EUR, AMR, AFR, ASN). 
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Sequencing Project Two 
 
2.6. CR1 Sequencing (Take Two) 
 
Due to the poor coverage obtained for the CR1 region in the first sequencing 
project, the gene was included in a second sequencing project conducted by 
the lab. Also included in this project were the other recently identified AD risk 
genes from GWAS (ABCA7, BIN1, the MS4A gene cluster, CD2AP, CD33 and 
EPHA1), in addition to other loci of interest to our group and collaborators 
(APOE, VAMP1, VAMP2, and the IDE/KIF locus). The details of these regions 
are presented in table 2.3.  
 
The basic methodology utilised in the second sequencing project was 
essentially the same as the first, but with a few differences and modifications. 
Firstly, following analysis of the initial sequencing project data, it was decided 
to utilise the repeat masker function offered in the design of the SureSelect 
baits, given that repetitive regions were poorly represented in the initial 
project, and that the inclusion of such regions was believed to contribute to the 
lower than expected percentage of reads mapping to the target regions. In the 
intervening time, a less stringent repeat masker had been incorporated into 
the eArray system, so this was utilised. Additionally, regions which can be 
problematic for ǰȱ ȱ ȱ	ȱ ȱ ǰȱ ȱ ȃȄȱ ȱ ȱ
ȱǰȱ ȱȱ ȱȂȱ ȱ -array system offers. This 
essentially means problematic regions were targeted by an increased number 
of baits, increasing the likelihood that these regions would be successfully 
sequenced.  
 
Given the advances in sequencing technology in the intervening time between 
the two projects, a different sequencing technology was utilised for the second 
sequenȱ ǯȱ Ȃȱ
ȱwas used for the second project. With 
advances in technology and chemistry, this meant a greater quantity and 
quality of data were produced. Furthermore, a longer read length was utilised, 
and paired-end reads instead of single-end reads were used. Both of these 
factors contribute to more reliable alignment of reads to the reference genome. 
The use of 100bp reads, rather than 35bp makes alignment easier, with more 
reads uniquely matching to a single position in the genome. The use of paired-
end reads also enhances alignment. This is where a fragment of DNA of a 
known approximate length is sequenced from both ends, giving 100bp of 
sequence information for each, as well as positional information. Since it is 
known how far apart these reads should be it aids the mapping process, and 
improves the elucidation of structural rearrangements and copy number 
variation. 
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Table 2.3 Ȯ Regions targeted by second sequencing project 
Locus Coordinates bp 
Target bp 
Covered 
% bp 
Baited bp Excised Extra +/- ~150bp 
CR1 Chr1:207667495-207816719 149224 110252 73.88 1:207667345-207816869 
ABCA7 Chr19:1038952-1066720 27768 21472 77.32 19:1038800-1066850 
BIN1 Chr2:127778085-127895723 117638 98261 83.53 2:127777935-127895873 
MS4A_LD_Locus Chr11:59856028-60041296 185268 129093 69.68 11:59855878-60041446 
VAMP1 Chr12:6566406-6584843 18437 13059 70.83 12:6566256-6584993 
VAMP2 Chr17:8057465-8071293 13828 10852 78.47 17:8057315-8071443 
TRIM15 Chr6:30132298-30138448 6150 4426 71.96 6:30132148-30138598 
SPARCL1 A - Chr4:88442070-88447047 4977 3981 79.97   
  B - Chr4:88426174-88435612 9438 7011 74.28   
  C - Chr4:88403759-88416324 12565 5467 43.51   
CD2AP Chr6:47427281-47601015 173734 120861 69.56 6:47427131-47601165 
CD33 Chr19:51718317-51748546 30229 18690 61.83 19:51718167-51748696 
EPHA1 Chr7:143082382-143110385 28003 24275 86.68 7:143082232-143110535 
IDE_KIF11_HHEX Chr10:94192885-94491751 298866 169051 56.56 10:94192735-94491901 
APOE Chr19:45260160-45451160 191000 96074 50.30 19:45260010-45451310 
 
Total/Average 1,267,125 832,825 69.89 
 Details of the targeted regions from the second sequencing project, including genes and coordinates, the size of the target region, and the amount of the target 
region and percentage successfully baited. Coordinates in the last column indicate the final region actually targeted. For the SPARCL1 targets, 150bp had 
already been added to the ends of the region, so this was not repeated. 
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Data analysis was largely conducted as before. Based on the first project, 
BFAST was selected as the alignment method of choice (with slight 
modifications to adapt to the different sequencing technology used), while 
CRISP was utilised for variant calling (as before). For the justification of these 
decisions, see Section 3 Ȯ defining the pipeline.  
 
BFAST 
Because the data for the second project was paired end data, the files had to be 
interleaved before BFAST could be run. This process involved taking the two 
separate files (one for the first read set, one for the second read set (the pairs)) 
and generating a single file with both reads aligned to the same strand 
(requiring the reverse complement of the second read set to be generated), 
whilst maintaining the quality score information for both. 
 
The script (shuffle_fastq_new_100412.pl) used to do this was written in-house, 
with guidance from Nils Homer, the creator of BFAST. The contents of this 
script are shown in Appendix section 2.3. 
 
Example command to run script: 
 
$ perl shuffle_fastq_new_100412.pl 
Extracted_Reads/L001_R1.fq Extracted_Reads/L001_R2.fq 
Sample1_R1R2.fastq 
 
After the interleaving step, alignment was run as documented for project 1, 
except that the indexes used were different since the reads here were longer 
(see figure 2.9). 
 
Figure 2.9 Ȯ Indexes for BFAST alignment of reads >40bp 
 
Indexes for BFAST indexing step when using Illumina data with a read length greater 
than 40bp. 
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2.7. Prioritisation and Validation 
 
Sanger Sequencing 
PCR primers were designed to amplify a region including at least 100bp either 
side of the positions of interest using Primer3 (Rozen and Skaletsky 2000) 
v0.4.0 (http://frodo.wi.mit.edu/). Specificity for each primer pair was checked 
ȱ Ȃȱ (Kent et al. 2002) Virtual PCR function 
(http://genome.ucsc.edu/cgi-bin/hgPcr), and the primer binding sites were 
determined to be free of known polymorphismȱ ȱ 	ȱȂȱ
SNPCheck v2.1 (https://ngrl.manchester.ac.uk/SNPCheckV2/snpcheck.htm). 
 
PCR optimisation and amplifications were completed following the standard 
laboratory protocol (reaction mix: 1xPCR buffer (Roche Diagnostics Corp.); 
ŘŖŖ“μȱȱǻǼǲȱŗ“μȱȱȱr (Eurogentec Biologics); 1 unit 
Taq DNA Polymerase (Roche Diagnostics Corp.); plus molecular grade water 
ȱȱȱȱȱȱřŖ“μǯȱȱȱ ȱȱȱŞǱŘŝŚŜŜşŘŚȱ
and doubled for 1:207690803 after optimisation. Thermal cycling conditions 
used were 94°C for two minutes; 30 cycles of 94°C for 30 seconds, appropriate 
annealing temperature for 1 minute, 72°C for 1 minute; and finally 72°C for 7 
minutes). Primer sequences and annealing temperatures for the SNPs 
validated by this method are shown in Table 2.4. Sequencing was conducted 
using PCR primers with Applied Biosystems BigDye Terminator v3.1 
chemistry, run on the ABI 3130xl (Applied Biosystems). Chromas Lite v2.01  
(http://www.technelysium.com.au/chromas_lite.html) was used to visualise 
electropherograms which were assessed by eye to determine genotype. In 
each case, one pool of samples (12 individuals) was Sanger sequenced. The 
pool to be sequenced was selected based on having the highest proportion of 
alternative reads in the NGS data at the position of interest. 
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Table 2.4 Ȯ PCR primers and annealing temperatures 
Variant 
(Chr:coordinate) 
Forward Primer Sequence Reverse Primer Sequence Annealing 
Temperature 
8:27452179 GCG-GTG-AGC-TAT-GAT-TCC-AC GCT-CAG-GTG-CCC-AAT-CCT-AT 64ºC 
8:27466924 CTG-CAC-CCT-ACT-GCT-TAG-AAA TGC-ATT-TGT-CAC-CAG-TGC-TAT 54ºC 
8:27473743 ATG-AGG-AAT-CGG-GAA-TGG-AT GGA-GCG-AGC-TCA-AAA-ACA-AT 60ºC 
11:85668102 CAC-CCA-GCT-CCT-TTT-CTG-AT GGA-TCA-AAA-GCT-TTG-CAT-TGA 58ºC 
11:85692077 TGG-AAT-ATG-TCT-GGC-ACA-AAG GGG-ATC-TAA-CTG-GCA-ACC-AA 58ºC 
11:85774424 TGT-CTC-ACA-AAG-CGT-ATG-AAA-G GGC-AGA-ACA-GAA-TGC-CTG-AG 60ºC 
1:207690803 GTG-TGT-GCA-GGA-TTG-CTC-AT TGT-TAC-ACA-AAT-TGT-TCC-AGA-CA 62ºC 
Primers and annealing temperatures for the variants selected for Sanger validation from the NGS data. 
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Exome Project 
Validation by Sanger sequencing is both expensive and time consuming: 
impractical for the large number of variants detected by our NGS 
experiments.  
 
ȱȱ ȱȱ
¢Ȃȱȱȱȱǻȱȱ
Rita Guerriero), we were able to pseudo-validate our coding variants. The 
group at UCL had exome sequencing data for up to 143 cases and 183 controls, 
and were able to look up our exonic variants in their data set, providing 
ȱȃȄȱȱȱSNPs, since variants present in both data sets 
were assumed to be genuine (data as published in (Guerreiro et al. 2013)).  
 
Imputation 
Imputation was used to enable us to perform association testing on detected 
variants within GWAS data available to us. This was in the form of a 
combined ARUK/Mayo GWAS data set, comprised of 2067 AD cases and 1376 
ǰȱ¢ȱȱȂȱ

p300v1. 6000 control samples 
from the WTCCC2 project (3000 from the 1958 birth cohort (58C), and 3000 
from the National Blood Service (NBS) cohort), genotyped using the Illumina 
1.2M (custom) chip were also utilised. These are population controls, so some 
may develop AD later in life.  
 
Both the merged data set and the WTCCC2 data sets were aligned to hg18, 
while the reference haplotypes to be used were aligned to hg19. To 
accommodate this, the GWAS data were converted to hg19 using plink 
(http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al. 2007) ȱȂȱ
liftOver program (available online at http://genome.ucsc.edu/cgi- 
bin/hgLiftOver or as a downloadable tool at http://hgdownload.cse.ucsc.edu 
/admin/exe/).  
 
To convert the Mayo/ARUK merged data set: 
 
$ ./plink --bfile MERGED_MAYO_ARUK --recode --out 
Merged_Mayo_ARUK_hg18 --noweb --allownosex 
Where MERGED_MAYO_ARUK specified the input files (.bed, .bim, .fam), 
and the output is in .map and .ped format. --noweb instructs plink not to 
connect to the web for updates, as this can disrupt the running of the 
program, and --allownosex allows individuals without gender information to 
be included. 
 
The input for liftOver required chromosome, start position, end position, and 
rsID. All of this information was extracted from the .map file using the 
following awk command: 
 
DZNµ^SULQW³FKU´³\W´³\W´³\W´`c¶
Merged_Mayo_ARUK_hg18.map > out_chr.bed  
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liftOver was then used to change the coordinates in the file to hg19, using a 
chain file downloaded from UCSC (hg18Tohg19.over.chain.gz, from 
http://hgdownload.cse.ucsc.edu/goldenPath/hg18/liftOver/): 
 
$ ./liftOver out_chr.bed hg18Tohg19.over.chain.gz 
Merged_hg19.bed unMapped 
The unMapped command means any coordinates that cannot be lifted over 
are printed to a separate file.  
 
To recode the actual GWAS data, plink required a file that was simply rsID 
and coordinate, separated by a tab. Again, awk commands were used to 
obtain this information: 
 
DZNµ^SULQW³\W´`¶0HUJHGBKJEHG!
hg19_Merged.txt 
 
Then plink was used to recode the GWAS data: 
 
$ ./plink --bfile MERGED_MAYO_ARUK --update-map 
hg19_Merged.txt --make-bed --out Merged_data_hg19 --noweb 
--allownosex 
 
This gave the .bed, .bim and .fam files for the combined data set in hg19. 
Regions of interest (in this case individual chromosomes) were then separated 
out of the whole genomic file: 
 
$ ./plink --bfile Merged_data_hg19 --chr8 --make-bed --
out chr8_Merged --noweb --allownosex 
Giving .bed, .bim and .fam for chromosome 8. 
 
$  ./plink --bfile chr8_Merged  --recode --out 
chr8_Merged --noweb --allownosex 
Giving .map and .ped files for the chromosome, which can then be converted 
via gtool (http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html) to 
the .gens and .samples files required by the imputation software. 
 
$ ./gtool -P --ped chr8_Merged.ped --map chr8_Merged.map 
--og chr8_Merged.gens --os chr8_Merged.samples 
 
This was done for all of the chromosomes of interest: 8, 1, 11, and 19, where 
the APOE locus lies. The .samples file required some editing (under 
ȃ¢Ȅȱȱ ȱȱȱȱȱȱȱȱȱȱ¢ȱǰȱȱ
ȂȱŗƸŘȱȱǻȱȱȱǼȱ  altered to 0+1 coding. A final 
ȱ ȱȱȱȱȱȱȱȃȄǰȱ ȱȱȱ ȱȱ
row (to demonstrate it was a discrete not continuous covariate). ARUK 
samples were coded 1, while Mayo samples were coded 4, allowing for 
correction based on centre when running association tests later. Any missing 
ȱ ȱȱȱȂȱȱȱ -şȱȱȃȄǰȱ ȱȱȱ
ȱȃȱȄȱ ȱȱȱȱȱȱǯȱ 
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For the WTCCC2 data, preparation was conducted slightly differently: firstly, 
the data was encrypted, so needed to be decrypted and unpacked using 
Kleopatra (http://www.kde.org/applications/utilities/kleopatra/) and the 
encryption key supplied. This data was also different in that each 
chromosome had a separate .gens file. To facilitate the alteration of the data 
from hg18 to hg19, a colleague, Christopher Medway, wrote a number of perl 
scripts.  
 
The first step was to unzip the .gens data file, then similar to above, use awk 
commands to extract the required information for the liftover step: 
 
DZNµ^SULQW³FKU´³\W´³´³\W´³\W´`¶
58C_chr8.gens > 58C_chr8.bed 
The chromosome number needed to be adjusted so that all chromosomes of 
interest, for both the NBS and 58C data were processed. 
 
This .bed file was then used in the liftOver process: 
 
$ ./liftOver 58C_chr8.bed hg18Tohg19_over.chain.gz 
chr8_hg19_58C.bed unMapped 
 
The output from this, plus the original .gens file (in this example, 
58C_chr8.gens) could then be called in to the perl script liftOverGen.pl (see 
Appendix section 2.4), which replaces the coordinate in the .gens file to match 
hg19 numbering: 
 
$ perl liftOverGen.pl chr8_58C.gens chr8_hg19_58C.bed 
N.B. The output file each time was named OUTPUT.txt, so needed renaming 
(in this case, to chr8_hg19_58C.gens) before running the program again, to 
ensure this is not overwritten. 
 
The WTCCC2 .samples files also required some recoding (e.g. recode 
phenotype, add centre information), which again, Christopher Medway 
compiled a perl script to complete - recode_WTCCC2.sample.pl (see 
Appendix section 2.5).  
 
To run the script: 
 
$ perl recode_WTCCC2.sample.pl WTCCC2_NBS.sample 
 
Once all the files were prepared, the imputation itself was run. Imputev2.2.2 
(http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) (Howie et al. 2009) 
was used - with each data file requiring separate processing (i.e. each of the 
chromosomes of interest, for each of the three (ARUK/Mayo Merged, 58C and 
NBS) datasets).  
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Example command: 
 
$ ./impute2 -m genetic_map_chr8_combined_b37.txt -h 
ALL_1000G_phase1integrated_v3_chr8_impute.hap.gz -l 
ALL_1000G_phase1integrated_v3_chr8_impute.legend.gz -g 
chr8_58C_hg19_58C.gens -align_by_maf_g -int 26450849 
28475277 -Ne 20000 -o CLU_58C_phased.impute2 
Where -m gives a fine scale recombination map for the region to be analysed 
(in this case, chromosome 8 (downloaded from impute2 website)), -h is a file 
of known haplotypes and -l is the corresponding legend file (both also 
downloaded from impute2 website). -g is the data file containing genotypes 
for the GWAS data (in .gens format, as created above), and requires a 
corresponding .samples file (again, as discussed above). The format of these 
files is shown in Figure 2.10. -int specifies the region to be imputed (26450849-
28475277 for CLU, 84665237-86870094 PICALM, 206667495-208816719 for CR1, 
and 44394477-46412650 for APOE). -Ne specifies the effective size of the 
population from which the imputed data was sampled. When using the full 
panel of reference hapotypes (as recommended), an -Ne of 20,000 is suggested. 
The command -align_by_maf_g was used for the WTCCC2 data, as no strand 
file was available for this data. This instructs impute2 to deduce the strand for 
each variant. For the Merged data, the strand file BDCHP-1x10-
HumanHap300v1-1_11219278_C-b37-strand.zip was used (downloaded from 
http://www.well.ox.ac.uk/~wrayner/strand/). This had to be unzipped, then the 
necessary information extracted (impute2 strand files only need coordinate 
and a + or - to specify the strand, the file as downloaded contained extra 
information) using an awk command: 
 
DZNµ^SULQW`¶%'&+3-1x10-HumanHap300v1-
1_11219278_C-b37-strand > HumanHap300v1.stand 
 
Figure 2.10 Ȯ Format for .gens and .samples files for Impute2 
 
 
Above: Format of the .gens file taken from the Impute2 file format website 
(http://www.stats.ox.ac.uk/~marchini/software/gwas/file_format.html). There is one 
line of information per SNP, including variant ID, rs ID, coordinate, allele A and allele 
B. The next numbers are the probabilities of genotypes (homozygous allele A, 
heterozygous, homozygous allele B) for that individual at the SNPs in question. 
Below: Format of the .samples file, example shown is for chromosome 8 from the 
ARUK/Mayo merged data set. The top line is the header, specifying the contents of 
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each column, followed by a line describing the type of variable in each column where 
necessary (D for discrete covariates, B for binary phenotypes (0 = controls, 1 = cases)). 
The following lines contain the information specified in the header for each of the 
individuals being included in the imputation, with one line per individual. 
 
Once the imputation was run for all regions and all datasets, another perl 
script written by Christopher Medway (remove_dup_lines.pl) was used to 
remove duplicate positions. The datasets were generated using different chips, 
so the command -overlap will need to be used when association testing, but 
this will not work if the files have more than one variant at a given position. 
The contents of this perl script are given in Appendix section 2.6, and an 
example command is given below: 
 
$ perl remove_dup_lines.pl CLU_58C_phased.impute2 
 
The output from this script was named in the form of 
CLU_58C_phased.impute2_duplicates_removed. Snptest_v2.4.1 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) 
(Marchini and Howie 2010) was then used to test the imputed variants for 
association with AD. An example command is given below:  
 
$ ./snptest_v2.4.1 -data 
CLU_Merged_phased.impute2_duplicates_removed 
chr8_Merged.samples 
CLU_NBS_phased.impute2_duplicates_removed 
chr8_NBS.samples 
CLU_58C_phased.impute2_duplicates_removed 
chr8_58C.samples -o CLU_Full_snptest.out -frequentist 1 -
method threshold -pheno phenotype -cov_names centre -
overlap 
 
2.8. In Silico Functional Analyses of Coding Variants 
 
A number of in silico functional analyses were conducted on the coding 
variants to prioritise those likely to be having functional consequences on 
protein structure, expression or regulation of the gene. 
 
LD Calculations 
Calculating the level of LD between the GWAS SNP and detected variants can 
help disentangle which variants could be underlying the reported association 
with AD from GWAS, and which may be independent from this effect.  
 
Christopher Medway wrote a perl program (LD_calculator.pl Ȯ script contents 
shown in Appendix section 2.8), utilising VCFtools (http://vcftools.sourceforge 
.net/) and Tabix (http://samtools.sourceforge.net/tabix.shtml), to calculate the 
level of LD between a specified SNP (in our case, the main GWAS SNP(s) for 
the locus) and a list of variants of interest presented by chromosome number, 
coordinate and rs number (if available) in a tab delimited text format. The files 
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Phase1_Samples_GBR_CEU and vcf-subset were needed to filter the samples 
to give only data for GBR and CEU populations (the most relevant to our 
study samples). 
 
Example command: 
 
$ perl LD_calculator.pl rs11136000 chr8 27464519 
CLU_SNPs.txt 
Where rs___ gives the identity of the reference variant (here, the CLU GWAS 
SNP), followed by the chromosome and coordinate of that variant 
 
ȱȱȱȱȱȱȱȱȱȂȱȱ2 for the variants, as 
well as the number of samples on which this has been calculated. 
 
Prediction of Non-synonymous Functional 
Consequences 
ȱȱȱȱȱȂȱȱ(McLaren et al. 2010) were Polyphen 
(Adzhubei et al. 2010) predictions for the consequence of the variants detected 
on the structural integrity and function of the proteins.  
 
Splicing Investigations 
A number of different programs were utilised to assess any impact on the 
splicing of the gene likely to arise from the observed variants in our samples.  
 
Preparing the input for the programs involved obtaining the sequence of the 
affected exon, plus at least 100bp of surrounding intronic sequence, for each of 
the variants of interest, both synonymous and non-synonymous changes. The 
wild type and variant forms of the sequence were run through the programs, 
and any differences between the two recorded. The programs used were all 
web based interfaces, all functioning in a similar way. 
 
ESEfinder v3.0: ESEfinder (Cartegni et al. 2003) incorporates two different 
functions for the assessment of splicing variants, both of which were utilised. 
The first (SpliceSites) predicts the actual donor and acceptor sites within the 
sequence provided. Mouse splice sites, included as default, were not included 
in our analysis. The other function, SRProteins predicts binding sites for the 
serine/arginine-rich splicing regulatory protein family and was used with 
default settings.  
 
BDGP: The Berkeley Drosophila Genome Project site (BDGP) (Reese et al. 
1997) offers a tool for predicting splice donor and acceptor sites. Used 
ȃ
ȦȄȱǰȱȱȱȱȱǯ 
 
NetGene2: Again, NetGene2 (Hebsgaard et al. 1996) provides a program for 
ȱȱȱȱȱǻǰȱȱȃ
Ȅȱǰȱȱȱȱȱ
default). 
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UTR variants and miRNAs 
Ten of the variants called at the CLU ȱ ȱ  ȱ ȱ Ȃȱ řȂȱ
untranslated region (UTR). Knowing variants in this region can have an 
impact on the regulation and expression of a gene, partly through the binding 
of miRNAs, TargetScan v6.1 (Garcia et al. 2011) was used. This predicts the 
binding sites of miRNAs by searching for conserved 7-8bp regions that match 
the seed region of known miRNAs. Entering the desired species (Human) and 
gene ID (CLU) gave the locations of all miRNA binding sites predicted within 
the UTR of that gene. These were then overlaid with the variants detected to 
see if any of the variants fell within these sites, and how this may affect the 
gene. 
 
Any variants which fell within predicted miRNA sites via this method were 
then followed up in a second program, PITA from the Segal Lab of 
Computational Biology at the Weizmann Institute (Kertesz et al. 2007). This 
looks at miRNA binding sites in a given UTR sequence, so it was possible to 
run predictions for the wild type version of the sequence, as well as the 
sequence of the UTR with the variant positions included individually. The 
ȃȱ ȱȄȱ ȱ ȱ ǰȱ ȱȱ ǰȱ ȱ ȱ ȱ
the UTR sequences. 
 
2.9. In Silico Functional Assessment of Non-coding 
Variants 
 
Due to the large number of detected non-coding variants, a number of in silico 
resources were utilised to assess which of the variants could be having 
functional consequences on gene regulation, and thus should be prioritised for 
further study. 
 
As above, levels of LD with the reference SNP were calculated. 
 
Conservation 
Conservation at the site of variants of interest could highlight potentially 
interesting SNPs, since those under strict genetic conservation are likely to be 
more damaging when altered. To assess the conservation at each of the variant 
sites, a perl script (conservation.pl, see Appendix section 2.7) was compiled by 
Christopher Medway to extract conservation information downloaded from 
the UCSC genome browser (tables > comparative genomics > conservation) for 
relevant positions. Two types of conservation score are contained within 
UCSC - Phastcons and PhyloP - mammalian conservation scores for each for 
the regions of interest were downloaded (Siepel et al. 2005; Pollard et al. 2010). 
To run the script, this data, plus a SNP list (bp coordinate only, in a text 
document) for the variants of interest were needed. An example command to 
run the script is shown below: 
 
$ perl conservation.pl CLU.phastcon CLU_SNPs.txt > 
CLU_phast.txt 
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ENCODE Data 
The UCSC genome browser contains a wealth of information from the 
Encyclopaedia of DNA Elements (ENCODE) project (ENCODE 2011). 
Colleague, Christopher Medway, wrote a perl script to extract information of 
interest (DNAseI hypersensitivity clusters, transcription factor binding sites 
(from ChIP-Seq) and acetylation/methylation data, all of which can imply 
ȱ¢Ǽȱȱȱȱȱ ǰȱȱȱȂȱǯȱ
This program is pending publication, so the perl code is not given. 
 
TaqMan Assays 
TaqMan assays were used to genotype two potentially functional SNPs in the 
rs3851179 LD block region in an independent case-control cohort to test for 
association with AD.  
 
The TaqMan assays for the two variants were designed and synthesised by 
Applied Biosystems. Table 2.5 gives the details of these assays (including 
primer and probe sequences, and the number of individuals (cases and 
controls) genotyped using each assay). All genotyping was carried out by Ng 
See May, as the basis of her dissertation for her MSc in Molecular Diagnostics. 
TaqMan reactions were conducted in a total volume of 20µl, with 0.9xTaqMan 
Universal PCR Master Mix, 1xTaqMan SNP Genotyping Assay Mix (both from 
Applied Biosystems), plus 10ng of genomic DNA and nuclease free water to 
reach the final volume. No-template controls (NTCs) were included in each 
run to test for contamination. An MX3000P Real-Time PCR Thermocycler 
from Stratagene was used for the experiment, with cycling conditions of 50°C 
for 2 mins, followed by a denaturation cycle at 95°C for 10 mins, and 50 cycles 
of denaturation and annealing (respectively, 92°C for 15 seconds, 60°C for 1 
Ǽǯȱ	¢ȱ ȱ¢ȱȱȂȱ¡TM software.  
 
ȱȱ ȱȱ¢ȱȂȱ¡ȱȱȱŗşǰȱȱ
the power of the study was assessed using Quanto.  
 
Table 2.5 Ȯ TaqMan assay design for rs3851179 LD block variants 
 
Information on TaqMan assay design, and the number of individuals genotyped with 
each assay, conducted by Ng See May. 
 
Sanger validation of the two variants was also conducted, as described above. 
As the variants were only ~250bp apart, the same primers could be used in the 
sequencing of the two variants. Details of the PCR and sequencing primers 
used are given in Table 2.6. The sequencing provided positive control samples 
to use in the TaqMan genotyping assays where appropriate.  
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Table 2.6 Ȯ Sanger sequencing rs3851179 LD block variants 
 
Information on the variants and primers for the SNPs Sanger sequenced by Ng See 
May in the LD block containing rs3851179 near PICALM. 
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3. Data Analysis 
 
This chapter describes in detail the processing of the NGS data, from raw 
reads in FastQ format to identified variants. A number of different programs 
were utilised and compared, enabling the development of a pipeline of 
programs best suited to handling data of this type.  
 
3.1. Next Generation Sequencing 
 
From the first sequencing project, a total of 380,589,701 38bp single end reads 
were obtained from Source Biosciences from the Illumina GaIIX. Each pool of 
samples was run on a separate lane of the flow cell. A breakdown of the reads 
and qualities per pool is given in Table 3.1. 
 
Table 3.1 Ȯ Sequencing statistics from NGS project 1 
Pool Yield 
(Mbases) 
% Clusters 
that passed 
filtering 
Number of 
reads 
% of >=Q30 
bases 
Mean quality 
score 
1 1418 80.73 46,208,988 94.57 37.48 
2 1405 82.77 44,684,019 95.13 37.66 
3 1478 75.79 51,324,331 93.27 37.02 
4 1227 61.80 52,242,572 87.86 35.35 
5 1385 67.04 54,350,139 88.23 35.48 
6 1392 83.13 44,061,669 95.04 37.62 
7 1254 85.18 38,748,346 96.04 38.00 
8 1467 78.83 48,969,637 94.09 37.30 
Information on data produced by Source Biosciences from NGS project 1, including 
information on the number and quality of reads produced. 
 
From the second sequencing project, 2,170,649,020 100bp paired end reads 
 ȱ ȱ ȱ ȱ ȱ ȱ Ȃȱ 
ǯȱ ǰȱ ȱ
pool of samples was run on a separate lane of the flow cell, and a summary of 
reads and qualities per pool is provided in Table 3.2. 
 
Table 3.2 Ȯ Sequencing statistics from NGS project 2 
Pool Yield 
(Mbases) 
% Clusters 
that passed 
filtering 
Number of 
reads 
% of >=Q30 
bases 
Mean quality 
score 
1 21,981 92.48 237,697,912 86.02 34.26 
2 25,032 90.47 276,674,942 84.15 33.69 
3 22,541 92.44 243,847,388 85.89 34.23 
4 25,668 89.86 285,634,842, 84.56 33.80 
5 24,206 91.22 265,350,864 85.57 34.11 
6 27,729 87.26 317,781,166 81.25 32.81 
7 23,356 91.60 254,987,838 85.19 34.01 
8 25,850 89.55 288,674,068 83.13 33.38 
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Information on data produced by Source Biosciences from NGS project 2, including 
information on the number and quality of reads produced. 
 
 
 
 
3.2. FastQC 
 
An initial assessment of the quality of the data produced by each NGS run 
was conducted using FastQC.  
 
The program gives summary statistics for multiple parameters, classifying 
each file with a pass, warning or fail, designed to highlight any potential 
isȱȱȱ ȱ ȱȱȱ ȱȱȱȱȃȄȱ	ȱ
dataset. The summary information from FastQC for the first sequencing 
project is given in Table 3.3, with the same information for the second 
sequencing run presented in Table 3.4. The program also provides graphical 
representations of these parameters. The graphs for the per-base sequence 
quality scores for each sample, which provides the most insight in to the 
overall quality of the data, are presented in Figure 3.1 and Figure 3.2 for NGS 
projects 1 and 2 respectively.  
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Table 3.3 Ȯ FastQC summary statistics for NGS project 1 
Sample Per base 
sequence 
quality 
Per base 
sequence 
quality 
scores 
Per base 
sequence 
content 
per base 
GC 
content 
Per 
sequence 
GC 
content 
Per base 
N 
content 
Sequence 
length 
distribution 
Sequence 
duplication 
levels 
Over-
represented 
sequences 
1 Pass Pass Pass Pass Warning Pass Pass Pass Warning 
2 Pass Pass Pass Pass Warning Pass Pass Pass Warning 
3 Pass Pass Pass Pass Warning Pass Pass Pass Warning 
4 Fail Pass Pass Pass Warning Pass Pass Pass Warning 
5 Fail Pass Pass Pass Warning Pass Pass Pass Warning 
6 Pass Pass Pass Pass Warning Pass Pass Pass Warning 
7 Pass Pass Pass Pass Warning Pass Pass Pass Warning 
8 Pass Pass Pass Pass Warning Pass Pass Pass Warning 
FastQC summary statistics on raw data quality from NGS project 1 
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Table 3.4 Ȯ Fast QC summery statistics for NGS project 2 
Sample Per base 
sequence 
quality 
Per base 
sequence 
quality 
scores 
Per base 
sequence 
content 
per base 
GC 
content 
Per 
sequence 
GC 
content 
Per base 
N 
content 
Sequence 
length 
distribution 
Sequence 
duplication 
levels 
Over-
represented 
sequences 
1 (R1) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
1 (R2) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
2 (R1) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
2 (R2) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
3 (R1) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
3 (R2) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
4 (R1) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
4 (R2) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
5 (R1) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
5 (R2) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
6 (R1) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
6 (R2) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
7 (R1) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
7 (R2) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
8 (R1) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
8 (R2) Fail Pass Warning Pass Warning Pass Pass Fail Pass 
FastQC summary statistics on raw data quality from NGS project 2. Each sample has two data files this time Ȯ the forward and reverse reads generated by the 
use of paired end reads, indicated by R1 and R2.  
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Figure 3.1 Ȯ FastQC graphs for NGS project 1  
 
Graphical representation of the per-base sequence quality from FastQC for each of the 
8 pools of samples. The red line and blue line represent the median and mean quality 
values respectively, with the yellow box showing the interquartile range and the 
whiskers showing the 10% and 90% values. The background colours represent 
different quality scores, with green indicating very good quality, orange representing 
reasonable quality and red showing poor quality.  
 
 
 
 
 
 
 
 
 
 
111 
 
 
 
Figure 3.2 Ȯ FastQC graphs for NGS project 2 
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Graphical representation of the per-base sequence quality from FastQC for the 
forward and reverse reads of each of the 8 sample pools. The red line and blue line 
represent the median and mean quality values respectively, with the yellow box 
showing the interquartile range and the whiskers showing the 10% and 90% values. 
The background colours represent different quality scores, with green indicating very 
good quality, orange representing reasonable quality and red showing poor quality. 
 
3.3. Discussion of NGS and FastQC data 
 
The difference between the number of reads generated by the first and second 
sequencing projects (~380.6 million vs. ~2,170.6 million) is a direct reflection of 
the advancements in sequencing technology in the intervening time (around 9 
months). The improvements in chemical and engineering technologies utilised 
by the later Illumina HiSeq model resulted in the generation of around 5.7x 
more reads from the latter NGS project, and those reads of a longer read 
length. 
 
The first parameter assessed by FastQC is the per base sequence quality. This 
gives an overview of the range of quality scores across all positions of a read. 
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Graphical representations of these are shown in Figures 3.1 and 3.2. From the 
summary information given in Tables 3.3 and 3.4 it can be seen that samples 4 
and 5 from NGS project 1 and all of the samples from NGS project 2 failed on 
this parameter. A fail is given if the lower quartile for any position is below 5, 
or the median for any position is below a score of 20. For samples 4 and 5 from 
project 1, it can be seen in Figure 3.1 that the quartile does indeed dip below a 
score of 5, hence why a warning has been provided. However, the median 
score for these reads remains reasonably high, indeed, comparable to the 
median for the other samples which have not failed this measure. Taken 
together, this suggests that there are a greater number of poor quality reads 
within these sample pools, however, the median quality is still high, and 
particularly poor reads will simply not be aligned, so should not affect the 
quality of data in further processing.  
 
The second project featured a much longer read length than did the first 
(100bp rather than 38bp). It is expected that per base quality will decrease 
across the length of a read, which is more markedly apparent when using 
ȱȱǯȱȱȃȄȱȱȱȱȱ ȱ  ȱȱ
fall below a quality score of 5. However, for the most part, the mean read 
qualities remain in the green section (indicative of good quality) until around 
the 80base mark, while the median remains in the green region for the full 
length of the read. Again, this shows that for the majority of the reads, the 
base quality is good across the full read, and the fail is more an indicator of a 
wider spread of qualities. As stated before, any particularly poor quality reads 
will simply fail to be aligned, so will not have an impact on data quality at 
further processing stages.  
 
The next parameter the program reports is the per sequence quality score, 
which identifies any subsets of reads that have unusually low quality scores. 
No warnings or failures were given for this parameter for any of the data files. 
Next is the per base sequence content, which all of the samples from the first 
project passed, and all of the files from the second project were given 
warnings for. This shows the proportion of each base at each position across 
the read, with strong differences potentially indicative of biases in the data. 
The score a sample is given for this can be biased by the sequencing primers 
that are added to each read, which are GC rich, and therefore the warnings 
given for the second sequencing project are not a cause for concern.  
 
The per base GC content shows the GC content for each position across the 
length of a read, which ideally should be consistent throughout. This was the 
case for our data, so no warnings or failures were issued for any of the 
samples. The per sequence GC content score compares the GC content across 
the sequence with a modelled normal distribution of GC content. All sample 
files for both sequencing projects received a warning for this parameter. 
Although unusually shaped distributions can be indicative of contamination 
of a sample, it is likely that in this case the deviation arose from the inclusion 
of the GC rich primer sequences, as mentioned above. The per base N content 
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 ȱ ȱȱȱ ȃȄȱ ȱ ȱ ȱȱ ȱ ȱ ǰȱȱ ȱȱ
exceed a few percent, which was the case for all samples from both projects. 
The sequence length distribution gives a score based on the consistency of 
read lengths within a file. For each of the projects, these were exactly as 
expected (38bp for project 1, 100bp for project 2). The sequence duplication 
levels for the first sequencing project all passed, but all files containing the 
ȱȂȱȱȱȱǯȱȱȱȱȱȱȱȱȱ
duplication for each of the sequences in the set, low levels of which can 
indicate good coverage. However, when enriching for a particular region of 
the genome, such has been done for these projects, and multiple individuals 
are included in each sample pool, a reasonable level of sequence duplication is 
expected. Due to the vast increase in the number of reads in the second project 
over the first, it would be expected that the duplication levels would be 
higher. It may also be indicative that the enrichment process worked better for 
ȱ ȱ ȱ ȱ ȱǯȱȱ ȱ ȱ ȱȂȱ ȱ
passed the over-ȱȱǰȱȱȱȱȂȱȱȱ
warnings. This test lists all sequences that make up more than 0.1% of the 
total, and can be indicative of contamination. However, the only sequence 
reported as featuring in this ¢ȱ ȱ  ȱ ȱ ȱ ȱ ȃȄǰȱ ȱ ¢ȱ
indicates a quality issue with these reads. All this means is the base qualities 
in >0.1% of reads were not high enough to definitively indentify which bases 
were present, and  ȱ ȱ ȱ ȱ ȃȄǯȱ 
 ver, as discussed 
above, poor quality reads will not be aligned, and so will not affect 
downstream processing.  
 
Although sample files from both projects received warnings or failures for 
various parameters, these were largely for expected or justifiable reasons. 
FastQC is not designed to give an exact representation of the quality of the 
data, but rather a comparison to a standard NGS dataset, which ours, with its 
target enrichment and sample pooling is not.  
 
3.4. Defining the pipeline 
 
A number of different programs were utilised in processing the data from 
NGS project 1 to allow an assessment of the best available processing pipeline, 
ȱȱȱ ȱȱȃȱȄȱȱȱȱȱǯȱ
The optimal set of programs to meet our requirements was determined based 
on the results and analyses presented below. 
 
Alignment 
Both BFAST and MOSAIK took around six weeks to align the 8 sets of NGS 
data to the reference human genome, requiring approximately equivalent 
processing power. After the alignment, the files were split in to regions 
corresponding to the four loci of interest (CLU, CR1, PICALM and the 
rs3851179 LD block). Testing of programs presented from here on mainly 
utilises the CLU data, given that this was the smallest of the regions sequenced 
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and would therefore allow a quicker assessment of programs, with the best 
being applied to the other regions in due course. 
 
SamStat was used to allow a comparison of the quality of the alignments 
produced by BFAST and MOSAIK. The aligned data pertaining to the four 
targeted loci for each of the 8 aligned samples were analysed using SamStat. 
Graphical information on the quality of the alignments produced by SamStat 
for the CLU region is provided in Figure 3.3, and is representative of the data 
as ȱ ǯȱȱřǯśȱȱřǯŜȱ ȱȱȱȱȂȱȱȱȱȱ
the four regions targeted in project 1 for MOSAIK and BFAST respectively. 
 
From the pie charts shown in Figure 3.3, it is obvious that BFAST consistently 
has a higher proportion of reads achieving the greatest quality score, and a 
lower proportion of reads attaining the lower quality scores. Whilst this 
immediately suggests BFAST is producing better alignment, the data 
contained within Tables 3.5 and 3.6 gives a more complete picture of the 
situation. 
 
MOSAIK actually aligned more of the data from the files in to the regions of 
interest (33.4 million reads vs. 14.4 million reads). The BFAST alignment 
consistently gave a higher percentage of reads achieving the maximum 
mapping quality score (>=30) than did MOSAIK. In terms of the actual 
number of reads, the CLU, PICALM and rs3851179 LD block all had a greater 
number of reads reaching the highest quality score in the BFAST alignment, 
although the CR1 region had a greater number of reads achieving quality >=30 
in the MOSAIK rather than BFAST alignment. The BFAST alignment had a 
lower percentage and number of reads achieving the lower quality scores (3 or 
lower) in all four regions of interest than MOSAIK. 
 
One thing that is notable from the data within the tables is that the alignment 
of reads to the CR1 region was poorer with both alignment programs than for 
the other regions. While the other regions for each alignment had 84-89% 
(MOSAIK) and 94-95% (BFAST) of reads achieving the highest mapping 
quality score, for CR1 this figure was only 58.5% and 67.6% from the MOSAIK 
and BFAST alignments respectively.  
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Figure 3.3 Ȯ Quality of alignment: BFAST vs. MOSAIK
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Graphs from SamStat showing pie charts of data mapping statistics for MOSAIK on 
the left and BFAST on the right.  
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Table 3.5 - SamStat mapping quality assessment for MOSAIK alignment of project 1 data 
 Total reads 
(all samples) 
Average reads 
per sample pool 
Average reads 
MAPQ>=30  
Average reads 
MAPQ>=20  
Average reads 
MAPQ>=10  
Average reads 
MAPQ>=3  
Average reads 
MAPQ<3  
CLU 1153189 144148.6 126433.3 (87.7%) 2625.8 (1.8%) 2944.4 (2.0%) 3163.8 (2.2%) 8981.5 (6.23%) 
PICALM 6569781 821222.6 731134.5 (89.0%) 15880.9 (1.9%) 18748.6 (2.3%) 16612.9 (2.0%) 38845.8 (4.7%) 
rs3851179 
LD block 
1732734 216591.8 182499.9 (84.3%) 3602.4 (1.7%) 6461.9 (3.0%) 5864.4 (2.8%) 18063.3 (8.3%) 
CR1 23925338 2990667.3 1750134.3 (58.5%) 199074.1 (6.7%) 359176.5 (12.0%) 224171.1 (7.5%) 458111.3 (15.3%) 
Combined 33381042 
Information from SamStat assessing the quality of the alignment by MOSAIK. Total reads gives all the reads aligned to the region by the program for all 
sample pools. The other columns provide a breakdown on the mapping qualities of these reads.  
 
Table 3.6 - SamStat mapping quality assessment for BFAST alignment of project 1 data 
 Total reads 
(all samples) 
Average reads 
per sample pool 
Average reads 
MAPQ>=30  
Average reads 
MAPQ>=20 
Average reads 
MAPQ>=10 
Average reads 
MAPQ>=3  
Average reads 
MAPQ<3 
CLU 1115695 139461.9 132052.4 (94.7%) 3788.4 (2.7%) 2552 (2.0%) 521.5 (0.4%) 122.625 (0.1%) 
PICALM 6437215 804651.9 753737.5 (93.7%) 29187.3 (3.6%) 18143 (2.2%) 2821.3 (0.4%) 762.5 (0.1%) 
rs3851179 
LD block 
1597505 199688.1 188102.4 (94.2%) 6569.8 (3.3%) 4159.5 (2.1%) 691.8 (0.3%) 164.8 (0.1%) 
CR1 5252304 656538.0 443405.5 (67.6%) 93126.3 (14.2%) 111849.3 (17.0%) 6989.9 (1.0%) 1167.1 (0.2%) 
Combined 14402719 
Information from SamStat assessing the quality of the alignment by BFAST. Total reads gives all the reads aligned to the region by the program for all sample 
pools. The other columns provide a breakdown on the mapping qualities of these reads.  
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Variant calling 
Two different variant calling platforms were utilised in the processing of the 
data from project 1 - Syzygy and CRISP. Again, CLU, the smallest of the genes 
targeted, was used as an example to determine which of these programs was 
most appropriate for our data.  
 
In the data, Syzygy identified a total of 73 variants within the BFAST aligned 
data, and 224 in the MOSAIK aligned data. CRISP identified 100 variants in 
the BFAST alignment, and 131 in the MOSAIK alignment. 
 
One way to compare the performance of the different variant calling 
algorithms is to look at the false negative and false positive rates in the 
variants identified. To look at the false negative rate, a list of known SNPs is 
needed. Although we cannot know which variants will be present within the 
samples sequenced, variants which are common within a similar population 
would be expected to be present, and so can be used to assess the false 
negative rate. A total of 24 variants with a frequency above 1% in the CEU 
population were contained within the dbSNP database at the time of analysis 
(22.09.11). The number of these SNPs which were identified in the aligned 
data for the CLU region using Syzygy and CRISP is presented in Table 3.7. 
Assessing the false positive rate is more problematic, as it is difficult to 
distinguish spurious from genuine variants without validation via an 
independent method. Table 3.7 also contains information on the number of 
novel variants (SNPs and indels) identified by each of the sequencing 
programs, which are necessarily genuine variants or false positive calls.  
 
Table 3.7 Ȯ Assessing false negative and positive variant call rates 
  No. of dbSNPs with 
MAF >1% detected 
No. of novel 
SNPs 
No. of novel 
indels 
MOSAIK Syzygy 20 142 23 
CRISP 21 20 44 
BFAST Syzygy 19 9 9 
CRISP 21 17 14 
Information on the number of false negative variant calls, and the numbers of novel 
variants detected by each of the variant calling algorithms. NB Ȯ the version of CRISP 
used in this analysis was the latest available at the time of processing. Subsequently a 
new version has been used, so the numbers of SNPs quoted here do not match the 
ones in subsequent analyses, which were run using the most up to date version of 
CRISP in November 2012. 
 
The locations of these variants were established by uploading the .bed file of 
the variants to the custom tracks section of the UCSC genome browser (Kent 
et al. 2002). Examples of the resultant images (MOSAIK aligned data, with 
variant calling by Syzygy and CRISP) are shown in Figure 3.4. 
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Figure 3.4 Ȯ Locations of variants called by Syzygy and CRISP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Images to show the locations of some of 
the variants identified by Syzygy and 
CRISP in the MOSAIK alignment using the 
ȱ ȱ  Ȃȱ ȱ ȱ
(Kent et al. 2002). The two panels show the 
same genomic location, featuring a 
repetitive stretch of DNA, and the variants 
called within this region by Syzygy (top) 
and CRISP (below) are displayed under 
ȱȱȃȱȱȄǯȱ ȱ
identified by an rs number are known 
variants which have been detected within 
our data. Any identified by chromosomal 
coordinate (Syzygy) or snp:# (CRISP) are 
novel. 
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3.5. Discussion of the Pipeline 
 
The world of NGS has progressed rapidly in the past decade, and the 
advancements in technology have been accompanied by an explosion in the 
software available to process the generated data. While GATK has been 
 ¢ȱȱȱ ȱȃȱȄȱȱȱprograms for processing NGS 
data for single individuals, it does not have the capacity to handle pooled 
data. It was therefore decided to try a number of different combinations of 
programs and establish what the best, most reliable combination of these was. 
Two different alignment programs and two different variant calling programs 
were utilised, and the best combination of programs was selected, as 
explained below.  
 
The first stage of processing NGS data is to align the data to a reference 
genome. BFAST and MOSAIK were the two programs selected for this stage. 
Each was comparable in terms of the processing power required and the time 
taken to perform the alignment, so this did not contribute to the decision 
between them.  
 
The number of dbSNP variants with MAFs >1% in the CEU population 
identified by CRISP was unaltered by the alignment program used, while 
Syzygy detected one less variant within the BFAST data than the MOSAIK 
data. In terms of the false negative rate, it was apparent from the data in Table 
3.7 that CRISP was able to identify a slightly greater number of the variants 
than Syzygy was. The maximum number of the 24 dbSNP variants detected 
was 21. It can be assumed that these are genuinely present within the samples 
sequenced; therefore anything below 21 is missing variants known to be 
present. Although the difference between variants identified by CRISP and 
Syzygy was small in the CLU region data, the same pattern was found in the 
data from the other three regions sequenced, with Syzygy consistently 
identifying fewer variants than CRISP. From this, it can be concluded that 
CRISP has a lower false negative rate than Syzygy. 
 
It is more difficult to assess the number of false positives found, since without 
comprehensive independent validation it cannot be known which variants are 
genuine and which are not. Although it is unknown how many genuine novel 
variants lay within the area, the vastly different numbers of variants called by 
the different combinations of alignment and variant calling algorithms 
highlighted that there were significant differences in performance, since only 
one (unknown) value represents the actual number of variants. The images 
presented in Figure 3.4 help explain these discrepancies. 
 
It can be seen from the top panel of Figure 3.4 that the combination of 
programs giving the highest number of novel variants (MOSAIK and Syzygy) 
is calling a vast excess of novel variants around the sites of repetitive regions 
within the gene when compared with CRISP (one example of many instances 
shown). The majority of these variants are likely to be false positive calls as a 
 
 
 
 
122 
result of difficulties aligning data around repetitive DNA (Treangen and 
Salzberg 2012). Although a much more modest number of putative SNPs were 
identified using the CRISP and MOSAIK combination, 44 novel indels were 
called. Such a high number within a small region is likely to be indicative of 
issues with alignment, rather than there being that number of genuine 
insertions and deletions present.  
 
It was therefore decided that BFAST and CRISP would be the programs of 
choice for both this NGS project, and for others going forward in the lab. The 
pipeline is displayed in Figure 3.5. 
 
Figure 3.5 Ȯ Pipeline for alignment and variant calling in NGS data 
 
Pipeline for processing NGS data as decided by a comparison of results from the 
different combinations of programs used. 
 
3.6. Applying the pipeline 
 
Once it had been decided which combination of programs would give the 
most reliable variant calls from the data we had, this was applied to the four 
loci sequenced in project 1, as well as the CR1 data from the second NGS 
project.  
 
Quality, coverage and enrichment 
The quality scores given by SamStat for the BFAST alignment of data from 
NGS project 1 were presented in Table 3.6. The same SamStat analysis was run 
when the CR1 locus data from the second NGS project was received. Table 3.8 
provides the mapping quality data for the CR1 locus from SamStat for both 
the first and second NGS projects. 
 
The data from SamStat enabled the calculation of the average depth of 
coverage per individual for each of the regions targeted. This information is 
presented in Table 3.9. 
 
However, although the average depth is reported here, the consistency of 
depth across the regions sequenced was by no means uniform. As mentioned 
previously, the repeat masker offered by Agilent was not utilised in the design 
of the first sequencing project but was in the second. However, in both 
sequencing projects, repetitive areas received virtually no coverage, even 
when directly targeted. Figure 3.6 shows images from the Integrated 
Genomics Viewer (IGV) displaying dropout in coverage around repetitive 
regions of DNA. This issue was particularly severe for CR1, which has a 
highly repetitive structure.  
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Table 3.8 - SamStat mapping quality assessment for BFAST alignment of CR1 locus from the two NGS projects 
 Total reads (all 
samples) 
Average reads 
per sample pool 
Average reads 
MAPQ>=30  
Average reads 
MAPQ>=20 
Average reads 
MAPQ>=10 
Average reads 
MAPQ>=3  
Average reads 
MAPQ<3 
Project 1 5252304 656538 443405.5 (67.6%) 93126.3 (14.2%) 111849.3 (17.0%) 6989.9 (1.0%) 1167.1 (0.2%) 
Project 2 148300000 18537500 7299770.7 (39.4%) 2702092.9 (14.6%) 3789404.8 (20.7%) 4124882.3 (22.3%) 604474.6 (3.3%) 
SamStat mapping quality score breakdown for the CR1 region from the first and second NGS projects. Total reads gives all the reads aligned to the region by 
BFAST for all sample pools. The other columns provide a breakdown on the mapping qualities of these reads. 
 
 
Table 3.9 Ȯ Average depth of coverage per individual  
 CLU PICALM rs3851179 LD block CR1 (project 1) CR1 (project 2) 
Coverage 18.1x 21.5x 21.7x 13.9x 1034.3x 
Average depth of coverage per individual across the entire targeted loci. 
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Figure 3.6 Ȯ Images from IGV to show dropout of coverage at repetitive regions 
 
                                                                                                                           ~44kb 
  Normal Coverage:                   
  Gap in CR1 (Pro1):                 
  Gap in CR1 (Pro2):                   
Images to show the dropout in coverage at repetitive regions. Top panel: representative section of CLU locus. Repetitive regions clearly coincide with reduced 
coverage in the IGV graph. Red boxes highlight these regions. Lower panel: three IGV graphs, the top showing a normal region of genomic DNA, with good 
coverage in general, but some areas of lower coverage where repetitive regions fall. The lower two show a region of CR1 coinciding with the tandem repeat 
responsible for the different isoforms of CR1 where coverage was particularly poor in each of the sequencing projects. 
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The information on reads from SamStat allowed for the analysis of the 
efficiency of the enrichment process. Firstly, the enrichment factor could be 
calculated. This is a comparison of the depth of coverage at the targeted 
regions versus the depth of coverage across the genome as a whole. For the 
first sequencing project, the enrichment factor was 321.9x, while for the second 
sequencing project, it was 6271.5x (data to calculate this provided by colleague 
James Turton: total reads 1949915034; reads mapping to regions of interest 
1209121676; combined size of regions of interest 832825bp). The percentage of 
reads mapping to the target region also signals how well the enrichment stage 
of the experiment worked. From the first sequencing project, 3.9% of the total 
reads produced mapped to the targeted regions. For the second project, this 
figure was 62.0%. 
 
Variants identified 
The number and types of variants detected by CRISP in each of the regions 
sequenced are presented in Figure 3.7, divided in to exonic and non-exonic 
variants, and containing details on the number of novel vs. known variants 
encountered. Excluding the 3'UTR SNPs, only 10% of the detected exonic 
variants were novel, while this figure was 23.8% for the non-coding ones. 
 
The numbers of HapMap SNPs with frequencies >5% identified in the regions 
is presented in Table 3.10.  
 
Table 3.10 Ȯ HapMap SNPs detected in NGS data 
 CLU PICALM rs3851179 
LD block 
CR1 
project 1 
CR1 
project 2 
No. of HapMap 
SNPs in region 
20 117 34 75 75 
No. detected in NGS 
data 
20 117 34 70 67 
Numbers of HapMap SNPs with frequencies >5% in the EUR population within the 
targeted loci, and how many of these were detected within the NGS data for those 
regions.  
 
Ts/Tv Ratios 
The Ts/Tv ratio was calculated separately for exonic and non-exonic regions. 
Across the four sequenced loci, there were 27 exonic transitions and 5 exonic 
transversions, while there were 555 non-exonic transitions and 352 non-exonic 
transversions. This gives a Ti/Tv ratio of 5.4 for exonic areas and 1.58 for non-
exonic ones.  
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Figure 3.7 Ȯ Variants identified at each locus sequenced 
 
 
 
Breakdown of the variants detected in the NGS data after the application of the data 
analysis pipeline. Panel A shows the variants in CLU, panel B shows the breakdown 
of variants at the PICALM locus, as well as the rs3851179 LD block (all variants non-
coding, as the region is ~88.5kb upstream of the gene). Panel C shows the results for 
the CR1 region from the first sequencing project, while panel D shows the variants 
ȱȱȱȱȱȱȱ	ȱǯȱȱ¢ȱȱȱȱȃȄȱ
were found to have no co-ȱȱ¢ȱȂȱǯȱ 
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HapMap Correlation 
As mentioned previously, a good way to assess the reliability of NGS data is 
to compare it to known variants. In order to assess the accuracy of the 
frequency estimates from CRISP, MAF estimates (based on percentage of 
alternative reads Ȯ a surrogate for MAF) from CRISP for the common SNPs 
called in the three genes were compared with frequencies from HapMap (EUR 
population). The relationships between these frequencies for each of the 
targeted areas are shown in Figure 3.8.  
 
Figure 3.8 Ȯ Correlation between CRISP frequency estimates and HapMap 
frequency data 
CLU         PICALM 
 
rs3851179 LD block      CR1 Ȯ Project 1 
 
CR1 Ȯ Project 2 
 
Comparison of frequency estimates from CRISP with MAF data from the HapMap 
project (EUR population) for common SNPs within targeted loci. On each graph, the x 
¡ȱ ȱȱȂȱȱȱȱǰȱ ȱȱ¢ȱ¡ȱ ȱȱ
ȱ
CEU allele frequencies. 
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MAFs from the 1000 genomes project (European population) were also 
compared to the frequency estimates from CRISP for all of the detected 
variants in the targeted loci (data from NGS project 2 used for CR1). Due to 
the high number of variants this entails, the data is not shown here, but upon 
analysis in SPSS, a strong, significant positive correlation was observed 
between the frequencies of the two datasets (Spearman Correlation 
Coefficient=0.964, p=<0.001). 
 
3.7. Discussion of applied pipeline 
 
The major aim of this stage of the study was to identify variants, an aim which 
was clearly met with the detection of over 1000 variants in the four targeted 
loci, 239 of which were potentially novel variants. The inclusion of the CR1 
target locus in two separate sequencing project allowed an assessment of the 
advances in technology which had been achieved in just a small period 
(approximately 10 months between the running of the two projects).  
 
One of the major differences in the CR1 data from NGS projects 1 and 2 is in 
the sheer quantity of data generated. The total number of reads generated by 
the first project was ~380 million, while the second project generated ~1209 
million reads. When considering the aligned data, the 5.25 million 38bp reads 
mapped to the CR1 region from the first sequencing project are eclipsed by the 
148.3 million 100bp reads mapped to the equivalent region in the second 
project. The CR1 data from the first project had a greater proportion of reads 
awarded the highest quality scores than did the second project, but because 
the second generated such an increased quantity of data, far more reads in 
total from the second project achieved the highest mapping quality (>=30).  
 
From the first sequencing project, CLU, PICALM and the rs3851179 LD block 
received a reasonable level of coverage. Generally, between 20 and 30x per 
individual is considered to be adequate for reliable variant identification. 
PICALM and the rs3851179 LD block both exceeded this lower recommended 
limit of 20x per individual, while CLU was close to this (18.1x). CR1 however 
fell short of this target, receiving an average of just 13.9x per individual. 
Because of this particularly poor coverage, it was decided that CR1 would be 
included in the second NGS project being conducted by a colleague in the lab. 
It was hoped that the issues of the first project would not be repeated in the 
second (this time the repeat masker was utilised, the enrichment process was 
conducted by Agilent themselves, and a newer sequencing technology with 
far superior capacity was utilised, with a longer read length and paired-end 
reads). This was indeed shown to be the case, with CR1 receiving an average 
coverage of 1034.3x per individual in the second sequencing project.  
 
However, the second sequencing project did not successfully address the 
other coverage issue with CR1. This issue stems from the structure of the gene, 
and its highly repetitive nature. As the top panel of Figure 3.6 shows, even in 
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the first project where repetitive regions were included in the design of the 
baits, repetitive areas received virtually no coverage. The inclusion of such 
regions in the experimental design is likely to be in part responsible for the 
poorer than expected coverage of the targeted areas obtained, and the fact that 
only 3.9% of reads mapped to the target regions. This figure is far less than 
Agilent's estimated on target return of 60% (from the SureSelect product 
information) or 40-50% reported by Gnirke et al. (Gnirke et al. 2009), the 
publication of the SureSelect technique. Another study published in 2010 
explored the issue of the repeat masker. As with our explorations, this group 
also found Agilent's repeat masking strategy to be overly conservative, so 
opted for their own custom repeat masking approach, and reported around 
20% of reads mapping to target regions (Kenny et al. 2010).  
 
The inclusion of repetitive sequences in the bait design essentially wastes 
sequencing capacity. A run on an NGS machine will generate a specific, finite 
quantity of data. Whatever proportion of the reads are generated from 
repetitive regions of the genome is essentially a proportion of the reads that 
are lost. Reads with multiple matches across the genome during the alignment 
process cannot be successfully mapped, and will therefore be lost, reducing 
the sequencing capacity available for reads which can be mapped. 
Additionally, allowing these repetitive regions to be included in the bait 
design will have reduced the specificity of the capture, as non-target, similar 
DNA will also have been pulled down, reducing the recovery of the true 
target region, and limiting the number of reads which could be uniquely 
mapped. 
 
The utilisation of the repeat masker in the second sequencing project meant 
that a minimal amount of reads were lost in this way, which is reflected in the 
much more respectable percentage of reads on target of 62%.  
 
However, there was still a major issue with the coverage of CR1, which is 
shown in the lower panel of Figure 3.6. The IGV graph at the top of this panel 
shows what a normal region of the genome would be expected to look like 
when sequenced in this way, with a high level of coverage across the region in 
general, along with a few areas of lower coverage, likely to be due to 
repetitive sequence. The lower two IGV graphs show a region of CR1, 
spanning a region of around 44kb from each of the two NGS projects. Here 
there was virtually no coverage, with very few reads at all mapping to the 
area. This problematic region stems from the structure of the CR1 gene, which, 
believed to have arisen through a sequence of segmental duplication events 
over time, is highly repetitive. The CR1 protein isoforms differ in the number 
of C3b binding sites present, and the different alleles are thought to have 
arisen from unequal crossover events involving a stretch of DNA encoding 
this, making the region problematic for sequencing. 
 
This problem is only exacerbated by the utilisation of the pooled sequencing 
strategy. Given the frequencies of the F and S alleles in European populations 
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(0.83 and 0.15 respectively), it is highly likely that each pool of 12 individuals 
(and thus 24 alleles) contains both the F and S alleles of the gene. Across the 
experiment as a whole (96 individuals, or 192 alleles), it is likely that the rarer 
genotypes will also feature. There is currently no way to disentangle which 
individuals have which genotypes from the pooled data based on the NGS 
data alone, and  no way to tell which alleles are present in the sample pools. A 
recent study which used multiplex amplicon quantification to distinguish F- 
and S- alleles found an association between the S-allele (with an extra C3b 
binding site) and increased AD risk (Brouwers et al. 2012), however, with our 
methodology it was not possible to determine genotypes for this 
polymorphism within sample pools, let alone within individual samples. 
 
When repetitive DNA comprises such a large proportion (~50% (Treangen and 
Salzberg 2012)) of the human genome, these regions cannot simply be ignored, 
but nor can they be accurately sequenced, given the current technology and 
data analysis methodologies available. The CR1 example above demonstrates 
that repetitive DNA can be biologically important and disease relevant, but 
whether this is a common phenomenon or an isolated example remains to be 
seen. 
 
Aside from this region, the performance of the second project was 
significantly greater than the first, with a much greater volume of data 
generated; well over half of that data mapping to the regions of interest; a 
robust enrichment factor (almost 20x greater than that of the first project); and 
a high level of coverage across the targeted loci (with the exception of the CR1 
repeat region). It is likely that the reasons for these improvements are three 
fold. Firstly, the huge increase in data produced is a reflection of the vast 
advances in NGS in just a small amount of time (less than one year). Better 
technology and improvement in the chemistry of the sequencing reactions in a 
short space of time lead to a leap from a single sequencing run producing ~380 
million 38bp single-end reads to ~1209 million 100bp paired-end reads. 
Secondly, the enrichment performed by Source for the first sequencing project 
did not seem to have worked as effectively as the one performed by Agilent 
for the second sequencing project. Finally, the repeat masker not being utilised 
in the design of the first project almost certainly had a negative effect on the 
specificity of the enrichment, and on the following data analysis.  
 
Over 1000 variants were identified by CRISP in the four target loci. Given that 
a much smaller proportion of the targeted regions were coding than non-
coding, it is unsurprising that the majority of variants identified by CRISP fell 
either up- or down-stream of the genes, or in intronic regions. Only 10% of the 
coding variants detected were determined to be novel by the VEP, whilst 
almost a quarter of the non-exonic ones were. There are likely to be a number 
of reasons for this. Historically, and even now, reflected in the popularity of 
whole exome sequencing, non-coding regions have been far less extensively 
investigated than coding ones. Coding regions are more likely to have been 
subjected to sequencing, and thus coding variants are more likely to already 
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be known. By the same logic, non-coding variants are less likely to be known, 
and perhaps also suffer from a reporting bias, with coding variants more 
likely to have been recorded and reported in the literature. However, it is also 
likely that non-coding regions contain genetic features which predispose to 
false-positive variant calls, such as indels and mononucleotide repeats, which 
will be discussed in further detail in Chapter 4 Ȯ Sanger Validation.  
 
The Ts/Tv ratios calculated for the variants detected were 5.4 for exonic 
regions and 1.58 for non-exonic regions. The estimates from 1000 genomes 
data puts the genome average to be ~2.1, although exonic regions tend to be 
higher (Le and Durbin 2011). Our variants show a trend in the right direction, 
with exonic regions having a higher ratio than non-exonic regions, but the 
non-exonic rate is lower than expected, and the exonic rate higher than 
expected (although the latter was based on a small number of sites). Ts/Tv 
ratios deviating significantly from the expected can be an indicator of 
unreliable variant calls (e.g. high false-positive or false-negative rates), which 
should be kept in mind when assessing the reliability of our variants. 
 
When considering the amount of known HapMap SNPs with frequencies 
greater than 5% in the European population, all variants were detected in the 
NGS data for CLU, PICALM and the rs3851179 LD block. For CR1, the first 
project missed five of 75 variants, while the second missed eight. Since the 
extra three of these variants were identified in the first project, it can be 
assumed they are present in the samples sequenced. Two of the missing three 
fell close together within a repetitive area which was not targeted by the 
second project due to the repeat masker. The third of these was in a targeted 
area, but was not identified. The numbers of exonic variants identified in CR1 
was very similar between the two projects. The major difference in variant 
calls between the first and second projects was in the number of non-coding 
variants, and particularly in the novel ones. In the first project's data, out of 
the 425 variants identified in non-coding regions, 151 were novel, meaning 274 
known variants were also found. In the second project, out of the 280 non-
coding variants, just 58 were novel, with 222 known. This gives a percentage 
of novel variants of 35.5% for project 1 and 20.7% for project 2.  
 
The reduction in known variants found between the two projects stems 
mainly from the inclusion of the repeat masker in the second project Ȯ many of 
the variants found in project 1 but missed by project 2 were in repetitive 
regions, and therefore were not targeted in the second. This does provide an 
argument in favour of not using the repeat masker in the design of baits, since 
more variants were found when the repetitive areas were included, although 
the necessary trade off in reducing the specificity of the enrichment may not 
be worth the gain.  
 
Less novel variants being detected in CR1 by the second project is likely to 
signify a decrease in the number of false positive variant calls being made. The 
35.5% of variants identified in the non-coding region for the first sequencing 
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attempt of CR1 is much higher than for the other regions sequenced in that 
study (CLU Ȯ 25.3%, PICALM Ȯ 26.0%, rs3851179 LD block Ȯ 20.4%), while the 
figure of 20.7% of variants detected being novel from the second project is 
more consistent with these. The major difference in the design of the projects 
is in the inclusion of the repeat masker in the second project, which would be 
expected to decrease the novel and known SNPs identified approximately 
equally, so the percentage of novel variants identified should be 
approximately equal between the two projects. Since this is not the case, and 
the percentage of novel variants in the second project is much lower than that 
from the first, the most probable explanation for the pattern of data observed 
is that the second project gave less false positive calls.  
 
Although information was lost, in that more known common dbSNP variants 
were missed in the calling of the second project's variants, and around 50 
known variants were missed, the false positive rate being lower is reflective of 
the better quality enrichment, greater coverage, increased quantity of data and 
more robust sequencing technology. An average coverage of 13.9x (as from 
the first project) was bound to give false positive calls, as it is far below the 
recommended depth for accurate calls of 20-30x. It is arguably better to 
sacrifice the identification of a number of known variants, than to have a huge 
quantity of novel variants, if many of those are likely to be false positive calls.  
 
It has previously been reported that frequency estimates from pooled NGS 
data can be generally regarded as reliable (Ingman and Gyllensten 2009; 
Bansal et al. 2011; Day-Williams et al. 2011). Frequency estimates from CRISP 
rely on certain assumptions being made. Largely, it is assumed that the 
number of reads is a reliable reflection of the frequency of variants being 
detected. This in turn is based on the assumption that each individual's DNA 
has equal representation within the pool. Whilst steps were taken to ensure 
that was the case (e.g. quantification using QuantIT, pooling samples of 
similar concentrations together, and maintaining a minimum pipetting 
volume of 1“μl to minimise pipetting errors), it cannot be guaranteed. 
Unreliable quantification or inaccurate pool preparation could lead to some 
individual's DNA samples being over- or under-represented in the initial 
sample pool. Even given equality at this stage, there is the possibility that 
naturally occurring variation may affect the efficiency of the enrichment 
process. The baits designed to capture the regions of interest by Agilent are 
complementary to the standard reference genome. Although their large size 
(120mer) is designed to minimise the chance of this happening, it is possible 
that deviance from the standard reference genome could destabilise the 
coupling of the RNA baits with the desired DNA targets, creating an enriched 
pool of DNA biased towards the wild type. While single SNPs are unlikely to 
have this effect in such large baits, insertions, deletions, or the occurrence of 
multiple variants within a specific bait's target could cause issues, and result 
in unequal representation of samples within the pools. Another potential 
source of such bias is differential amplification at the PCR stage of the 
enrichment process, which could lead to certain templates being under- or 
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over-represented. Any deviance from equal representation could skew the 
frequency estimates from CRISP, which are based on the number of reads in 
possession of alternate allele calls. In a pool of 12 individuals, or 24 alleles, 
each allele should contribute to 4.2% of reads. If the DNA of an individual 
with a specific variant is not equally represented within the pool, there will be 
deviance from this figure.  
 
Strong correlation scores were found between the frequencies of the common 
HapMap SNPs for CLU, PICALM and the rs3851179 LD block. The frequency 
correlation is stronger for the CR1 project one data than for the second 
Ȃȱǯ However, the second project is based on a smaller number of 
ȱ ǰȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȃȱ
data. It is also likely that any biases in the pooling or enrichment in the second 
project would have been amplified by the vast quantity of data produced, 
explaining why the frequency estimates may be less reliable. Since reliable 
estimation of frequency was not the aim of this project, the lower reliability is 
not an important factor. The data from the second project appeared more 
reliable for variant identification, which was the aim of the study. 
 
The HapMap correlations are only based on a small number of variants, all of 
which can be classed as common. For a more complete picture, the frequencies 
of all known variants detected in the NGS data were compared with the 
frequency data from the 1000 genomes project. Here, a strong, positive, 
significant correlation was found, indicating that the CRISP frequency 
estimates can be regarded as reliable. A further assessment of the accuracy of 
CRISP frequency estimates is given in the discussion of Chapter 4 Ȯ Sanger 
validation. 
 
It is also worth noting that while a good correlation in frequencies is indicative 
of reliable frequency estimates, deviance from correlation can be not only an 
indicator of unreliable frequency estimates, but of association with AD. Since 
the 1000 genomes project used population controls for their samples and the 
NGS projects used AD samples only, differences in allele frequencies between 
the two could be an indicator of involvement in AD risk. However, in just 96 
samples, there is insufficient power to deduce any real information on this.  
 
To summarise, this chapter has explored the process of analysing pooled NGS 
data. A variety of programs were utilised and their performance compared to 
enable the development of a robust pipeline for analysing such data. When the 
pipeline was applied, over 1000 variants were detected within the data. The 
quality of the raw data, the alignments and the variant calls were assessed and 
were generally found to be good, although coverage in the CR1 region was 
extrememly uneven, leaving large areas of the gene effectively not sequenced. 
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4. Sanger validation 
 
Given the current high error rates of NGS technologies and issues achieving 
accurate alignment, particularly around repetitive regions (Treangen and 
Salzberg 2012), validation of putative variants detected in NGS data via an 
independent method is important. With over 1000 variants detected, 
independent validation of all variants would be prohibitively time consuming 
and expensive. This chapter explores the Sanger sequencing of certain 
variants, which were selected for validation based on the possession of 
unusual characteristics. 
 
4.1. Results of Sanger validation 
 
Within the data, there were a number of variants identified which were 
ȱȱȱ¢ȱȂȱǰȱȱ ȱȱ ȱȱȱȱȱ
our sequencing pools, with MAF estimates ranging from 5% to 24%. It seemed 
highly unlikely that variants with such frequencies would not have been 
previously documented were they genuine SNPs, so they were highlighted as 
being potential false positive calls, and validation via Sanger sequencing was 
sought.  
 
Seven ȱ ȱ  ȱ ȱ ǻȱ  Ȃȱ ȱ ȱ ȱ ȱ
within Table 4.1 is classed as targeted). Since several other variants identified 
by CRISP fell within the region sequenced, these were also analysed, taking 
the total number of SNPs considered to 12. Information on all of these variants 
is provided in Table 4.1.  
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Table 4.1 - Information on SNPs for validation by Sanger sequencing  
Gene Chr Coordinate Alleles 
Frequency 
Alternative Calls 
Fold Coverage 
per individual Location in gene* rs number 
Inclusion in 
project 
CLU 
  
  
  
8 27452179 G/T 0.07 23.69 3.5kb downstream   Targeted 
8 27452243 A/T 0.05 24.13 3.5kb downstream   Incidental 
8 27466924 C/A 0.11 17.89 Intron 2   Targeted 
8 27473743 T/A 0.19 18.11 1.5kb upstream   Targeted 
PICALM 
  
  
  
  
  
11 85668102 G/A 0.11 16.74 1.5kb downstream    Targeted 
11 85668163 G/A 0.27 19.11 1.5kb downstream  rs622110 Incidental 
11 85692077 C/T 0.05 22.90 Intron 18 rs139710547 Targeted 
11 85692181 A/C 0.63 18.46 
Exon 18 
(synonymous) rs76719109 Incidental 
11 85774424 T/G 0.24 16.41 Intron 2   Targeted 
11 85774562 T/G 0.46 18.55 Intron 2 rs3016786 Incidental 
CR1 
  
1 207690803 T/C 0.07 19.57 Intron 4 rs144047769 Targeted 
1 207690871 G/C 0.19 18.40 Intron 4 rs10863358 Incidental 
Information on all of the SNPs for which validation by Sanger sequencing was attempted. Coordinates stated give genomic position in hg19. *Relative to CLU 
transcript ENST00000316403, PICALM transcript ENST00000447890, CR1 transcript ENST00000367049. Distances stated are approximate. 
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Of the 12 putative SNPs included in Sanger sequenced regions, six were found 
to be genuine (see Figure 4.1 and Table 4.2).  Reliability of frequency estimates 
could also be assessed once the number of actual alternative alleles in a pool 
was established by Sanger sequencing. Each alternative allele should 
contribute ~4.2% of reads to the pool total, assuming equal representation. The 
relationship between the number of actual alternative alleles and the 
proportion of NGS reads they make up is shown in Table 4.2. 
 
Figure 4.1 Ȯ Sanger validated SNPs 
PICALM 
11:85668163 Ȯ C/T 
WT                            Heterozygous       Homozygous Mutant 
     
 
11:85692077 Ȯ C/T                                      11:85692181 Ȯ A/C 
WT        Heterozygous                 WT         Heterozygous 
       
 
11:85774562 Ȯ T/G 
WT                          Heterozygous        Homozygous Mutant 
     
 
CR1 
1:207690803 Ȯ T/C                              1:207690871 Ȯ G/C 
WT                        Heterozygous             WT                      Heterozygous 
              
Images showing electropherogram traces from the successfully Sanger validated SNPs 
in PICALM and CR1. Where all three allelic combinations were found, all three are 
shown. 
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Table 4.2 Ȯ Successfully validated SNPs 
Chr Coordinate Alleles 
Alternative Allele 
Call Frequency 
(CRISP - all pools) 
1000 
genomes 
MAF (EUR) 
Alternative Allele Call 
Frequency (CRISP - 
sequenced pool) 
Alternative Alleles 
(Sanger - 
sequenced pool) 
Alternative Allele 
Frequency (Sanger 
Ȯ sequenced pool) 
11 85668163 G/A 0.268 0.244 0.707 10 0.417 
11 85692077 C/T 0.046 0.016 0.103 3 0.125 
11 85692181 A/C 0.632 0.583 0.929 19 0.792 
11 85774562 T/G 0.460 0.422 0.362 10 0.417 
1 207690803 T/C 0.067 0.021 0.333 3 0.125 
1 207690871 G/C 0.194 0.214 0.050 4 0.167 
SNPs which were successfully validated by Sanger sequencing. The number of alternative alleles within the pool sequenced facilitated the determination of 
the genuine MAF within that pool (assuming Sanger results reflect true allelic counts).  This was then compared to the alternative allele call frequency from 
the same pool in CRISP, giving a reflection of the accuracy of the CRISP frequency estimates at a much finer level than the total 96 samples allows. 
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Three of the remaining SNPs were not found to be present in the samples 
Sanger sequenced, but instead small indels were found at the suggested 
variant sites (all which were also called by CRISP). These variants are 
summarised in Table 4.3, with examples from the Sanger sequencing shown in 
Figure 4.2.  
 
Figure 4.2 Ȯ Sanger confirmed indels miscalled as SNPs 
CLU 
8:27452179 Ȯ Called as G/T SNP, actually +T indel 
WT                                        Homozygous +T 
       
 
8:27452243 Ȯ Called as A/T SNP, actually +T indel                                    
WT                         
 
Heterozygous +T 
      
 
PICALM 
11:85774424 Ȯ Called as T/G SNP, actually -TA deletion 
WT (3x TA repeats)                     Homozygous (2x TA repeats) 
    
Heterozygous (one allele with 2x TA and one with 3x TA repeats) 
 
Electropherograms showing the absence of the SNPs predicted by CRISP, but 
featuring genuine indels at the same site. Where individuals heterozygous for the 
indels are shown, the sequence traces for each allele following the site of the indel will 
be offset by the number of bases the indel contains.  
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Table 4.3 Ȯ Sanger validated indels 
Chr Coordinate 
CRISP 
called 
SNP 
Actual 
Variant 
Indel 
coordinate 
Indel 
MAF 
(CRISP) 
1000 
genomes 
MAF (EUR) rs number  
Indel MAF 
(CRISP - 
sequenced pool) 
Alternative 
Alleles (Sanger - 
sequenced pool) 
Indel MAF 
(Sanger Ȯ 
sequenced pool) 
8 27452179 G/T +T ins 27452180 0.145 0.26 rs146954978  0.232 3 0.125 
8 27452243 A/T +T ins 27452242 0.099 0.17 rs35598594 0.115 1 0.042 
11 85774424 T/G -TA del 85774420 0.42  Not 
available 
rs112671434  0.455 17 0.708 
Details of the indels discovered at the sites of false positive SNP calls, all of which were also identified by CRISP and had been previously recorded in dbSNP. 
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The final three SNPs (8:27466924, 8:27473743 and 11:85668102) were not 
validated by Sanger Sequencing. Figure 4.3 shows examples of some of the 
sequencing traces from these variants (NB Ȯ reverse primer used in 
sequencing of 8:27466924 and 11:85668102, so sequence shown is the reverse 
complement to the standard genome oriented sequence). All three of these 
putative variants occurred adjacent to mononucleotide polyA repeats, with 
numerous other potential variants in the immediate area, called by CRISP or 
present in dbSNP 134 (see Figure 4.4). Within each of the polyA repeats, 
CRISP also called a +A insertion. There are also multiple +A insertions 
reported in dbSNP for each of the mononucleotide repeat sites, which 
suggests these may be genuinely variant. Due to the issues even Sanger 
sequencing has in dealing with mononucleotide repeats, our findings were 
inconclusive as to whether there were genuine variations in the number of A 
nucleotides present at these sites. 
 
Figure 4.3 Ȯ Electropherograms showing mononucleotide repeat regions 
CLU 
8:27466924 Ȯ Called as G/T SNP                                        
 
8:27473743 Ȯ Called as T/A SNP 
 
PICALM 
11:85668102 Ȯ Called as C/T SNP 
 
Electropherograms to demonstrate the failure to validate SNPs identified in the data 
by CRISP. In each of the instances, the false positive SNP call occurred at the location 
of a stretch of mononucleotide repeats. The stars in each case mark positions which 
are potentially heterozygous, given the offsetting of the sequence for the two alleles 
beyond these points, but may just be due to slippage in the sequencing because of the 
repetitive nature of the region, making homozygous DNA appear heterozygous. NB Ȯ 
sequencing of variants 8:27466924 and 11:85668102 was conducted using the reverse 
sequencing primer as this gave a more clear picture of the sequence at the site of the 
variant (because the variant fell before the mononucleotide repeat stretch when 
sequenced from this direction) so the sequence shown for these two is the reverse 
complement of the sequences displayed in Figure 4.4. 
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Figure 4.4 - Sequence context of spurious SNPs called next to 
mononucleotide repeats 
 
Sequence context of the three SNPs next to mononucleotide repeats which failed 
validation by Sanger sequencing. The SNP shown in bold is the variant Sanger 
sequencing was designed to validate. Variants shown below the sequence are all 
present in dbSNP. A. False C/A variant call within CLU at position 8:27466924 
(8:27466910-27466925 shown). B. Spurious T/A SNP call in CLU at 8:27473743 
(8:27473741-27473756 shown). C. False positive SNP call at position 11:85668102 
within PICALM (11:85668090-85668104 shown). *Other variants called by CRISP. 
 
4.2. Discussion of Sanger validation 
 
Despite the immense power of NGS, and the capacity it has to revolutionise 
genetics, there is still a limitation in terms of the error rate, which compared to 
Sanger sequencing, is still very high. Although great progress has been made 
in terms of decreasing this error rate through technological and chemical 
advances, as well as through improvements to alignment and variant calling 
softwares, there still remains an uncertainty in variant calls, which can only 
really be alleviated by validating these variants via an independent method. 
Because even modestly sized NGS experiments can generate a huge quantity 
of variant calls, the cost and time involved in validating each by Sanger 
sequencing is prohibitively high. Whilst the comparison with the data from 
the exome project (discussed in Chapter 5 Ȯ Exonic variants) allowed a 
pseudo-validation of the majority of variants detected within the exons of the 
genes of interest, there were still a high number of unvalidated variants.  
 
Of the variants identified in the first sequencing project, a number stood out as 
ȱ ȱ ǯȱ ȱ  ȱ ȱ  ȱ Ȃȱ ȱ
identified as being novel (although some subsequently proved to have been 
given rs numbers), yet were identified within multiple pools in our cohort, 
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suggesting they would be at a high frequency in a comparable population, 
thus seeming unlikely they would not have been previously identified.   
 
Half of the putative SNPs in the Sanger sequenced regions were validated as 
being genuine SNPs, but this included only two which were deliberately 
targeted for validation, and almost all of the variants which were incidentally 
sequenced as they fell within the amplicons to be sequenced. Bansal et al. 
estimated a false positive rate of <1% using CRISP (Bansal et al. 2011), which is 
significantly lower than our 50% error rate. However, our rate would be 
expected to be higher than this, since many of the SNPs selected for validation 
were in possession of unusual characteristics (e.g. being present in all pools 
sequenced).  
 
The location of these variants relative to the major transcripts of their 
respective genes is given in Table 4.1. The majority are deeply intronic, so are 
unlikely to be affecting splicing activity. One variant (11:85668163) falls 
around 1.5kb downstream of PICALM, where it is not likely to be affecting the 
Ȃȱ ȱ ȱ ǯȱ ȱ ȱ ȱ ȱ  ȱ ȱ ȱ ȱ ȱ
conservation. The other SNP, at 11:85692181, is a synonymous exonic change, 
which whilst not affecting the primary sequence of the protein, could be 
having an effect on splicing regulatory elements. This will be discussed in 
further detail in Chapter 5 Ȯ Exonic variants. 
 
The remainder of the potential SNPs sequenced did not turn out to be 
genuine. These constitute false positives. However, three of these transpired to 
be next to genuinely variant sites of small indels; two +T insertions and a ȮTA 
deletion, all of which had been previously documented and were identified by 
CRISP.  
 
The final three putative SNPs which were not validated were each next to a 
string of polyA mononucleotide repeats. These repeats are too small for the 
issue to be solved by masking repeats in the design of SureSelect baits. Unlike 
longer repeats, short stretches of mononucleotide repeats do not make 
alignment of reads impossible, as enough unique sequence is present, even in 
short 38bp reads to allow mapping. It is likely that these are genuinely variant 
sites, since CRISP calls +A insertions within each of them, and all have 
multiple rs number +A insertions falling within the repeat region. However, 
the problems presented by repetitive DNA even to the relatively robust 
Sanger sequencing meant it was not possible to tell whether these sites were 
polymorphic in our samples, or whether apparent variance was simply an 
artefact of slippage during Sanger sequencing or PCR amplification (Clarke et 
al. 2001) 
 
The main message from these findings is that it is important to be aware of 
documented indels and mononucleotide repeats within regions being 
sequenced, as these could cause potential issues with accurate identification of 
variants, and any variants called at such sites should be pursued with caution 
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and independently validated before making any assumptions about their 
existence.  
 
ȱ ȱ ȱ ȱ ȱ ȱ  ȱ ȱ Ȃȱ ȱ
estimates and those from the HapMap and 1000 genomes projects suggests in 
general our method was reasonably accurate at establishing the frequency of 
variants, Sanger sequencing allowed the determination of the exact number of 
alternative alleles within a pool. This meant that the actual percentage of 
ȱȱȱ¢ȱȱȱȱȱȱȱȂs 
estimate for that pool. Frequency estimates from pooled data are based on the 
assumption that each allele contributes equally to the total number of reads. If 
this assumption is incorrect, frequency estimations will not be accurate. For 
the majority of the variants considered in this study, there is a discrepancy 
between the number of alternative alleles within the Sanger sequenced pools, 
and the frequency estimation from CRISP, which could indicate the 
assumption is invalid and alleles are not equally represented. This could occur 
as a result of inaccurate pooling, resulting in DNA from certain subjects being 
over or under represented. Alternatively, it may reflect inherent biases in the 
target enrichment or NGS processes if DNA from certain individuals is 
captured or sequenced to a lesser extent. The more samples included in a 
study, the more accurate estimations of frequency will become (Ingman and 
Gyllensten 2009), so when the full 96 are considered, frequency estimates 
improve, but this does not mean samples are being equally represented, which 
should be acknowledged during analysis. Although keeping the number of 
samples per pool small maximises the chance of identifying variants, it 
reduces the reliability of frequency estimates for those pools. 
 
With a sample size of 96, no meaningful association testing can be conducted 
using the NGS data alone, as there would simply be insufficient power. A 
much larger cohort is needed to facilitate meaningful association testing. This 
could be achieved by genotyping detected variants in a large case-control 
cohort. However, given the financial and time costs of such a study, it is 
impractical to conduct this for all of the variants detected. Methods for 
prioritising variants, and of association testing without extensive genotyping 
are explored in Chapters 5 and 6.  
 
This chapter has detailed the Sanger sequencing experiments done to validate 
variants identified by CRISP within the NGS data. While six variants were 
established to be genuine SNPs, the majority of those with unusual 
characteristics (common in our samples, but novel) were revealed to be false 
positive SNP calls at the sites of either small indels or strings of 
mononucleotide repeats, highlighting the importance of awareness of such 
genetic features when conducting NGS experiments.   
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5. Exonic variants 
 
This chapter explores the exonic variants detected within the NGS data. 32 
such variants, falling within coding regions or UTRs of CLU, PICALM and 
CR1 were identified. These variants were investigated for any potential 
relationship with AD using a two-pronged approach, firstly, testing them for 
association with AD in an imputed data set, and secondly, exploring potential 
functional implications of the variants using various in silico resources.  
 
5.1. Identification of exonic variants 
 
Ȃȱȱ ȱȱȱȱ ȱȱȱȱȱ ȱ
the three targeted genes fell within exonic regions (coding variants, and those 
ȱ ȱ řȂȱ ȱ śȂȱ Ǽǯȱ ȱ ȱ ȱ ȱ ȱ ȱ śǯŗǰȱ ȱ  ȱ
information on their frequencies, validation status and LD. Where the variants 
lie in relation to the genes is depicted in Figure 5.1. Testing the variants for 
association with AD was facilitated by imputing the variants in a GWAS 
dataset. The results of this are shown in Table 5.2. Table 5.3 is provided as a 
ȃȱ ȱ Ȅȱ ȱ ȱ ȱ ȱ ȱ  ȱ ȱ ȱ ȱ
genuine associations with AD, showing imputation and association testing 
outcomes for the three GWAS SNPs which first implicated CLU, PICALM and 
CR1 in AD risk, along with findings for the APOE SNPs rs429358 and rs7412 
which dictate the different alleles of APOE. A summary of the investigations 
ȱ ȱ Ȃȱ ¢ȱ onality using in silico resources are presented in 
Table 5.4, followed by more detailed explanations of some of these.  
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Table 5.1 - Exonic variants detected in NGS data 
Variants Coordinate Ref/Alt rsID 
CRISP 
freq. 1kg freq. 
Exome 
validated 
LD with GWAS 
SNP (r2) 
LD with GWAS 
ȱǻȂǼ 
CLU coding 27457477 G/A rs9331939 0.017 0.007 Yes 0.018 1 
27462481 A/G rs7982 0.609 0.606 Yes 0.976 0.998 
27462662 G/A rs41276297 0.005 0.004 Yes 0.006 1 
CLU řȂȱ 27454493 T/C - 0.010 - Yes - - 
27454575 C/T rs10503814 0.047 0.042 Yes 0.024 0.852 
27454682 G/A rs9331950 0.207 0.219 Yes 0.171 1.000 
27454686 T/C rs9331949 0.030 0.033 Yes 0.015 0.790 
27454730 A/G rs150082283 0.013 0.008 Yes 0.004 1.000 
27454877 A/G rs9331947 0.026 0.050 Yes 0.055 0.816 
27454957 A/G rs9331945 0.005 0.013 Yes 0.008 1.000 
27455114 A/G rs9331942 0.027 0.038 Yes 0.017 0.806 
27455442 T/C rs3087554 0.131 0.161 Yes 0.134 1.000 
27455570 C/T - 0.004 - Yes - - 
PICALM 
coding 
85685793 G/A - 0.008 - Yes - - 
85685820 T/C - 0.005 - No - - 
85692181 A/C rs76719109 0.630 0.583 Yes 0.005 0.076 
85707933 C/A - 0.004 - Yes - - 
85725937 C/T rs592297 0.838 0.818 Yes 0.812 0.259 
CR1 coding 207669717 G/C - 0.508  - * - - 
207679307 A/G rs4844600 0.371 0.784 Yes 0.828 1 
207760772 A/G rs61734514 0.038 0.016 * 0.003 1 
207760773 C/T rs3737002 0.269 0.269 * 0.084 1 
207760906 T/C rs61734513 0.021 0.004 * 0.002 1 
207782707 A/G rs17259045 0.111 0.092 * 0.019 1 
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207782769 G/A rs41274768 0.017 0.037 * 0.010 1 
207782856 A/G rs17047660 0.006 0.000 * - - 
207782889 A/G rs17047661 0.005 0.003 * - - 
207782916 A/T rs4844609 0.955 0.980 * 0.120 1 
207782931 A/G rs6691117 0.196 0.216 * 0.063 1 
207790088 C/G rs3811381 0.111 0.174 Yes 0.049 1 
207791434 A/G rs41274770 0.060 0.020 * 0.005 1 
207795320 A/G rs2296160 0.489 0.805 * 0.742 0.908 
Information on the exonic variants detected in the NGS data.  
*CR1 received poor coverage in the Exome Project, so only a small number of our variants could be validated in this way. However, with the exception of one, 
all have rsIDs and so are likely to be genuine variants. 
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Figure 5.1 - Locations of coding variants relative to gene transcripts 
 
Ribbon diagram to show the locations of the detected variants within CLU, PICALM and CR1, relative to transcripts ENST00000316403, ENST00000393346, 
and ENST00000400960 respectively (Hubbard et al. 2002). CLUȂȱřȂȱȱ¢ȱȱ ȱ¡ȱşǰȱȱȱȱȱȱȱȱȱȱ ȱ
exon 9.  
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Table 5.2 Ȯ Association testing of exonic variants using imputed data 
Variants Coordinate 
Ref/
Alt rsID Info AD Freq 
Control 
Freq OR (95% CI) p-value 
CLU 
coding 
27457477 G/A rs9331939 0.924 0.0017 0.0076 0.224 (0.104-0.482) 0.85174 
27462481 A/G rs7982 0.995 0.3582 0.3979 1.184 (1.101-1.273) 0.00065 
27462662 G/A rs41276297 0.846 0.0007 0.0038 0.193 (0.060-0.617) 0.34400 
CLU řȂȱ
UTR 
27454493 T/C - - - - - - 
27454575 C/T rs10503814 1.000 0.0375 0.0415 0.900 (0.751-1.078) 0.62956 
27454682 G/A rs9331950 0.980 0.2428 0.1969 1.308 (1.199-1.425) 0.00269 
27454686 T/C rs9331949 0.942 0.0144 0.0227 0.629 (0.470-0.841) 0.02268 
27454730 A/G rs150082283 0.780 0.0007 0.0036 0.205 (0.064-0.656) 0.07772 
27454877 A/G rs9331947 0.955 0.0165 0.0399 0.402 (0.308-0.526) 0.06516 
27454957 A/G rs9331945 0.891 0.0119 0.0110 1.083 (0.779-1.506) 0.07940 
27455114 A/G rs9331942 0.934 0.0150 0.0232 0.642 (0.482-0.855) 0.01555 
27455442 T/C rs3087554 0.980 0.1015 0.1673 0.562 (0.492-0.642) 0.76905 
27455570 C/T - - - - - - 
PICALM 
coding 
85685793 G/A - - - - - - 
85685820 T/C - - - - - - 
85692181 A/C rs76719109 0.999 0.4062 0.4125 1.026 (0.956-1.102) 0.36776 
85707933 C/A - - - - - - 
85725937 C/T rs592297 0.999 0.1771 0.1947 1.123 (1.027-1.230) 0.65868 
CR1 
coding 
207669717 G/C - - - - - - 
207679307 A/G rs4844600 0.958 0.1947 0.1837 0.931 (0.846-1.024) 0.06633 
207760772 A/G rs61734514 0.278 0.0000 0.0005 -1.000 0.07874 
207760773 C/T rs3737002 1.000 0.2554 0.2638 0.957 (0.884-1.036) 0.28854 
207760906 T/C rs61734513 0.766 0.0027 0.0014 1.877 (0.898-3.920) 0.69471 
207782707 A/G rs17259045 0.984 0.0495 0.1023 0.457 (0.387-0.540) 0.65984 
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207782769 G/A rs41274768 0.991 0.0221 0.0255 0.864 (0.685-1.091) 0.69434 
207782856 A/G rs17047660 0.954 0.0024 0.0011 2.137 (0.969-4.713) 0.51066 
207782889 A/G rs17047661 0.975 0.0041 0.0029 1.419 (0.805-2.500) 0.64195 
207782916 A/T rs4844609 0.975 0.0041 0.0029 1.419 (0.805-2.500) 0.64195 
207782931 A/G rs6691117 1.000 0.1997 0.1933 1.041 (0.955-1.136) 0.12276 
207790088 C/G rs3811381 0.995 0.1691 0.1637 1.040 (0.947-1.142) 0.09718 
207791434 A/G rs41274770 0.382 0.0000 0.0027 -1.000 0.04293 
207795320 A/G rs2296160 0.998 0.2006 0.1811 0.881 (0.807-0.962) 0.22102 
Association testing of exonic variants detected in the NGS data using imputed data. ȱȱȱşśƖȱȱȱȱȱȱȱȱȱȃȄǰȱȱȱ
MAF refers to which ever allele has the lower frequency, so these do not always correspond. Yellow highlighting indicates statistically significant finding, 
while orange highlighting indicates significance at the p<0.05 level. 
 
 
Table 5.3 Ȯ Imputation and association testing findings of GWAS and APOE SNPs 
Gene SNP Ref/Alt Info. MAF AD MAF Controls OR (95% CI) p-value 
CLU rs11136000 T/C 0.9999 0.3616 0.3990 1.172 (1.090-1.260) 0.00089 
PICALM rs3851179 T/C 0.9999 0.3313 0.3731 1.201 (1.116-1.292) 0.01913 
CR1 rs6656401 A/G 0.9824 0.1766 0.1628 0.907 (0.824-0.998) 0.04176 
APOE rs429358 T/C 0.9745 0.3351 0.1466 2.934 (2.691-3.198) 1.93x10-71 
rs7412 C/T 0.9755 0.0323 0.0795 0.386 (0.317-0.470) 1.13x10-9 
Findings from imputation and association testing of the originally identified AD GWAS risk variants, plus variants from the APOE locus which dictate APOE 
“?Řǰȱ“?řȱȱ“?ŚȱallelesǯȱȱȱȱşśƖȱȱȱȱȱȱȱȱȱȃȄǰȱȱȱȱȱȱ ȱȱȱȱȱ ȱquency, so 
these do not always correspond.  
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Table 5.4 Ȯ Functional assessment of exonic variants using in silico resources 
Variants Coordinate 
Ref/
Alt rsID Consequence Exon AA change Polyphen-2 
CLU 
coding 
27457477 G/A rs9331939 Synonymous 8 - - 
27462481 A/G rs7982 Synonymous 6 - - 
27462662 G/A rs41276297 Missense 6 T255I Benign(0.013) 
CLU řȂȱ
UTR 
27454493 T/C - řȂȱ 9 - - 
27454575 C/T rs10503814 řȂȱ 9 - - 
27454682 G/A rs9331950 řȂȱ 9 - - 
27454686 T/C rs9331949 řȂȱ 9 - - 
27454730 A/G rs150082283 řȂȱ 9 - - 
27454877 A/G rs9331947 řȂȱUTR 9 - - 
27454957 A/G rs9331945 řȂȱ 9 - - 
27455114 A/G rs9331942 řȂȱ 9 - - 
27455442 T/C rs3087554 řȂȱ 9 - - 
27455570 C/T - řȂȱ 9 - - 
PICALM 
coding 
85685793 G/A - Synonymous 19 - - 
85685820 T/C - Synonymous 19 - - 
85692181 A/C rs76719109 Synonymous 17 - - 
85707933 C/A - Missense 12 Q398H Probably damaging(0.987) 
85725937 C/T rs592297 Synonymous 5 - - 
CR1 
coding 
207669717 G/C - Synonymous 1 - - 
207679307 A/G rs4844600 Synonymous 2 - - 
207760772 A/G rs61734514 Missense 26 T1408A Probably damaging(0.974) 
207760773 C/T rs3737002 Missense 26 T1408M Probably damaging(0.997) 
207760906 T/C rs61734513 Synonymous 26 - - 
207782707 A/G rs17259045 Missense 29 N1540S Benign(0.001) 
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207782769 G/A rs41274768 Missense 29 V1561M Benign(0.039) 
207782856 A/G rs17047660 Missense 29 K1509E Probably damaging(0.988) 
207782889 A/G rs17047661 Missense 29 R1601G Possibly damaging(0.876) 
207782916 A/T rs4844609 Missense 29 T1610S Benign(0) 
207782931 A/G rs6691117 Missense 29 I1615V Benign(0) 
207790088 C/G rs3811381 Missense 33 P1827R Benign(0.033) 
207791434 A/G rs41274770 Missense 34 K1853R Possibly damaging(0.823) 
207795320 A/G rs2296160 Missense 36 T1969A Benign(0.001) 
Information on the exonic variants detected in the NGS data from various bioinformatic resources used to prioritise variants on likely functionality, including 
prediction of consequences in terms of the protein sequence and structure. Possibly and probably damaging effects on the protein predicted by Polyphen-2 
highlighted in orange and yellow respectively.  
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Functional investigations 
Polyphen-2 was used to predict whether any of the 13 missense mutations 
called by CRISP within the NGS data would have detrimental effects on the 
structure and/or function of the encoded protein, since some amino-acid 
changes can be tolerated while others can have a significant deleterious 
impact. As can be seen from Table 5.4, one variant within PICALM and three 
within CR1 were predicted to probably be damaging to the structure of the 
protein, while a further two in CR1 were classified as possibly damaging. 
 
Splicing 
As well as disrupting the sequence of the protein, non-synonymous SNPs may 
be affecting the splicing of the genes, while synonymous variants may be 
exerting an effect on the regulation of the genes via this mechanism. Three 
programs with four functions were used to investigate the effect the detected 
variants may be having on splicing, with the results of these investigations 
presented in Table 5.5. Further information on variants predicted to be 
affecting splicing is given in Figure 5.2. No significant effects on splicing were 
ȱ¢ȱ¢ȱȱȱǰȱȱȱȂȱin prediction 
function. 
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Table 5.5 Ȯ Splicing investigations of variants detected by NGS 
Gene Variant rsID ESEfinder - SpliceSites 
ESEfinder - 
SRProteins BDGP NetGene2 
CLU 27457477 rs9331939 - - New (weak) acceptor site 
introduced by variant 
- 
27462481 rs7982 - - - - 
27462662 rs41276297 - Yes - - 
PICALM 85685793 - - - - Acceptor site slightly weaker in 
variant sequence 
85685820 - - - - Acceptor site slightly weaker in 
variant sequence 
85692181 rs76719109 Donor site slightly stronger 
in variant sequence 
Yes - - 
85707933 - Acceptor site slightly 
weaker in variant sequence 
Yes - - 
85725937 rs592297 - Yes - - 
CR1 207669717 - - Yes - New (weak) acceptor site 
introduced by variant 
207679307 rs4844600 - - - - 
207760772 rs61734514 - Yes - - 
207760773 rs3737002 - Yes - - 
207760906 rs61734513 - - - - 
207782707 rs17259045 - - - Acceptor site slightly weaker in 
variant sequence 
207782769 rs41274768 - - - - 
207782856 rs17047660 - - - - 
207782889 rs17047661 - - - Donor site slightly stronger in 
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variant sequence 
207782916 rs4844609 - - - Donor site slightly stronger in 
variant sequence 
207782931 rs6691117 - - - Donor site slightly stronger in 
variant sequence 
207790088 rs3811381 - Yes - Donor site slightly stronger in 
variant sequence 
207791434 rs41274770 - - - - 
207795320 rs2296160 - Yes New (weak) acceptor site 
introduced by variant 
Acceptor site slightly stronger 
in variant sequence 
Results from the in silico splicing investigations conducted on the coding variants detected in the NGS data. A dash (-) in the box signifies no notable 
differences between the wild type and variant versions of the sequence. Where strong differences were predicted, the results are highlighted in yellow. Where 
ȱȃ¢ȄȱȱǰȱȱȱśǯŘȱȱȱ¡ȱȱȱǯ 
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Figure 5.2 Ȯ ȱȱȱȂȱȱ 
Key -  
 
 
CLU - rs41276297 
Wild Type                       Variant 
 
 
Sequence at site:       ATACCTA                        ATATCTA 
 
PICALM - rs76719109 
Wild Type                        Variant 
  
Sequence at site:   
                TGCTGCA                            TGCGGCA 
 
11:85707933 C>A 
Wild Type                        Variant 
   
Sequence  
at site:          GCAGCCA                    GCATCCA 
 
 
 
SRSF6 (SRp55) 
SRSF6 (SRp55) SRSF2 (SC35) 
SRSF1 
(SF2/ASF) 
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rs592297 
Wild Type                       Variant 
  
 
Sequence at site:            TCAGATG      TCAAATG 
 
CR1 - 1:207669717 G>C 
Wild Type         Variant 
 
Sequence at site: 
                          TGCGCTG                               TGCCCTG 
 
rs61734514 
Wild Type         Variant 
 
 
Sequence at site:       CCTACGA                        CCTGCGA 
 
 
 
 
 
 
 
 
 
 
 
SRSF5 (SRp40) 
SRSF1 (SF2/ASF) 
 
SRSF2 (SC35) 
SRSF1 (SF2/ASF) 
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rs3737002 
Wild Type          Variant 
 
 
Sequence at site:       CTACGAT              CTATGAT 
 
rs3811381 
Wild Type                       Variant 
 
 
Sequence at site:           ACCCTCA        ACCGTCA 
 
rs2296160 
Wild Type                       Variant 
 
Sequence  
at site:   GGTACAC                               GGTACAC 
 
Figure showing the results from the splicing investigations conducted on the coding 
ȱ ȱ 	ȱ ȱ ȱ Ȃȱ ȱ ǯȱ ȱ ȱ ǰȱ ȱ
SRProtein prediction for the wild type sequence is shown on the left, while the variant 
Ȃȱ ȱ ȱ  ȱ ȱ ȱ ǯȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
particular SRProtein(s) affected (see key at top of figure), while the height of the bars 
are proportional to the expected strength of the predicted sites. Differences are 
highlighted by arrows, and the sequences of the wild type and variant sites are shown 
below the graphs. 
 
SRSF1 (SF2/ASF) 
SRSF2 (SC35) 
SRSF5 (SRp40) 
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¶875613V 
Ten of the variants detected in the NGS data at the CLU locus fell within the 
Ȃȱ řȂǯȱȱȱ ȱ ¢ȱȱ ȱȱ ȱ ¢ȱ ȱȱ
affecting the regulation of the gene by altering the binding sites of miRNAs, it 
was ascertained whether any of the variants fell within the predicted binding 
sites of any miRNAs listed in the TargetSan (www.targetscan.org) database 
(Garcia et al. 2011). The website listed 12 miRNA binding sites within the 
řȂȱȱCLU on the date of analysis (16.04.13). When the locations of these 
 ȱȱ ȱȱȱȱȱřȂȱǰȱ  ȱȱǻşřřŗşŚśȱ
and rs9331947) were found to fall within miRNA sites, with rs9331947 
intersecting four potential binding sites. PITA enabled a comparison of the 
miRNA sites predicted for the wild type and variant sequences for each of the 
ǰȱ ȱ ȱ ȃȱ ȱȄȱ ǯȱȱ ¢ȱ ȱ ȱ ȱ ȱ
these investigations is given in Table 5.6. 
 
Table 5.6 Ȯ Investigations of miRNA binding sites in CLUȂȱřȂ 
rsID miRNA (TargetScan) ȱ“E“E	ȱǻǼ ȱ“E“E	ȱǻǼ 
rs9331945 hsa-miR-3138 Not found Not found 
rs9331947 
 
hsa-miR-1184 -1.62 -1.05 
hsa-miR-4418 Not found Not found 
hsa-miR-509-3-5p -1.12 -1.02 
hsa-miR-509-5p -0.51 -0.41 
Co-located SNPs and predicted miRNA sites in CLUȂȱřȂȱȱǯȱȱ“E“E	ȱȱ
from PITA is a measure of how strong the binding between the miRNA and the 
binding site would be expected to be. 
 
5.2. Discussion of exonic variants 
 
It is estimated that around 85% of variants with large effects on disease related 
traits are exonic, despite coding regions only comprising around 1% of the 
total genome (Choi et al. 2009). When even relatively small scale sequencing 
projects such as this can identify a large number of variants, prioritisation is 
crucial to ensure only variants likely to be affecting the phenotype in question 
are pursued. This ensures minimal time and resources are consumed 
investigating variants unlikely to be contributing to the disease process. 
Concentrating on coding variants is a simple way to reduce the total number 
of variants being investigated, while maintaining those more likely to be 
disease relevant. Exonic variants are simpler to predict and verify the 
functional consequences of. This chapter explores the exonic variants found in 
the NGS data. 
 
A two-pronged approach was adopted in the further prioritisation of coding 
variants in this study. Firstly, imputation was used to predict genotypes of 
SNPs of interest in a GWAS data set, enabling testing for association with AD. 
Secondly, likely functional consequences of the variants were assessed using 
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in silico prediction programs, which highlighted variants likely to be affecting 
the normal functioning of the gene. 
 
13 exonic variants were called within the NGS data for CLU, with three falling 
in codiȱ ¡ǰȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȃȱ řȂǯȱ ȱ ¡ȱ
variants were called within PICALM, while 14 were detected in CR1. In each 
of these genes, all of the detected exonic variants fell within coding regions.  
 
NGS notoriously has a high rate of false positive variant calls, due to the 
nature of the technology used, so validation of variants via an independent 
method is imperative (Lord et al. 2012). All of the variants bar one in the CLU 
and PICALM genes were confirmed as being genuine by comparison with 
data from the Exome Project at UCL. The PICALM SNP not validated, at 
position 11:85685820, is a putative synonymous variant which showed no 
evidence of functional effect on the gene, so was not deemed to be worth 
validating by Sanger sequencing.  
 
Validation via comparison with the Exome Project data was not possible for 
the majority of variants called in the NGS data in the CR1 region because of 
coverage issues they experienced in the area (again, reiterating how 
problematic the highly repetitive gene structure is for NGS). However, all but 
one of the CR1 coding variants identified already had rs numbers assigned, so 
can be assumed to be genuine, given their prior documentation. The 
remaining variant, at position 1:207669717 is a putative synonymous variant, 
which does show some evidence of affecting the activity of a splicing enhancer 
signal. However, despite being apparently novel, the alternative allele had an 
estimated frequency of 0.508 in the CRISP data, which as discussed in the 
previous chapter, is indicative of a false positive call. Upon closer inspection 
of the CRISP data, the average coverage at the position per individual was just 
0.28. These pieces of evidence combine to make it highly likely this is a false 
positive call, and thus not worthy of pursuit. 
 
ȱ ȱȱ ȱ ȱȱ ȱȱȱ ȱ ȱ ȱ ȱȂȱ
transcripts, CLUȂȱ ȱ ¡ȱ ȱ ȱ ȱ  ȱ ¡ȱ Ŝ-8 is 
ȱ  ȱ Ȃȱ ȱ ȱ ȱ ȱ  ȱ ȱ ȱ
encoding the CLU “?-chain (exons 5-8), although three variants is too small a 
number to draw any meaningful conclusions from this (Bettens et al. 2012). 
CLUȂȱ¡ȱşȱȱȱȱȱȂȱřȂǰȱȱȱȱȱȱřȂȱȱȱ
within this exon. Clustering in to a small number of exons in this way can be 
indicative of involvement in a phenotype Ȯ ȱ ȱ řȂȱ ȱ CLU be 
harbouring multiple risk affecting variants? Association testing in the imputed 
data and investigations of functionality using in silico resources of these 
variants is discussed later. The exonic variants detected within PICALM show 
ȱȱȱ ȱ ȱȂȱ¡ǯȱ ȱŗǰȱ  ȱȱ ȱ
identified within the first two exons of the gene (although as discussed, one of 
these is not believed to be genuine), while the remainder fell between exons 26 
and 36, with the majority in exons 26 and 29. While such clustering can be 
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indicative of functional involvement of the gene in the disease process (e.g. the 
exons encode a particular domain of importance), it is likely in this case the 
apparent clustering is an artefact of the poor sequencing coverage of a large 
proportion of the CR1 gene. The ~44kb gap in sequencing spans the same 
region where a distinct lack of variants were detected, providing a much more 
mundane explanation for the apparent clustering.  
 
Imputation allowed a method for the variants to be tested for association with 
AD, without needing costly and time consuming direct genotyping of a large 
number of variants in a large sample cohort. The utilisation of our own 
combined Mayo/ARUK GWAS data, in combination with publically available 
control data from the WTCCC2 project gave a combined sample set of 2067 
AD cases and 7376 controls.  
 
There are certain caveats when using imputation in this way, which should be 
considered when analysing data from this methodology. The use of 
imputation reduces the power of association testing when compared to 
directly genotyped data, because of the inherent uncertainty in genotypic 
calls. This issue is particularly pronounced when imputing rare variants, since 
there are less of the variants present in the reference set on which to base the 
imputation, giving a higher level of uncertainty in the genotypic calls. 
Association testing has a lower power for rarer variants anyway (less variants 
to make comparisons between), which is only exacerbated by this uncertainty. 
Another potential issue with this particular methodology is the inclusion of 
the WTCCC2 project data, which are not ideal control samples for AD since 
the age of recruitment for such control cohorts are typically earlier than the 
average age at onset for AD. It is inevitable that some individuals being 
classed as controls here will actually develop AD in later life. This 
misclassification in phenotype is another source of loss of power in association 
studies. This is more likely to be a source of error in rarer variants than 
common, since small numbers of misclassifications will have more 
pronounced effects when the variants in question are rare.  
 
While it is not possible to know how these factors will affect our association 
testing, it was possible to look for positive controls to establish whether 
associations could be found via this methodology in a sample set of this size.  
 
Imputation using the same GWAS sample set was also conducted on the two 
APOE allele defining SNPs. The APOE locus is the longest known genetic risk 
factor for late-onset AD because of its strong effect size. As such, these SNPs 
should be clearly associated with AD in the imputation sample set.  
 
The three alleles of APOE are defined by genotype at two variant sites Ȯ 
ŚŘşřśŞȱȱŝŚŗŗŘǯȱȱȱ“?Řȱȱȱȱ¢ȱȱȱȱȱȱ
ȱ  ȱǲȱ ȱ ȱ“?řȱ ȱ ȱ ȱ ¢ȱ ȱ ȱ ȱ ȱ ȱ ȱ
position, and a C at the second positionǲȱ  ȱ ȱ ǰȱ ¢ǰȱ “?Śȱ ȱ ȱ
defined by Cs at each position. Thus, within our imputed data, the C allele at 
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rs429358 would be expected to have an OR showing increased risk of AD (OR 
of 2.9), while the T allele at the second position, rs7412, would be expected to 
show a protective effect on AD risk (OR of 0.4). This was indeed found to be 
the case, with highly significant associations with AD in the expected 
directions for both variants (p=1.93x10-71 and p=1.13x10-9, respectively).  
 
Once it had been established that the imputation methodology was capable of 
finding associations of the magnitude of APOE, the original GWAS SNPs were 
also tested for association with AD. For each of the three genes, the original 
GWAS SNP did show association with AD in the imputed data (with nominal 
p-values of 0.0009, 0.0191, and 0.04176 for CLU, PICALM and CR1 
respectively). The directions of effect were consistent with those reported in 
the Harold et al. and Lambert et al. GWAS for all three SNPs (although the 
reporting in the GWAS papers was for the opposite allele to the one tested in 
our association test Ȯ our OR indicates the C allele at rs11136000 is risky, the 
GWAS papers reported the T allele at the same SNP to be protective. These 
equate to the same thing, thus our directions are consistent with the published 
data) (Harold et al. 2009; Lambert et al. 2009). This is good evidence that this 
methodology is capable of detecting associations of lower magnitudes. The 
GWAS variants, however, are all common, with MAFs >0.16, so it remained to 
be seen whether effects of this magnitude in rarer SNPs could be identified.   
 
The two coding variants successfully imputed within the PICALM region 
showed no evidence of association with AD. Just one out of the 13 successfully 
imputed coding SNPs within the CR1 locus (rs41274770) was found to be 
associated with AD at the p<0.05 level. No OR could be calculated for this 
variant given that no alternative alleles were imputed in the case samples. 
Another variant, rs61734514, which was only imputed in control samples and 
not cases also showed a suggestive association with the condition (p=0.0787). 
With 13 coding variants successfully imputed, 13 multiple tests of association 
are being conducted. A Bonferroni correction for this number of tests would 
require a p-value <0.0038 for statistical significance, which neither of these 
variants achieves, so they are at best suggestive. However, both of these are 
rare variants, with 1000 genomes project EUR MAFs of 0.020 and 0.016 
respectively. The known limitations of imputation of low frequency variants 
may be holding these SNPs back from achieving statistical significance. 
Although no alternative alleles of these variants were imputed in case 
samples, it is clear that these variants do occur in AD patients since they were 
found in the NGS data generated from AD patient samples only, which calls 
into question the apparent protective effect of the variants implied by the 
imputed data. To establish whether these variants are involved in AD risk, 
direct genotyping in a case-control cohort large enough to give sufficient 
power would be required.  
 
These two variants are in strong LD with the CR1 	ȱ ȱ ǻȂȱ ȱ ŗȱ ȱ
both). rs41274770 falls within exon 34 and rs61734514 lies within exon 26 (in 
the transcript of the common F allele). Both of these SNPs are missense 
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mutations, causing changes to the encoded protein of K1853R and T1408A, 
which are predicted by Polyphen-2 to be possibly and probably damaging 
respectively (0.823 and 0.974). Again, this renders the implied protective effect 
of the variants from the imputed data unlikely. There is additionally some 
evidence that rs61734514 may disrupt a binding site for the splicing SR-
protein SRSF1 (SF2/ASF). If this is indeed the case, it could offer another 
explanation as to how the variant may be causatively linked to AD, by 
disrupting the normal splicing of the gene. Given the known limitations of in 
silico functional prediction programs, it would be necessary to characterise 
these effects experimentally to assess whether the variants are indeed 
pathogenic to the structure of the protein or the expression of the gene, and 
how this could be related to AD pathology.  
 
None of the other variants predicted to be damaging to the protein structure 
in either PICALM or CR1 were suggestive of association with AD, so whether 
they are indeed having an effect on protein structure, and whether this is 
relevant to AD pathology remains unclear.  
 
Although none of the PICALM variants were found to be associated with AD 
in this dataset, only two of the variants were actually imputed; those which 
were not imputed successfully showed some evidence of potential 
functionality, so should also be considered. These are all variants without rs 
numbers. The unvalidated variant, at position 11:85685820 had no evidence of 
functional effects, and this is also true of the variant at 11:8568793 Ȯ both were 
synonymous with no evidence of effects on splicing. The other variant, at 
position 11:85707933, is a missense mutation within exon 12 of the gene, 
encoding the amino acid change Q398H, which Polyphen predicted would 
probably be damaging (0.987). The variant also showed evidence of affecting 
the binding site of splicing SR-protein SRSF1, so could potentially be 
influencing the splicing pattern of the gene. The variant had a frequency of 
0.004 in the CRISP data, which is indicative that just one alternate allele was 
present in the whole pool of 192 alleles. Without a listed frequency in the 1000 
genomes project data, it is likely that this allele is highly rare. Genotyping in a 
very large case-control cohort would be needed to establish if there was any 
association with AD, given the low frequency of the variant. Experimental 
characterisation of the predicted functional effects to the protein structure and 
splicing patterns could help ascertain whether the variant was likely to have a 
pathological role in the gene, and how this may related to AD pathogenesis.  
 
Although it has already been stated that PICALM SNP rs592297 was not 
associated with AD in the imputed data set, there is the suggestion that it may 
be having an effect on the splicing of the gene, with evidence that the variant 
may alter a splicing SR-protein binding site within exon 5 of the gene, such 
that an SRSF1 site is abolished, and a SRSF5 site is introduced. During the 
course of this project, another paper reported this as a possible splicing 
mutation relevant to AD based on in silico evidence, but again, found no  
association between the SNP and the condition (Schnetz-Boutaud et al. 2012). 
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Similarly, although rs76719109 showed no evidence of association with AD, it 
did show evidence of an effect on splicing, potentially altering a SRSF2 site 
 ȱȱȂȱŗŝth exon. Functional characterisation of the effects of these 
variants on splicing would allow it to be established whether these SNPs do 
indeed affect the splicing of the gene, and may help to determine whether and 
how this is of consequence in AD development.  
 
One of the three imputed coding variants within CLU (rs7982) showed 
association with AD in our imputed dataset (p=0.00065). Harold et al. in their 
GWAS paper had reported the variant as being in strong LD with rs11136000 
(r2 ŖǯşŝŜǰȱȂȱ ŖǯşşŞǼǰȱ ȱ  ȱ ȱ ȱ ȱ ȱ ȱ ith AD as 
rs11136000 in their data (Harold et al. 2009). In other studies, the SNP has not 
been found to be significantly associated with AD, perhaps due to insufficient 
sample sizes to give the power required (Guerreiro et al. 2010; Bettens et al. 
2012). In the imputed data, rs7982 showed a more significant association with 
AD than did rs11136000. This difference, although only marginal, may suggest 
that the variant is causative. As a synonymous variant, any effect on 
phenotype is not via the alteration of the amino acid sequence of the protein, 
and the in silico resources used did not suggest the variant was likely to be 
affecting the splicing of the gene, so it is unclear from these investigations how 
the variant could be related to AD pathogenesis. The greater significance of 
this SNP over the GWAS SNP in the imputed data set is only slight, so may 
simply be a quirk, and the SNP may simply be tagging the same unknown 
causative factor(s) tagged by rs11136000.  
 
Of the ten SNPs found in CLUȂȱ řȂȱ ȱ ȱ 	ȱ ǰȱ ȱ  ȱ
successfully imputed, and three (rs9331950, rs9331949 and rs9331942) showed 
evidence of association with AD at the p<0.05 level. When corrected for the 
eight multiple tests being conducted, statistical significance would require 
p<0.0065, which only SNP rs9331950 surpassed. However, whilst rs9331950 is 
common (1000 genomes EUR MAF 0.197), the other two are rare, both with 
1000 genomes EUR MAFs of 0.023, so as before, it could be the limitations of 
imputing rare variants bringing the power of the association testing down, 
and preventing the variants from reaching significance. All three of these 
ȱȱȱȱȱ ȱŗŗŗřŜŖŖŖȱǻȂȱȱȱȱŖǯŝşǼǰȱȱ¢ȱȱ
further tags for the same source, or may themselves be causal in some way. 
 
ȱ ȱ ȱ ȱ ȱ ȱ řȂȱ ǰȱ in silico resources were 
ȱǯȱȱřȂȱȱȱȱ ȱȱȱ¢ȱȱ
implicated in multiple regulatory process, including control of translational 
efficiency, transcript cleavage and stability, as well as polyadenylation (Barrett 
et al. 2012; Pichon et al. 2012). One method by which post-transcriptional 
regulation of gene expression is mediated is via the binding of miRNAs to 
ȱ  ȱ ȱ Ȃȱ řȂȱ (Barrett et al. 2012). In silico prediction 
programs were used to determine whether any of the CLU řȂȱ ȱ
identified in the NGS data could be having an effect on the expression of the 
gene via the disruption of miRNA binding.  
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Two of the variants (rs9331945 and rs9331947), which were not associated at 
the p<0.05 level, but were suggestive of association (with p-values of 0.079 and 
0.065 respectively) were found to fall within potential miRNA binding sites. 
Both of these are relatively rare variants (1000 genomes MAFs of 0.013 and 
0.050 respectively), so again the weakness of imputation in rarer variants may 
have affected this, and genotyping in a case-control cohort would be needed 
ȱ¢ȱ¢ȱǯȱȱřȂȱȱ hich were associated with AD 
at the p<0.05 level did not fall within any miRNA sites.  
 
For the two variants which did fall in miRNA binding sites according to 
Target Scan, PITA enabled the comparison of the wild type and variant UTR 
sequences in terms of miRNA binding site strengths. Two of the five sites 
predicted to be affected by Target Scan were not detected by PITA. This lack 
of concordance between programs is likely to indicate they are not genuine 
binding sites. The other three potential sites affected by the SNPs were 
ȱ¢ȱǰȱ ȱ ȱ ȱ ǰȱ ȱ“E“E	ȱȱ ȱ ȱ¢ȱ ȱ
ȱȱȱȱǯȱ
 ǰȱȱȱȱ“E“E	ȱȱ ȱ ǯȱȱ
ȱȱȱ“E“E	ȱȱǰȱȱȱȱȱȱȱȱȱȱ
target site is expected to be, with -10 recommended as a rough cut-off point Ȯ 
any sites with a score more negative than -10 are likely to be functional at 
endogenous miRNA expression levels. None of the sites within the CLU 
řȂȱ  ȱ ȱ ȱ ȱ s cut-off, thus the sites are not 
¢ȱȱȱ¢ȱȱȱȱȂȱǰȱȱȱȱȱȱ
“E“E	ȱȱ ȱȱȱȱȱ¢ȱȱȱȱ¢ȱǯȱ 
 
This chapter has explored the exonic variants detected within the NGS data, 
with the aim of prioritising those variants most worthy of follow up research 
based on functional in silico investigations and testing for association with AD 
in an imputed data set. Within CLU, four variants either significantly or 
suggestively associated with AD were identified, but a lack of functional 
evidence from the in silico resources renders these a low priority for follow up. 
PICALM contained two variants with evidence of affecting splicing, but were 
not associated with AD in the imputed data set. A third variant within 
PICALM, a novel SNP which could not be imputed, was predicted to both 
affect splicing, as well as being a missense mutation, which Polyphen-2 
predicted would probably be damaging, rendering it a high priority for 
further study. Two missense variants within CR1, which were predicted to be 
damaging by Polyphen-2 also showed suggestive association with AD, 
considering their rarity (with p-values of 0.04 and 0.08 and frequencies of 
around 1-2%), and so present strong candidates for further research.  
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6. Non-coding variants 
 
This chapter explores the variants detected within the NGS data that did not 
fall within exonic regions. While non-coding variants are often overlooked, 
they can affect the regulation and expression of genes, and may well have an 
effect on disease risk. It is particularly important to consider such variants 
when there is evidence that the GWAS signal does not stem from coding 
changes, such as is the case for CLU. As with the coding variants discussed in 
the previous chapter, a two-pronged approach was adopted, combining data 
on potential functional activity from in silico resources with AD association 
testing in an imputed data set. 
 
6.1. Identification of non-coding variants 
 
Whȱ Ȃȱ ȱ  ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
detected relative to the genes, it was established that over 850 of the variants 
detected were non-coding. It was decided that CLU ȱȱȱȱȱśȂȱȱ
PICALM, along with the rs3851179 LD block were likely to be the most 
interesting in terms of non-coding variation (see discussion 6.4 for details). 
The results of the investigations of these regions are presented below. 
 
6.2. CLU 
 
75 non-coding variants were detected within the targeted CLU locus, falling in 
the upstream, downstream and intronic regions. Of these, nine fell upstream 
of the gene (two of which were novel), 19 fell downstream (five novel), while 
the remaining 47 (including 12 novel) were situated in the intronic regions of 
the gene. It was necessary to prioritise these variants, so those in areas with 
multiple lines of evidence of functionality from ENCODE were selected, and 
are presented in Table 6.1. Table 6.2 shows the ENCODE data for these 
variants, upon which the prioritisation was based. Association testing of these 
variants in imputed data was performed, with the results presented in Table 
6.3. 
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Table 6.1 Ȯ Summary of CLU non-coding SNPs of interest 
Coordinate 
Ref/
Alt rsID 
CRISP 
freq. 
1kg 
freq. PhyloP Phastcons 
Location relative to 
CLU  
LD with GWAS 
SNP (r2) 
LD with GWAS 
ȱǻȂǼ 
27466157 T/C rs1532276 0.593 0.603 -0.7211 0 Intronic 0.976 0.988 
27466181 T/C rs1532277 0.592 0.603 0.0564 0 Intronic 0.976 0.988 
27466315 T/C rs1532278 0.573 0.606 0.3340 0 Intronic 0.976 0.988 
27468503 C/A rs867230 0.597 0.591 0.0937 0 Intronic 0.930 0.988 
27469971 G/C rs9331883 0.007 0.003 -1.8881 0 Intronic 0.004 1.000 
27470010 G/T - 0.006 - 0.0037 0 Intronic  -  - 
27470597 G/A rs34109053 0.302 0.272 0.5443 0.0215 Intronic 0.178 0.887 
27471673 C/T - 0.004 - 2.0935 0.6673 Intronic  -  - 
27471748 C/A - 0.053 - -0.0156 0 Intronic  - -  
27472859 C/A rs76646010 0.022 0.033 0.1443 0 Upstream (311bp) 0.019 1.000 
27474202 A/G rs9314349 0.379 0.393 -0.5716 0 Upstream (1654bp) 0.099 0.467 
27474541 G/A rs117148275 0.009 0.007 -0.7374 0 Upstream (1993bp) 0.001 0.370 
27474587 C/G rs56025648 0.050 0.055 0.0914 0 Upstream (2039) 0.036 0.605 
27474599 C/T rs1982229 0.358 0.368 -0.0191 0 Upstream (2051bp) 0.108 0.503 
27474871 G/A rs77336101 0.010 0.021 -0.8479 0 Upstream (2323bp) 0.013 1.000 
Information on the non-coding SNPs identified in the NGS data for the CLU region. Variants shown are those filtered based on multiple lines of evidence 
from ENCODE (see Table 6.2) that the region in which they fall is functionally active. Variants showing conservation scores above 0.5 (by either measure) are 
highlighted in yellow. 
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Table 6.2 Ȯ ENCODE data on Ȃ non-coding variants 
Coordinate Ref/Alt rsID TFBS DNASE NHA_H3K4me1 NHA_H3K4me3 NHA_H3K27ac 
27466157 T/C rs1532276 * See Footnote 33 5.724864     
27466181 T/C rs1532277 * See Footnote 33 5.724864     
27466315 T/C rs1532278 * See Footnote 33 5.724864     
27468503 C/A rs867230  72 5.724864 4.907665   
27469971 G/C rs9331883 * See Footnote 11 5.724864     
27470010 G/T - * See Footnote 11 5.724864     
27470597 G/A rs34109053  4 5.724864   7.681592 
27471673 C/T - * See Footnote 135 5.724864 11.0377 7.681592 
27471748 C/A - * See Footnote 135 5.724864 11.0377 7.681592 
27472859 C/A rs76646010    5.724864 11.0377 7.681592 
27474202 A/G rs9314349 * See Footnote   5.724864   7.681592 
27474541 G/A rs117148275 * See Footnote 14 5.724864 8.594284 7.681592 
27474587 C/G rs56025648 * See Footnote   5.724864   7.681592 
27474599 C/T rs1982229 * See Footnote   5.724864   7.681592 
27474871 G/A rs77336101 * See Footnote 133 5.724864   7.681592 
ENCODE data for non-coding variants within the targeted CLU locus for parameters suggestive of regulatory activity. In the ENCODE data, TFBS is 
transcription factor binding sites, DNASE is DNaseI hypersensitivity clusters, NHA refers to normal human astrocytes (the most relevant cell type to AD 
available), with H3K4me1, H3K4me3 and H3K27a all being histone modifications indicative of active or potentially active DNA. A value for any of these may 
indicate the DNA position is in some way functionally active. *Each of these variants fell within the locations of multiple putative transcription factor binding 
sites. For details of which SNPs occurred at which TFBS, see Appendix section 6.1.  
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Table 6.3 Ȯ Association testing of non-coding variants at the CLU locus in imputed data 
Coordinate Ref/Alt rsID Info AD MAF Control MAF OR (95% CI) p-value 
27466157 T/C rs1532276 0.995 0.360 0.395 1.164 (1.083-1.252) 0.0009 
27466181 T/C rs1532277 0.993 0.352 0.393 1.194 (1.110-1.285) 0.0005 
27466315 T/C rs1532278 0.994 0.353 0.393 1.184 (1.101-1.274) 0.0008 
27468503 C/A rs867230 0.966 0.364 0.411 1.220 (1.126-1.321) 0.0094 
27469971 G/C rs9331883 0.193 0.001 0.001 0.988 (0.205-4.756) 0.0553 
27470010 G/T -          
27470597 G/A rs34109053 0.952 0.267 0.244 1.129 (1.027-1.242) 0.1154 
27471673 C/T -          
27471748 C/A -          
27472859 C/A rs76646010 0.725 0.004 0.007 0.597 (0.345-1.034) 0.4942 
27474202 A/G rs9314349 1.000 0.371 0.382 0.954 (0.888-1.025) 0.4274 
27474541 G/A rs117148275 0.938 0.009 0.007 1.324 (0.909-1.929) 0.2835 
27474587 C/G rs56025648 0.941 0.031 0.040 0.766 (0.626-0.936) 0.9849 
27474599 C/T rs1982229 0.988 0.356 0.367 0.952 (0.884-1.025) 0.4809 
27474871 G/A rs77336101 0.939 0.014 0.018 0.780 (0.585-1.040) 0.7197 
Results of association testing for the variants showing evidence of functionality in the targeted CLU locus using imputed data. The OR and 95% CI given 
ȱ ȱ ȱ ȱ ȱȱ ȃȄǰȱ ȱ ȱȱ ȱ ȱ ȱȱ ȱ ȱ ȱ  ȱ ¢ǰȱ ȱ ȱ ȱ ȱ ways correspond. Statistically 
significant variants are highlighted in yellow, one variant significant at the p<0.05 level but not withstanding correction for multiple testing highlighted in 
orange. 
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6.3. PICALM and the rs3851179 LD block 
 
Given the evidence that the association signal within the PICALM gene tracks 
ȱȱśȂȱȱtream region, this was the focus of the search within PICALM. 
Of the 516 non-coding variants detected within the PICALM target locus, 14 
fell upstream of the gene and had multiple lines of evidence of falling in a 
functional region from the ENCODE data. These spanned a region from 102bp 
away from the transcription start site, to 3.25kb away. Nine of these had rs 
numbers already assigned, while the remaining five were novel. Details on 
these 14 variants and the investigation of their functionality are presented in 
Table 6.4, with data from the ENCODE project reported in Table 6.5. Results 
from the association testing using imputed data are given in Table 6.6.  
 
The other prioritised area of interest was the rs3851179 LD block. In this area, 
113 variants were identified, with 23 of those determined to be novel by 
Ȃȱ ǯȱ  eight variants with multiple lines of evidence for 
functionality are presented in Table 6.7, with data from the ENCODE project 
on these variants presented in Table 6.8. Highlighted within these tables are 
two variants of particular interest, which fell within a small region with strong 
evidence of regulatory activity.  
 
It was decided to validate these variants, and determine whether there was 
evidence of suggestive association with AD using TaqMan genotyping assays 
in a cohort of AD cases and controls. Figure 6.1 shows the results from the 
Sanger sequencing validation of the variants along with TaqMan genotyping 
assay output. Table 6.9 shows the results from the TaqMan genotyping assays, 
including the numbers of samples genotyped, and association testing for one 
of the SNPs  ȱȱȱȂȱ¡ȱȱ ȱȱȱȱ ȱŗŖŖŖȱ
genomes data included to give additional control samples. 
 
Association testing in the imputed data set was also performed on all eight 
variants falling in regions with the best evidence of functionality or regulatory 
capacity. This data is provided in Table 6.10.  
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Table 6.4 Ȯ Summary of variants upstream of PICALM 
Coordinate Ref/Alt rsID CRISP freq. 1kg freq. PhyloP Phastcons 
Distance from 
PICALM (bp)  
LD with GWAS 
SNP (r2) 
LD with GWAS 
ȱǻȂǼ 
85780073 G/T rs3016326 0.9999° 1.0000 -0.1086 0.9843 102 - - 
85780448 T/C rs3016327 0.8419 0.7889 -0.2136 0 477 0.199 0.676 
85780582 G/T rs10898433 0.1006 0.1504 -1.5252 0 611 0.013 0.337 
85780924 A/G - 0.0050 - 0.9596 1.0000 953 - - 
85780962 T/C rs188367538 0.0024 0.0013 2.1640 1.0000 991 - - 
85781279 C/G - 0.0048 - 0.7187 0.0157 1308 - - 
85781322 C/T rs669556 0.8563 0.8166 0.1165 0.8346 1351 0.268 0.833 
85781523 C/A rs75172533 0.0608 0.0567 -0.6663 0 1552 0.031 0.795 
85781597 CA/C rs5793180 0.8113 0.8166 -0.3652 0.0236 1627 0.268 0.833 
85781599 A/G rs11304990 0.2446 - 0.2370 0.0157 1628 - - 
85781600 G/T - 0.2316 - 0.5381 0.0157 1629 - - 
85781600 GT/G - 0.2699 - 0.5381 0.0157 1630 - - 
85781634 C/G rs55886146 0.0546 0.0172 0.8994 0.9921 1663 0.015 1 
85781856 C/G - 0.0049 - -1.4302 0 1885 - - 
Information on the variants upstream of PICALM including frequency estimates from CRISP and the 1000 genomes project, conservation scores from both 
PhyloP and Phastcons, and the distance from the transcription start site. Variants showing conservation scores above 0.5 (by either measure) are highlighted 
in yellow. 
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Table 6.5 Ȯ ENCODE data on variants upstream of PICALM 
Coordinate Ref/Alt rsID ENC_TFBS ENC_DNASE NHA_H3K4me1 NHA_H3K4me3 NHA_H3K27ac 
85780073 G/T rs3016326 See footnote*   28.941935 13.490137 
85780448 T/C rs3016327 See footnote*  8.547032 28.941935 13.490137 
85780582 G/T rs10898433 See footnote* 18 8.547032 28.941935 13.490137 
85780924 A/G - See footnote* 136 8.547032 28.941935 13.490137 
85780962 T/C rs188367538 See footnote* 136 8.547032 28.941935 13.490137 
85781279 C/G -   8.547032 28.941935 13.490137 
85781322 C/T rs669556  4 8.547032 28.941935 13.490137 
85781523 C/A rs75172533   8.547032 28.941935 13.490137 
85781597 CA/C rs5793180  37 8.547032 28.941935 13.490137 
85781599 A/G rs11304990  37 8.547032 28.941935 13.490137 
85781600 G/T -  37 8.547032 28.941935 13.490137 
85781600 GT/G -  37 8.547032 28.941935 13.490137 
85781634 C/G rs55886146  37 8.547032 28.941935 13.490137 
85781856 C/G -  37 8.547032 28.941935 13.490137 
ENCODE data for variants upstream of the PICALM gene for parameters suggestive of regulatory activity In the ENCODE data, TFBS is transcription factor 
binding sites, DNASE is DNaseI hypersensitivity clusters, NHA refers to normal human astrocytes (the most relevant cell type to AD available), with 
H3K4me1, H3K4me3 and H3K27a all being histone modifications indicative of active or potentially active DNA. A value for any of these may indicate the 
DNA position is in some way functionally active. *Each of these variants fell within the locations of multiple putative transcription factor binding sites. For 
details of which SNPs occurred at which TFBS, see Appendix section 6.2.  
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Table 6.6 Ȯ Association testing of variants upstream of PICALM in imputed data 
Coordinate Ref/Alt rsID Info AD MAF Control MAF OR (95% CI)b p-value 
85780073 G/T rs3016326 0.9037 0.0000 0.0075 -1.0000 0.3091 
85780448 T/C rs3016327 0.9781 0.1918 0.2044 1.0827 (0.9869 - 1.1878) 0.9138 
85780582 G/T rs10898433 0.9975 0.1329 0.1385 0.9530 (0.8603 - 1.0558) 0.4773 
85780924 A/G - - - - - - 
85780962 T/C rs188367538 0.0413 0.0000 0.0000 -1.0000 -1.0000 
85781279 C/G - - - - - - 
85781322 C/T rs669556 0.9994 0.1782 0.1951 1.1184 (1.0218 - 1.2241) 0.7498 
85781523 C/A rs75172533 0.9929 0.0659 0.0552 1.2069 (1.0458 - 1.3928) 0.1533 
85781597 CA/C rs5793180 0.9971 0.1744 0.1926 1.1298 (1.0318 - 1.2372) 0.7721 
85781599 A/G rs11304990 - - - - - 
85781600 G/T - - - - - - 
85781600 GT/G - - - - - - 
85781634 C/G rs55886146 0.9906 0.0292 0.0274 1.0663 (0.8661 - 1.3128) 0.0959 
85781856 C/G - - - - - - 
Results of association testing of the variants showing evidence of functionality upstream of PICALM in imputed data. The OR and 95% CI given correspond to 
ȱȱȱȱȃȄǰȱȱȱȱȱȱ ȱȱȱȱȱ ȱ¢ǰȱȱȱȱȱ ¢ȱd. 
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Table 6.7 Ȯ Variants in areas with multiple lines of evidence of functionality in the rs3851179 LD block 
Coordinate Ref/Alt rsID CRISP freq. 1kg freq. PhyloP Phastcons 
LD with GWAS 
SNP (r2) 
LD with GWAS 
ȱǻȂǼ 
85859598 G/A - 0.0041 - 0.7114 0.1012 - - 
85862491 A/G rs187016120 0.0261 0.0053 -0.5417 0 0.0090 1.0000 
85862739 G/A - 0.0054 - 0.5737 0 - - 
85863014 C/G rs3862786 0.1233 0.1781 1.3011 1.0000 0.0475 1.0000 
85863080 A/C rs56157503 0.1306 0.1306 0.2342 0.9843 0.1051 1.0000 
85863473 G/A rs34731047 0.1004 0.0594 0.2423 0.0236 0.0350 1.0000 
85863683 C/G rs3889743 0.0429 0.0343 0.5844 0.0866 0.0249 1.0000 
85863769 T/G rs11234562 0.2100 0.203 -2.5515 0 0.1823 1.0000 
Information on the variants upstream of PICALM including frequency estimates from CRISP and the 1000 genomes project, conservation scores from both 
PhyloP and Phastcons, and the distance from the transcription start site. The two yellow highlighted variants are those TaqMan genotyped to test for 
association with AD. . Variants showing conservation scores above 0.5 (by either measure) are highlighted in yellow. 
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Table 6.8 Ȯ ENCODE data on variants in the rs3851179 LD block 
Coordinate Ref/Alt rsID ENC_TFBS ENC_DNASE NHA_H3K4me1 NHA_H3K4me3 NHA_H3K27ac 
85859598 G/A - See footnote* 4 4.203475     
85862491 A/G rs187016120 See footnote* 116   7.903122 5.130389 
85862739 G/A - See footnote* 116 4.483236 7.903122 5.130389 
85863014 C/G rs3862786  116 4.483236 7.903122 5.130389 
85863080 A/C rs56157503 See footnote* 116 4.483236 7.903122 5.130389 
85863473 G/A rs34731047 See footnote* 116 4.483236 7.903122 5.130389 
85863683 C/G rs3889743 See footnote*     7.903122 5.130389 
85863769 T/G rs11234562 See footnote*     7.903122 5.130389 
ENCODE data for variants in the rs3851179 LD block for parameters suggestive of regulatory activity. In the ENCODE data, TFBS is transcription factor 
binding sites, DNASE is DNaseI hypersensitivity clusters, NHA refers to normal human astrocytes (the most relevant cell type to AD available), with 
H3K4me1, H3K4me3 and H3K27a all being histone modifications indicative of active or potentially active DNA. A value for any of these may indicate the 
DNA position is in some way functionally active. *Each of these variants fell within the locations of multiple putative transcription factor binding sites. For 
details of which SNPs occurred at which TFBS, see Appendix section 6.3. The two yellow highlighted variants are those TaqMan genotyped to test for 
association with AD. 
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Figure 6.1 Ȯ Sanger validation and TaqMan genotyping assays of rs3851179 LD block variants of interest 
rs187016120 
 
11:85872739 
  
TaqMan readouts and Sanger sequencing validation of SNPs at rs187016120 and 11:85872739 in each case showing wild type homozygous samples on the left, 
and heterozygous samples on the right. No individuals homozygous for the minor allele were detected for either SNP. 
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Table 6.9 Ȯ TaqMan genotyping assay results for rs3851179 LD block SNPs 
  TaqMan genotype 
distribution 
TaqMan and 1kg 
genotype distribution MAF 
  
Variant Genotype Case Control Case Control Case Control OR (95% CI) p-value 
rs187016120 AA 254 204 254 579 0.78% 0.34% 2.27 (0.57-9.11) 0.259 
AG 4 0 4 4 
11:85862739 GG 246 194 
GA 1 0 
Results from the TaqMan genotyping assay for variants 11:85862739 and rs187016120. As no minor alleles were found in the controls for either variant, 
association testing was not possible on this data alone. For the variant at rs187016120, 1000 genomes data was available and was combined with the 
¢ȱȱȱ ȱȱȂȱ¡ȱȱȱȱǰȱȱȱǰȱşśƖȱȱȱp-value for which are shown in the table above. As the variant at 
11:85862739 was novel, no extra control data was available for association testing.  
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Table 6.10 Ȯ Association testing of variants in areas with good evidence of functionality in the rs3851179 LD block in imputed data 
Coordinate Ref/Alt rsID Info AD MAF Control MAF OR (95% CI)b p-value 
85859598 G/A -      
85862491 A/G rs187016120 0.8133 0.0024 0.0023 1.0613 (0.5213 - 2.1607) 0.7442 
85862739 G/A -      
85863014 C/G rs3862786 0.9917 0.1697 0.1598 1.0746 (0.9784 - 1.1803) 0.4285 
85863080 A/C rs56157503 0.9880 0.1070 0.1102 0.9668 (0.8629 - 1.0833) 0.7670 
85863473 G/A rs34731047 0.9749 0.0641 0.0662 0.9675 (0.8369 - 1.1184) 0.7527 
85863683 C/G rs3889743 0.9897 0.0363 0.0315 1.1573 (0.9580 - 1.3981) 0.7080 
85863769 T/G rs11234562 0.9897 0.1850 0.1941 0.9423 (0.8597 - 1.0329) 0.7740 
Results of association testing of the variants with evidence of functionality in the rs3851179 LD block in imputed data. The two yellow highlighted variants are 
those TaqMan genotyped to test for association with AD. The OR and 95% CI given ȱȱȱȱȱȱȃȄǰȱȱȱȱȱȱ ȱȱ
allele has the lower frequency, so these do not always correspond. 
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6.4. Discussion of non-coding variants 
 
Non-coding variants are sometimes overlooked in the search for 
causative mutations for a given genotype, and indeed, the vast majority 
of known detrimental variants are coding ones. It is harder both to 
predict and to prove the functional consequences of non-coding 
variants, and as there is such a vast quantity in the human genome, it is 
harder to know where to begin the search. 
 
Over 850 non-exonic variants were detected in the NGS data of the four 
targeted loci (taking CR1 variants from project two). To narrow down 
the quantity of variants to focus on, it was decided that only the non-
exonic variants within CLUǲȱȱȱśȂȱȱȱȱPICALM gene; and in 
the rs3851179 LD block would be investigated. 
 
Several published studies have sought to characterise the source of the 
association signal within CLU, generally focussing on exonic regions, 
and consistently, no coding variants which can explain the GWAS signal 
have been found (Guerreiro et al. 2010; Bettens et al. 2012; Ferrari et al. 
2012). Given the assumption that the GWAS SNP is tagging a variant or 
variants implicated in AD risk at the CLU locus, it is logical to turn the 
search to non-coding variants. 
 
Attempts at tracking down the source of PICALMȂȱ ȱ ȱ
have been less extensive than those for CLU, but again, no coding 
variants to date have been found to explain PICALMȂȱ ȱ ȱ
AD, so again, perhaps the regulatory regions hold the answers. The fact 
that the initial GWAS SNP fell so far from the actual gene (~88.5kb 
upstream) (Harold et al. 2009) implies the alteration in AD risk 
attributable to this region might be regulatory in nature, particularly 
ȱȱśȂȱȱȱȱȱ(Sleegers et al. 2010). 
 
For the CR1 association signal, there is evidence that suggests the 
alteration in AD risk may stem from the different isoforms of the 
protein, with the S allele associated with an increased risk of AD 
(Brouwers et al. 2012). Given that there are also many coding variants 
within CR1 which have not been thoroughly investigated for their 
potential functional role in the condition, CR1Ȃȱ -coding variants 
were not seen as a priority for pursuit. Since large quantities of non-
coding DNA in the CR1 region were not adequately covered by the 
sequencing, any analysis at this stage would be piecemeal at best. 
 
As was done for the assessment of coding variants, a two pronged 
strategy was adopted, using evidence of functionality, as well as 
association testing in the imputed case-control cohort. This time, 
however, only variants which had three separate lines of evidence of 
functionality from ENCODEȂȱȱ ȱȱȱǰȱȱȱ
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large number of non-coding variants would have made the necessary 
correction for multiple testing prohibitively harsh, given the size of the 
cohort and the limitations of imputation, as discussed in the previous 
chapter.  
 
Five different parameters from ENCODE were used in this assessment 
of functionality Ȯ TFBS, DNASE, and three histone modifications, 
H3K4me1, H3K4me3 and H3K27ac. The data given for these latter three 
is based on the normal human astrocyte cell line, since this was the most 
relevant to AD of all the available cell lines. The first, TFBS, or 
transcription factor binding sites, gives details of any conserved TFBS, as 
determined by ChIP-seq, at the position of each variant. Any SNPs 
falling within these binding sites may be affecting the affinity of the 
sites, so could potentially disrupt the regulatory role the transcription 
factor normally fulfils. The binding motifs for transcription factors are 
normally degenerate, so the variants may or may not affect the site, but 
this would need to be determined. The next, DNASE, refers to DNAseI 
hypersensitivity clusters, based on 125 cell types. Regulatory regions 
and particularly promoters tend to be DNAseI hypersensitive, as the 
DNA here is not tightly wound around histones and being exposed, it is 
vulnerable to enzymatic cleavage. Variants falling within hypersensitive 
sites may therefore be falling in regions of regulatory activity, and may 
potentially be disrupting the normal regulatory function of the region, 
so could be of interest. Histone marks are specific modifications to 
histone proteins which contribute to gene regulation by altering the 
accessibility of the region to transcriptional activity. The levels given are 
of specific histone marks (H3K4me1, which is associated with enhancers; 
H3K4Me3, which is associated with active (or potentially active) 
promoters; and H3K27Ac, which is associated with active transcription, 
possibly via preventing the spread of another, repressive histone mark, 
H3K27Me3), at the sites of the variants detected, determined by ChIP-
seq in the ENCODE data.  
 
None of these parameters individually are conclusive evidence a variant 
could be functional, however, when multiple lines of evidence converge 
at the position of a certain variant, this can suggest functionality, and 
can flag up those variants worthy of further investigation.  
 
Out of the 75 non-coding variants detected within the targeted CLU 
locus, 15 met the filtering criteria ascribed, having at least 3 lines of 
evidence of function from ENCODE. 12 of these 15 variants were 
imputed in the GWAS dataset, although one (rs9331883) had a poor info 
score and a vast range in its 95% CI, thus despite a seemingly suggestive 
p-value of 0.055, it will be disregarded as a potential artefact of 
imputation.  
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Three variants (rs1532276, rs1532277 and rs1532278) showed an 
association with AD (p-values of 0.0009, 0.0005, and 0.0008 respectively), 
which remained significant after Bonferroni correction for the twelve 
multiple tests being conducted (0.05/12 = 0.0042). rs867230 fell short of 
this stringent significance threshold, but at p = 0.0094, it is certainly 
suggestive of significance. All four had strong info scores (>0.96), and all 
were common variants (MAFs in controls all around 0.4). Each of the 
variants appeared to convey a modest increase in AD risk, with ORs 
ranging from 1.16 to 1.22. All of these variants are in strong LD with the 
original GWAS SNP, rs11136000, which itself had a p-value of 0.00089, 
and an OR of 1.172 (95% CI 1.090-1.260). This signifies these variants do 
not represent new, independent association signals. Could any of these 
variants explain the association signal in terms of function, or are these 
merely further tag SNPs for the same elusive source of the original 
signal? 
 
Two of the variants (rs1532277 and rs1532278) had more significant p-
values than the GWAS SNP, which could suggest a causative role in the 
GWAS signal, but the difference was only marginal. That said, the 
GWAS SNP was directly genotyped in the majority of samples used for 
imputation, while the other variants were purely imputed, which 
despite the strong info scores, has an inherently lower power to detect 
associations, so perhaps with direct genotyping these variants would 
further exceed the significance of rs11136000.  
 
The three significantly associated variants, rs1532276, rs1532277 and 
rs1532278 all fall within the third intron of the gene, while the 
suggestive variant, rs867230, falls within intron 1. None of the variants 
showed strong evidence of being in a particularly conserved region, 
from the PhyloP and Phastcons scores. These are measures of 
conservation at a specific position (PhyloP) or across a small region, 
taking in to account neighbouring sites (Phastcons). The scores given for 
PhyloP reflect Ȯlog p-values under the null hypothesis of neutral 
evolution, with positive scores reflecting conservation. The score given 
for Phastcons is a compressed conservation score reflecting the 
likelihood of conservation in an area (on a scale of 0-1, with 1 being 
conserved). A combination of a large positive PhyloP score and a 
Phastcons score approaching 1 therefore gives good evidence a variant is 
affecting an area of high conservation. Such variants are more likely to 
be damaging functionally, as conservation implies evolutionary restraint 
and thus potential functional significance.  
 
The data from ENCODE for the four variants suggests they all fall 
within transcriptionally active DNA regions. All show moderate 
DNASE scores, and all are positive for H3K4me1 histone marks. The 
suggestive variant, rs867230 is also positive for the H3K4me3 histone 
mark. rs1532276, rs1532277 and rs1532278 all fall within potential TFBS 
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according to the ENCODE data. Experimental characterisation would be 
necessary to confirm whether these TFBS are actually actively utilised in 
the regulation of the CLU gene, and whether the presence of the 
detected variants has a detrimental effect on this process. The variants 
which show both evidence of association and evidence of functionality 
are the ones with highest priority for further pursuit.  
 
Of the 14 variants in the region immediately śȂȱȱȱPICALM gene with 
multiple lines of evidence of functionality from ENCODE, eight were 
successfully imputed. None of the variants showed a significant 
association with AD at the p<0.05 level, let alone a Bonferroni corrected 
level of significance. One variant showing evidence of suggestive 
significance was rs55886146 (p=0.0959). This is a rare variant (1000 
genomes project EUR MAF 0.017), with strong evidence of conservation 
(PhyloP 0.8994, Phastcons 0.9921), showing a high level of LD with the 
ȱ	ȱȱǻȂȱŗǼǯȱBecause of the low MAF, it may be that the 
association test in the imputed data lacked power (due to the issues 
imputing rare variants covered in the previous chapter). The variant 
showed evidence of falling within a region of DNAseI hypersensitivity, 
and was positive for all three histone marks assessed, so is potentially 
falling within a regulatory region, although without falling in a 
predicted TFBS, how this regulatory effect could be mediated is unclear.  
 
There were two further variants of potential interest. These fell within 
multiple TFBS in the ENCODE data, had high evidence of falling in a 
DNAseI hypersensitive site, and were positive for all three histone 
marks. These two variants both fell in conserved DNA (PhyloP 2.1640 
and 0.9596 respectively, Phastcons 1 for both), so had strong evidence 
suggesting regulatory functionality. One of the variants, rs188367538, 
was classed as being imputed, but had a poor info score, so was not 
adequately tested for association with AD by our method. The other, at 
position 11:85780924, was a novel variant so could not be imputed. 
Direct genotyping of the variants would be necessary to adequately 
address whether they are associated with AD, while further in silico and 
experimental functional investigations would be needed to elucidate if 
and how they are related to AD pathology.   
 
Eight variants within the rs3851179 LD block showed three or more lines 
of evidence of functionality in the ENCODE data. When the project 
began, a choice was made whether to include simply PICALM, the gene 
tagged by the GWAS association signal, or whether to also include the 
region in which the GWAS SNP fell, in an LD block ~88.5kb upstream of 
the gene. Analysis of the information available, particularly ENCODE 
data, for the LD block suggested that the region may contain some 
regulatory activity. Of particular interest was a ~500bp span of DNA 
with high DNAseI hypersensitivity, multiple TFBS, and evidence of high 
levels of the three histone marks associated with regulatory activity 
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considered (H3K4me1, H3K4me3 and H3K27ac). For these reasons, the 
LD block was also targeted in the NGS project. When the variants were 
identified in the NGS data, two (rs187016120 and the variant at position 
11:85862739) fell within this ~500bp region, with high levels of evidence 
of functionality. An MSc student in Molecular Genetics and Diagnostics, 
Ng See May, undertook validation of these two variants via Sanger 
sequencing, and used TaqMan assays to genotype the variants in a case-
control cohort, to facilitate association testing. The novel variant, at 
position 11:85862739 was successfully validated in the sample from the 
NGS data, but no further alternative alleles were detected in the 440 case 
and control samples genotyped. Since it has also not been reported in 
the 1000 genomes project data, the variant is certainly rare, and may be a 
private mutation, whose relationship with AD would be difficult to 
assess. The other variant, rs187016120, was also successfully validated, 
and was found in four case samples out of 258 in the TaqMan data, and 
in none of the 204 control samples. Since no alternative alleles were 
found in the control samples, it was not possible to test for association 
with AD in the TaqMan data alone, but combining the TaqMan case 
data with 1000 genomes data for the variant enabled this. 379 control 
samples from the 1000 genomes EUR population had data available for 
this variant, including four heterozygotes. When this was tested for 
association with AD in the TaqMan and 1000 genomes data, no evidence 
of association was found, and the imputed data showed no suggestion 
of association either. Despite all of the suggestions of functional activity, 
this SNP, and indeed the other potentially functional SNPs within the 
region showed no evidence of association with AD, even when in strong 
LD with the GWAS SNP.  
 
This chapter has detailed the prioritisation of non-coding variants for 
follow up research. Those falling within the areas thought most likely to 
harbour functional variants (CLUǰȱ ȱ ȱ ȱ ȱ ȱ śȂȱ ȱ
PICALM, and the rs3851179 LD block) were assessed for likely 
functionality using in silico resources, and any with multiple lines of 
evidence of functionality were tested for association with AD in the 
imputed data set. Three intronic variants within the targeted CLU region 
occurred at the sites of ENCODE database TFBS, and were significantly 
associated with AD, so were classed as a high priority for further 
research. A fourth showed suggestive significance but did not withstand 
correction for multiple testing, and had less compelling evidence of 
functionality, so was classed as a low priority for follow up. Only one 
ȱ ȱ ȱ ȱ ȱ ȱ śȂȱ ȱ PICALM showed suggestive 
significance, but had limited evidence of functionality. Two variants 
upstream of PICALM coincided with the sites of ENCODE database 
TFBS. These were both inadequately tested for association with AD (one 
was novel so could not be imputed, and the other was poorly imputed), 
so were determined to be a high priority for future work.  
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7. General Discussion 
 
7.1. Summary of main findings 
 
There are take home messages from each of the chapters presented here, as 
well as from the project as a whole. Chapter 3 Ȯ Data analysis provided a 
robust pipeline for the analysis of pooled sequencing data. The development 
of the pipeline during the first sequencing project was crucial for the handling 
of the second, which had a significantly increased volume of data and thus 
was extremely time consuming to process. It also allowed the assessment of 
the quality of the data produced, and the reliability of variant calls, which was 
generally good, although problems of coverage in the CR1 region were 
identified. Chapter 4 Ȯ Sanger validation was based on a publication which 
highlighted some of the issues caused by indels and mononucleotide repeats 
for NGS (Lord et al. 2012). Chapters 5 and 6 (Exonic and Non-exonic variants) 
present a new method for prioritising variants based on combined evidence of 
functionality from in silico resources, and evidence of association from 
imputed data. The utilisation of these steps ensure only variants with the best 
evidence of involvement in AD risk are pursued with expensive and time 
consuming functional experimentation and direct genotyping. Several coding 
and non-coding variants within the three genes were identified as worthy of 
follow up research, which will be discussed in section 7.2. Next steps. The 
methods used in general provide a cost-effective framework for following up 
GWAS identified risk loci, in AD as well as other conditions. The utilisation of 
pooled targeted sequencing has been shown to be capable of identifying 
variants, significantly reducing the costs involved in individual sequencing. 
Whilst this project cannot claim to give a comprehensive catalogue of rare 
variation in the loci targeted, given the modest sample size, it contributes to 
the general body of knowledge of AD genetics, and may be a small stepping 
stone on the long path to understanding AD aetiology, and turning that 
understanding into advances for those affected by the condition.  
 
7.2. Next steps 
 
Out of more than 1000 variants detected within the NGS data, Table 7.1 shows 
the 16 variants deemed most worthy of further research, the reasons behind 
this prioritisation, and the vein in which follow up research would proceed. 
Each of the variants was given a level of priority for follow up research. Those 
with no evidence of functionality in the investigations conducted were 
deemed to be low priority, irrespective of their level of association with AD. 
Variants which did show evidence of functionality, but had been successfully 
imputed and not been found to be associated with AD were classed as 
medium priority. The SNPs were classed as high priority if they showed 
evidence of functional effects, directing the course of follow up studies, as well 
as evidence of association (significant or suggestive) in the imputed data. Rare 
variants showing suggestive association may be particularly promising 
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candidates for involvement in AD, given rarity is known to reduce power in 
imputed data. Also classed as high priority were those that showed evidence 
of functionality but had not been adequately tested for association with AD, 
either because they could not be imputed or were poorly imputed.  
 
The follow up research for the variants depends on what type of functional 
evidence was found for them. The list included four missense mutations, all of 
which were predicted by Polyphen-2 to be possibly or probably damaging. 
While Polyphen-2 normally compares favourably with other mutation 
prediction programs when tested alongside experimental functional data (Di 
et al. 2009; Adzhubei et al. 2010; Wei et al. 2010), no in silico prediction 
programs are 100% accurate. With estimated correct prediction rates ranging 
from 91.7% (Zou et al. 2011) to 66.7% (Di et al. 2009), a Polyphen-2 deleterious 
prediction alone is not confirmation a variant is functional. Experimental 
confirmation is necessary to clarify the accuracy of the predictions for these 
SNPs. Often, to achieve this validation, variant and wild type versions of the 
protein are expressed in a relevant cell line, and the function of the protein 
(e.g. enzymatic activity) is measured (Brunham et al. 2005; Di et al. 2009; Zou 
et al. 2011). However, for PICALM and CR1, it is not known what aspect of the 
Ȃȱȱȱ¢ȱȱȱȱ¢ǰȱȱȱ ȱȱȱ
ȱ ȱȱȱǯȱȱȱ¡ȱ“?ȱ¢ȱȱȱ
useful measure, but it would be unclear whether a lack of effect indicated that 
the wild-type and variant sequences had the same effect on this level, or 
whether it indicated that the PICALM or CR1 proteins do not affect AD risk 
via this mechanism. Without a specific parameter to measure, a more 
generalised approach could be adopted. Transgenic mice can be created with 
specific mutations using homologous recombination. Replacing the wild-type 
gene with sequence containing the variant of interest, and monitoring the 
effect on the resultant animals in terms of brain development and cognitive 
function when compared to the wild type would allow a method to assess the 
consequences of the variants without knowing what specific molecular 
mechanism is involved. However, such experimentation is highly specialised 
and expensive to conduct, thus it could not be justified without stronger 
evidence supporting these variants roles in AD.  
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Table 7.1 Ȯ Variants of interest and future research directions 
Type Gene Variant Associated Functional  Priority Follow up functional research 
Exonic CLU rs7982 Yes No  Low  
rs9331950 Yes No  Low  
rs9331949 Suggestive (rare) No  Low  
rs9331942 Suggestive (rare) No  Low  
PICALM 11:85707933 Not imputed  Missense, probably damaging 
SRSF1 site disrupted 
High Investigate variant protein 
Investigate splicing 
rs592297 No SRSF1 site disrupted Medium Investigate splicing 
rs76719109 
 
No SRSF2 site disrupted Medium Investigate splicing 
CR1 rs41274770 Suggestive (rare) Missense, possibly damaging High Investigate variant protein 
rs61734514 Suggestive (rare) Missense, probably damaging 
SRSF1 site disrupted 
High Investigate variant protein 
Investigate splicing 
Non-
coding 
CLU rs1532276 Yes TFBS High Investigate TFBS 
rs1532277 Yes TFBS High Investigate TFBS 
rs1532278 Yes TFBS High Investigate TFBS 
rs867230 Suggestive No Low  
PICALM rs55886146 Suggestive (rare) No Low  
rs188367538 Low info score (rare) TFBS High Investigate TFBS 
11:85780924 Not imputed TFBS High Investigate TFBS 
Summary information on the variants with the strongest evidence of links to AD, either from association testing or the in silico functional prediction programs 
used. Ideas for further research on these variants designed to clarify associations and validate the predictions of the in silico resources are listed, along with the 
level of priority for follow up for each of the variants. For strengths of associations (ORs and p-values) see Table 5.2 for exonic SNPs and Tables 6.3 and 6.6 for 
CLU and PICALMȁȱ-exonic variants respectively. 
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For the four variants which showed evidence of affecting the binding sites of 
SR-splicing proteins, an experimental approach utilising a mini-gene vector 
system would be adopted. This involves the introduction of wild-type and 
variant versions of the affected exon in to mini-gene vectors, and transfection 
in to a relevant cell line. The mRNA generated from the vectors can then be 
analysed (e.g. PCR and gel electrophoresis to assess large scale effects, Sanger 
sequencing to confirm or to check for smaller scale alterations), and any 
differences in the splicing of the exon would indicate that that variant does 
indeed have an effect on splicing.  These experiments are currently on going. 
 
Five of the variants fell within TFBS according to the ENCODE data. To follow 
up these variants further in silico analyses would be wise to guide 
experimental characterisation attempts. It would need to be established which 
of the putative disrupted sites were actually utilised in the regulation of the 
genes in question, and how the variants would affect these, since many TFBS 
are degenerate and the variants may be tolerated even if they fall within 
actively used sites. There are multiple other tools and databases available for 
the investigation of TFBS, such as TRANSFAC (Matys et al. 2006) and JASPAR 
(Sandelin et al. 2004), and collation of the predicted binding sites from each of 
these would strengthen the evidence. Several potential experimental 
approaches would be appropriate following thorough in silico investigations. 
EMSA (electrophoretic mobility shift assay) allows an in vitro method for 
assessing TF binding. The wild-type and variant sequences would need to be 
labelled, and incubated with relevant cell nuclear extracts (e.g. neuronal cells). 
When subjected to electrophoresis, labelled DNA alone will show a different 
motility than DNA bound by TFs, and any differences in pattern between the 
sequences could indicate disruption of TFBS. Alternatively, the wild-type and 
variant sequences could be cloned upstream of a reporter gene in a promoter 
construct plasmid and be transfected in to a relevant cell line, with any 
differences in reporter gene expression indicative of differential activity (de 
Vooght et al. 2009). 
 
Two of the prioritised variants were novel, and thus could not be imputed, 
and a third was poorly imputed within our dataset, so they were not 
adequately tested for association with AD via the methodology used. 
Genotyping of the variants (e.g. using TaqMan and/or KASP assays) could be 
conducted to facilitate association testing. However, as all of these variants are 
rare, the number of samples needed to give the study sufficient power would 
be very high, and this would therefore be very costly. For these variants, 
experimental characterisation of functional effects would be more cost 
effective as a first step rather than genotyping all in a large number of 
samples. Any which showed compelling evidence of functionality could then 
be followed up by genotyping.  
 
Direct genotyping would also be useful for those variants showing suggestive 
associations with AD in our imputed data. The greater power afforded by this 
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method over imputation would establish which variants were genuinely 
associated with the disease. Particularly for the rarer variants, on which the 
limitations of imputation would have had the greatest effect, this would allow 
thorough association testing, although the rarer variants would also require 
larger sample sizes to give sufficient power. Even for the variants which were 
associated with AD in the imputed data, replication in an independent cohort 
is important for any such genetic findings, and even more so when the 
associations are in imputed data, so genotyping in a case-control cohort would 
also be useful here, but this is not the top priority for future work.  
 
7.3. AD genetics - update 
 
Our results suggest some exciting potential directions for future work in 
exploring how these three genes relate to AD, but there are still no real 
answers as to how these genes are linked to the pathology of the condition, 
and which variants are responsible for these links. Four years on from the 
publication of the first two major GWAS, the source of the three association 
signals detected remains largely elusive.  
 
As mentioned previously, there is some evidence that the CR1 GWAS 
association signal may stem from the different alleles of the gene, essentially a 
copy number variation in the number of binding sites in the protein (Brouwers 
et al. 2012). The larger S allele is associated with an increased risk of the 
condition, while the smaller F allele appears to be protective. This is a 
contradiction to many of the hypothesised ways in which CR1 was thought to 
be related to AD pathology, such as the peripheral sink hypothesis. If CR1 was 
ȱ ȱȱ ȱ ȱ ¢ȱ ȱ ȱ ȱ ȱȱ ǰȱ ȱ“?ȱ
ȱ ȱ ǰȱ ȱ ȱ ȱ ȱ “?ȱȱ ȱ ǰȱ ȱ
would be expected that the larger isoforms would be more efficient at this 
process, and thus would be protective. Since this is not the case, it strengthens 
arguments for CR1Ȃȱ ȱ  ȱ ȱ ȱ ȱ ȱ ȱ
neuroinflammation, or perhaps, as suggesteȱ¢ȱȱ ȱ ǯȂȱ ǰȱ ¢ȱ
ȱ ȱ ȱ ȱ ȱ ȱȱ ȱ ȱ ǰȱ ȱ ȱ Ȃȱ
ability to cope with AD processes when they occur later on (Bralten et al. 
2011). 
 
For CLU and PICALM, the causal source underlying the GWAS signals 
remains a mystery. Although attempts to track down the underlying causative 
variants have been more extensive for CLU (Harold et al. 2009; Guerreiro et al. 
2010; Bettens et al. 2012; Ferrari et al. 2012) than for PICALM (Harold et al. 
2009; Ferrari et al. 2012; Schnetz-Boutaud et al. 2012), neither have been 
particularly fruitful, with no real explanatory causal variation found.  
 
The lack of success in tracking down the source of the original three 
association signals is not a reflection of a lack of progress in the AD genetics 
field in general in the past four years. Indeed, the extensive exome and other 
next generation sequencing projects embarked on in the last three years are 
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beginning to reach fruition, and publication of their results in AD and other 
relevant traits are beginning to appear, identifying new variants and new 
genes which appear to be involved in AD risk. Pottier et al. conducted exome 
sequencing in 14 autosomal dominant early onset AD cases with no known 
APP, PSEN1 or PSEN2 mutations, as well as a further 15 replication cases 
(Pottier et al. 2012). 29 previously unknown variants were identified within 
the cases in the SORL1 gene, 7 of which were predicted to have pathogenic 
effects. SORL1Ȃȱ ȱ ȱ ȱ ȱ  ȱ ȱ ȱ ȱ ȱ “?ȱ
production (Rogaeva et al. 2007). The gene had already been linked to the late 
onset form of AD (Rogaeva et al. 2007), which has recently received 
replication in several independent studies (Jin et al. 2013; Lambert et al. 2013; 
Miyashita et al. 2013; Wen et al. 2013). Using exome sequencing and genotype 
imputation in MCI patients, Nho et al. sought coding variants associated with 
rate of hippocampal volume loss in 16 patients, 8 of whom showed rapid rates 
of atrophy while 8 showed slow or steady rates of atrophy (Nho et al. 2013). 
Three variants were found that were present in at least 6 of the rapid atrophy 
samples, but absent from the slow atrophy group in the genes HYAL4, PARP1, 
and CARD10, the latter two of which were predicted to be damaging by 
Polyphen-2. Genetic variation within PARP1 and CARD10 was found to be 
associated with the rate of neurodegeneration in the hippocampus in APOE 
“?řȦ“?řȱȱ(Nho et al. 2013). CARD10 is involved in regulation of apoptosis 
and inflammation (Wang et al. 2001; Nho et al. 2013), while PARP1 has roles in 
a number of cellular processes, such as DNA repair, cell proliferation and cell 
death (Menissier de Murcia et al. 2003; Nho et al. 2013). Its protein product 
had previously been reported to show enhanced activity in AD affected brains 
(Love et al. 1999). 
 
Following extensive exome and genome sequencing, imputation and 
genotyping, two independent studies were simultaneously published, 
reporting a number of variants within the TREM2 gene to be associated with 
AD (Guerreiro et al. 2013; Jonsson et al. 2013). Of particular interest was SNP 
rs75932628 (encoding the missense mutation R47H, which was predicted to be 
damaging by Polyphen-2). This was the most significantly associated variant 
in both studies. Homozygous loss of function of the TREM2 gene is known to 
cause the rare Nasu-Hakola disease, a severe condition characterised by bone 
cysts and early onset dementia resulting in premature death (Bianchin et al. 
2004). Within the brain, TREM2Ȃȱ ȱ ȱ ȱ ¡ȱ ȱ ȱ ȱ
(Sessa et al. 2004), it is thought to be a mediator of inflammation in the brain, 
ȱ¢ȱȱȱȱ“?ȱȱ(Piccio et al. 2007; Takahashi et al. 2007; 
Frank et al. 2008).  
 
Recently, the largest AD GWAS to date was published, comprised of a meta-
analysis of GWAS in individuals of European ancestry (Lambert et al. 2013). 
The two stage approach saw 7,055,881 SNPs genotyped or imputed in 17,008 
AD cases and 37,154 controls in stage one, with 11,632 SNPs genotyped in a 
second independent cohort consisting of 8572 AD cases and 11,312 controls. 19 
loci reached genome wide significance in the combined data set, of which 11 
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represented new AD risk loci (HLA-DRB5ȮHLA-DRB1, PTK2B, SORL1, 
SLC24A4-RIN3, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2 and 
CASS4) (Lambert et al. 2013). Many of these genes fit with previously 
ȱȱ ¢ǰȱ ȱȱ ȱ ȱ ȱ ȱ“?ȱǰȱ
with potential new pathways including cytoskeletal function, axonal transport 
and hippocampal synaptic function (Lambert et al. 2013). Use of the methods 
presented here, with pooled NGS to detect variants in coding and non-coding 
regions, and a combination of in silico functional analyses and imputed 
association testing to prioritise variants of interest would be an advisable way 
ȱȱȱȱȱȂȱȱȱǯȱ 
 
So how much do we now know about ȱȱȱ£Ȃȱ, and 
what is there still to find out? Recently, Ridge et al. estimated the phenotypic 
variance in AD explained by common variants in the human genome to be 
33.1%, and that 7.78% of that was attributable to APOE and the nine AD 
associated genes from GWAS prior to the Lambert meta-analysis, leaving 
25.3% to be explained by as yet unidentified common variants (Ridge et al. 
2013). Although the 11 new loci found in the recent meta-analysis (Lambert et 
al. 2013) will also contribute to the explained variance, the effect sizes of the 
new variants were generally smaller than those for the nine previously known 
loci, so a large proportion of missing heritability still remains. Part of this 
discrepancy is likely to be due to the variants identified by GWAS not being 
the actual causative variants, but imperfect tags for them, which leads to an 
underestimation of the effect size. In CrohȂȱ ȱ ǻǼǰȱ ȱ ŝŖȱ ȱ
associated with the condition have been found using GWAS, but only around 
ŘřǯřƖȱ ȱ ȱ Ȃȱ ¢ȱ ȱ ¡ȱ ¢ȱ ǯȱ
 ǰȱ ȱ  ȱ
reported that at one of the loci (NOD2), the most significant SNP in the GWAS 
explained around 0.8% of CD risk, but three known coding mutations within 
the gene accounted for 5% (Franke et al. 2010). This is over six times greater 
than the value for the GWAS tag SNP alone. If a similar pattern is true in some 
of the known AD risk loci, this could render the total heritability explained by 
the known genes higher than current estimates suggest. Identifying the causal 
variants underlying the GWAS signals would enable a true assessment of the 
Ȃȱȱȱȱǰȱȱȱȱȱȱȱȱȱ¢ȱǯȱȱ
potential sources of missing heritability in AD include: unknown associated 
variants at known loci; other as yet unknown loci, which could be identified 
through further GWAS and meta-analyses (such as the 11 new loci Lambert et 
al. identified (Lambert et al. 2013)) or sequencing based investigations (e.g. the 
TREM2 locus); and epistatic interactions between variants or genes.  
 
Despite the vast quantity of disease associated loci that have been detected 
since the advent of GWAS, few causal variants underlying these association 
signals have been definitively established. Many of the attempts to track down 
causal variants underlying the AD GWAS signals have focussed on coding 
regions only, and have largely proved unfruitful (Guerreiro et al. 2010; Bettens 
et al. 2012; Ferrari et al. 2012). Bettens et al. did find evidence of rare variants 
within CLU impacting on AD risk, but these were independent of the GWAS 
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SNP (Bettens et al. 2012). This could be indicative that the GWAS SNPs are 
actually tagging non-coding, regulatory variants rather than coding ones. In 
order to find such variants, projects such as the one presented here will be 
important, focussing not just on coding variants but the entire gene and its 
surrounding regulatory regions. Assessing the involvement of such variants is 
less easy than assessing the impact of coding ones, but if coding variants are 
not responsible, then we have no choice but to pursue non-coding ones. It is 
also possible that other phenomena, such as the CNV underlying at least in 
part the CR1 GWAS signal (Brouwers et al. 2012), may play a greater role than 
anticipated.  
 
As for the common disease, common variant hypothesis versus the multiple 
rare variants hypothesis presented in the introduction, which has been an 
ongoing debate since the inception of GWAS, the answer appears to be both. 
The most extensively sequenced of the three genes from the first GWAS 
studies is CLU, and within CLU, it appears that there are multiple rare 
variants of large impact which affect AD risk (Bettens et al. 2012), but that 
these are independent of the common association signal found by GWAS, 
which is likely to be tagging regulatory variants. Perhaps most disease 
associated loci contain variants both common and rare, with varying levels of 
ǯȱȱ ȱ ȱ ȃȄȱȱ ȃȄȱ  a false dichotomy, 
over-simplifying a spectrum of different allele frequencies into two groups, 
and the same could be said for high and low impact classifications.  
 
The aetiology of AD is clearly very complex, and as it is a disease of old age, 
this is exacerbated Ȯ genes have a long time to interact, environmental factors 
have longer to act, interactions between genes and environmental factors 
whose exposure levels may be changing all the time may all contribute. Given 
this immense complexity, it seems unlikely the full aetiology of AD will ever 
be completely understood, but progress is being made, and with this increase 
in knowledge comes an improvement in prospects for treatments that could 
actually make a difference to individuals suffering from this devastating 
condition. 
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URLs: 
 
UCSC Virtual PCR - http://genome.ucsc.edu/cgi-bin/hgPcr 
 
UCSC - http://genome.ucsc.edu/ 
 
UCSC liftOver - http://genome.ucsc.edu/cgi-bin/hgLiftOver or downloadable from  
 
http://hgdownload.cse.ucsc.edu/admin/exe/ 
 
UCSC Tables - http://genome.ucsc.edu/cgi-bin/hgTables?command=start 
 
ENCODE @ UCSC - http://genome.ucsc.edu/ENCODE/ 
 
ECR browser - http://ecrbrowser.dcode.org/ 
 
dbSNP - http://www.ncbi.nlm.nih.gov/SNP/ 
 
Source Bioscience - http://www.sourcebioscience.com/ 
 
eArray - https://earray.chem.agilent.com/earray/ 
 
FastQC - http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ 
 
MOSAIK aligner - http://code.google.com/p/mosaik-aligner/ 
 
BFAST - http://bfast.sourceforge.net 
 
SAMtools - http://samtools.sourceforge.net/ 
 
SAMStat - http://samstat.sourceforge.net/ 
 
IGV - http://www.broadinstitute.org/igv/ 
 
Syzygy - http://www.broadinstitute.org/software/syzygy/ 
 
CRISP - https://sites.google.com/site/vibansal/software/crisp 
 
Impute2 File Formats: 
http://www.stats.ox.ac.uk/~marchini/software/gwas/file_format.html 
 
Impute2 - http://mathgen.stats.ox.ac.uk/impute/impute_v2.html#home 
 
Plink - http://pngu.mgh.harvard.edu/purcell/plink/ 
 
Gtool - http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html 
 
VCFtools - http://vcftools.sourceforge.net/ 
 
Tabix - http://samtools.sourceforge.net/tabix.shtml 
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SIFT - http://sift.jcvi.org/ 
 
Polyphen - http://genetics.bwh.harvard.edu/pph2/ 
 
ESEfinder - http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home 
 
BDGP - http://www.fruitfly.org/seq_tools/splice.html 
 
NetGene2 - http://www.cbs.dtu.dk/services/NetGene2/ 
 
TargetScan - http://www.targetscan.org/ 
 
PITA - http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html 
 
Quanto - http://hydra.usc.edu/gxe/ 
 
HapMap - http://hapmap.ncbi.nlm.nih.gov/ 
 
Haploview - http://www.broadinstitute.org/scientific-
community/science/programs/medical-and-population-genetics/haploview/haploview 
 
Repeat Masker - www.repeatmasker.org 
 
RepBase - http://www.girinst.org/repbase/ 
 
GATK - http://www.broadinstitute.org/gatk/ 
 
Ensembl - http://www.ensembl.org/index.html 
 
Ensembl's VEP - http://www.ensembl.org/tools.html 
 
1000 genomes project data site - http://www.1000genomes.org/data (for information), 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/ (for data access) 
 
Primer3 - http://bioinfo.ut.ee/primer3-0.4.0/ 
 
NGRL Manchester SNP check - 
https://ngrl.manchester.ac.uk/SNPCheckV3/snpcheck.htm 
 
Chromas lite - http://technelysium.com.au/?page_id=13 
 
SNPtest - https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html 
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Appendix 
 
2.1 Ȯ Sample pooling strategy 
Pool 
No. 
Sample 
No. ID 
Conc. 
(ng/µl) Dilution 
Volume added to 
pool (µl)* 
1 
 
1 AD219 106.08 - 5.66 
2 AD232 112.08 - 5.35 
3 M547 191.26 - 3.14 
4 AD218 225.07 - 2.67 
5 AD236 269.44 - 2.23 
6 M659 320.08 - 1.87 
7 AD221 320.08 - 1.87 
8 M523 349.18 - 1.72 
9 M551 394.15 - 1.52 
10 M641 400.98 - 1.50 
11 M604 414.92 - 1.45 
12 AD235 417.42 - 1.44 
2 
 
13 AD222 425.85 - 1.41 
14 AD224 447.25 - 1.34 
15 AD245 463.41 - 1.29 
16 AD233 479.74 - 1.25 
17 AD197 493.48 - 1.22 
18 M596 503.88 - 1.19 
19 M565 520.05 - 1.15 
20 AD220 524.70 - 1.14 
21 AD238 542.07 - 1.11 
22 M540 543.15 - 1.10 
23 M546 568.51 - 1.06 
24 AD257 612.08 1 in 2 1.96 
3 
 
25 AD231 618.17 1 in 2 1.94 
26 M605 644.26 1 in 2 1.86 
27 AD227 650.27 1 in 2 1.85 
28 AD251 667.24 1 in 2 1.80 
29 AD207 670.96 1 in 2 1.79 
30 AD246 686.33 1 in 2 1.75 
31 AD212 698.82 1 in 2 1.72 
32 M651 704.82 1 in 2 1.70 
33 M530 719.72 1 in 2 1.67 
34 AD253 738.23 1 in 2 1.63 
35 AD203 741.81 1 in 2 1.62 
36 AD210 780.08 1 in 2 1.54 
4 
 
37 AD255 792.41 1 in 2 1.51 
38 M571 820.01 1 in 2 1.46 
39 M094 821.84 1 in 2 1.46 
40 AD206 821.87 1 in 2 1.46 
41 AD249 886.29 1 in 2 1.35 
42 M589 889.20 1 in 2 1.35 
43 M531 890.77 1 in 2 1.35 
44 M593 895.00 1 in 2 1.34 
45 51/05 978.55 1 in 2 1.23 
46 AD201 1015.50 1 in 2 1.18 
47 AD216 1022.11 1 in 2 1.17 
48 M576 1031.98 1 in 2 1.16 
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5 
 
49 M643 1034.59 1 in 2 1.16 
50 AD243 1048.06 1 in 2 1.14 
51 M579 1057.61 1 in 2 1.13 
52 M562 1111.66 1 in 2 1.08 
53 M543 1134.91 1 in 2 1.06 
54 M522 1144.07 1 in 2 1.05 
55 AD213 1146.90 1 in 2 1.05 
56 AD244 1170.06 1 in 2 1.03 
57 AD225 1267.00 1 in 3 1.42 
58 AD199 1283.91 1 in 3 1.40 
59 M524 1294.32 1 in 3 1.39 
60 AD242 1301.59 1 in 3 1.38 
6 
 
61 AD248 1394.94 1 in 3 1.29 
62 M573 1455.10 1 in 3 1.24 
63 M526 1518.86 1 in 3 1.19 
64 M647 1679.06 1 in 3 1.07 
65 M528 1679.65 1 in 3 1.07 
66 M646 1719.55 1 in 3 1.05 
67 AD117 1768.54 1 in 3 1.02 
68 AD252 1802.82 1 in 3 1.00 
69 M577 1841.86 1 in 4 1.30 
70 M599 1848.20 1 in 4 1.30 
71 M590 2018.11 1 in 4 1.19 
72 AD254 2046.27 1 in 4 1.17 
7 
 
73 M637 2073.50 1 in 4 1.16 
74 M645 2124.15 1 in 4 1.13 
75 AD211 2130.62 1 in 4 1.13 
76 M648 2138.16 1 in 4 1.12 
77 M594 2214.87 1 in 4 1.08 
78 AD208 2225.99 1 in 4 1.08 
79 M575 2291.49 1 in 4 1.05 
80 M639 2346.48 1 in 4 1.02 
81 M527 2441.02 1 in 5 1.23 
82 M536 2531.52 1 in 5 1.19 
83 M649 2651.15 1 in 5 1.13 
84 M644 2882.31 1 in 5 1.04 
8 85 M529 2935.57 1 in 5 1.02 
86 AD115 3063.75 1 in 6 1.18 
87 M638 3096.46 1 in 6 1.16 
88 M642 3161.98 1 in 6 1.14 
89 AD141 4793.94 1 in 8 1.00 
90 AD146 4833.60 1 in 9 1.12 
91 AD112 5548.82 1 in 10 1.08 
92 AD107 5999.41 1 in 10 1.00 
93 AD123 6342.72 1 in 11 1.04 
94 AD125 7340.78 1 in 13 1.06 
95 AD157 7643.78 1 in 13 1.02 
96 AD109 7937.67 1 in 14 1.06 
Details of samples used in NGS project, their concentrations, and the pooling strategy 
utilised. *Where a dilution is stated in the previous column, this is the volume of 
diluted DNA added to the pool. 
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2.2 Ȯ Perl script for obtaining 1000 genomes project frequency data 
 
Contents of the perl script, written by Hui Shi, used for obtaining frequency estimates 
for variants of interest based on 1000 genomes phase 1 data. Shown above is the 
version of the script edited to obtain the 1000 genomes frequency data for the 
PICALM rs3851179 LD block. ȱ ȱȃȄȱȱȃȄȱȱȱȱȱ
the perl script print_allele_count and print_sample_ID determines whether these 
pieces of information are included in the output file. 
 
2.3 Ȯ Script to interleave paired-end reads 
 
The script opens read file A (i.e. the forward reads) and interrogates read file B for 
the read with the matching header (i.e. the pairs, aligned to the reverse strand), 
calculating the reverse complement of the second read and reversing the quality 
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scores. The output contains the interleaved reads in the format 1Read1, 1Read2; 
2Read1, 2Read2, which can then be used to run the BFAST alignment. 
 
2.4 Ȯ Perl script for converting WTCCC2 data from hg18 to hg19 
 
Contents of the perl script liftOverGen.pl used in the preparation of WTCCC2 data 
for imputation. The script converts the coordinates of variants from hg18 to hg19. 
 
2.5 Ȯ Perl script to recode WTCCC2 .samples files 
 
Contents of the perl script recode_WTCCC2.sample.pl, utilised in the preparation of 
WTCCC2 data for imputation. The script recodes phenotype information to a format 
which Impute2 will recognise, as well as adding centre information and changing the 
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format of missing values to ones Impute2 can process. The script is altered at line 27 
depending on the centre (58C = 2, NBS = 3). 
 
2.6 Ȯ Perl script to remove duplicate lines 
 
Contents of the perl script used to remove duplicate positions from the imputed data 
sets, enabling the Ȯoverlap command to be used when running association testing 
with snptest. 
 
2.7 Ȯ Perl script to calculate conservation at positions of interest 
 
Contents of the perl script used in calculating the level of conservation at the 
positions affected by variants found in the NGS data. 
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2.8 Ȯ Perl script to calculate LD between variants of interest 
 
Contents of the perl script used to calculate the level of LD between index GWAS 
SNPs and variants detected by NGS. 
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6.1 Ȯ CLU variants at the sites of ENCODE TFBS  
Coordinate rsID ENC_TFBS 
27466157 rs1532276 GATA-2,TAF1 
27466181 rs1532277 GATA-2,TAF1,USF-1 
27466315 rs1532278 GATA-2,Max,NANOG_(SC-33759),USF2,TAF1,USF-1,USF1_(SC-8983) 
27469971 rs9331883 FOXA2_(SC-6554),FOXA1_(SC-101058),FOXA1_(C-20) 
27470010 - FOXA2_(SC-6554),FOXA1_(SC-101058),FOXA1_(C-20) 
27471673 - BATF,eGFP-FOS,CEBPB,c-Fos,GATA-2,JunD,STAT3,c-Jun,RFX5_(N-494) 
27471748 - BATF,eGFP-FOS,FOSL2,eGFP-JunD,c-Fos,GATA-2,JunD,TCF4,STAT3,c-Jun,RFX5_(N-494) 
27474202 rs9314349 Pol2(b) 
27474541 rs117148275 TAF1,GR,AP-2alpha,AP-2gamma,Pol2,GATA-1 
27474587 rs56025648 GR,AP-2alpha,AP-2gamma,Pol2,GATA-1 
27474599 rs1982229 GR,GATA-2,AP-2alpha,AP-2gamma,Pol2,GATA-1 
27474871 rs77336101 p300_(N-15),Pol2-4H8,GATA-2,c-Fos,p300,YY1_(C-20),RFX5_(N-494),MafK_(ab50322),JunD,STAT3,c-Jun,GATA-1 
Full list of the ENCODE TFBS falling at the positions of variants of interest from the NGS project data in the CLU region. 
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6.2 - PICALM variants at the sites of ENCODE TFBS 
Coordinate rsID ENC_TFBS 
85780073 rs3016326 Egr-1,RFX5_(N-494),YY1,HEY1,USF2,SP1,HA-E2F1,PU.1,NRSF,GTF2F1_(RAP-74),TCF12,YY1_(C-
20),Pol2,NFKB,E2F6,USF1_(SC-8983),Pol2(phosphoS2),ETS1,TAF1,Pol2-4H8,TBP,Pbx3,GATA2_(CG2-
96),GABP,SRF,GATA-1,Sin3Ak-20,c-Myc,USF-1,ELF1_(SC-631) 
85780448 rs3016327 TAF1,Egr-1,Pol2,TCF12,ZBTB7A_(SC-34508),PAX5-N19,USF1_(SC-8983),IRF4_(M-
17),HEY1,RXRA,SP1,NFKB,USF-1,c-Myc,Pol2-4H8 
85780582 rs10898433 TAF1,Pol2,TCF12,ZBTB7A_(SC-34508),PAX5-N19,IRF4_(M-17),HEY1,E2F6_(H-50),SP1,NFKB,c-Myc,Pol2-
4H8,Oct-2,POU2F2 
85780924 - eGFP-JunD,TBP,c-Jun,TAF1,SRF,Pol2,YY1,Sin3Ak-20,NRSF,CEBPB,p300_(N-15),Pol2-4H8,GATA-2,YY1_(C-
20),GABP,ELF1_(SC-631),BCL11A,GATA2_(CG2-96),FOXA1_(C-20),CCNT2,Pol2(b),Mxi1_(bHLH),GATA3_(SC-
268),BATF,STAT3,SMC3_(ab9263),Rad21,JunD,GTF2F1_(RAP-74),c-Fos 
85780962 rs188367538 eGFP-JunD,TBP,c-Jun,TAF1,SRF,Pol2,YY1,Sin3Ak-20,NRSF,CEBPB,p300_(N-15),Pol2-4H8,GATA-2,NF-
YB,YY1_(C-20),GABP,ELF1_(SC-631),BCL11A,PU.1,GATA2_(CG2-96),FOXA1_(C-
20),CCNT2,Pol2(b),Mxi1_(bHLH),GATA3_(SC-268),BATF,STAT3,SMC3_(ab9263),Rad21,JunD,GTF2F1_(RAP-
74),c-Fos 
Full list of the ENCODE TFBS falling at the positions of variants of interest from the NGS project data in the PICALM region. 
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6.3 - rs3851179 LD block variants at the sites of ENCODE TFBS 
Coordinate rsID ENC_TFBS 
85859598 - MafK_(ab50322),eGFP-GATA2,p300_(F-4),GATA-1,Ini1,Pol2,CCNT2,TAL1_(SC-12984),GATA-2,Brg1 
85862491 rs187016120 CEBPB,TAL1_(SC-12984),IRF1,Brg1,STAT2,HDAC2_(SC-6296),Pol2,GATA-2,eGFP-JunD,p300_(F-4),GATA-1,eGFP-
GATA2,Mxi1_(bHLH),SMC3_(ab9263) 
85862739 - TAL1_(SC-12984),Brg1,Pol2,eGFP-JunD,GATA-1,eGFP-GATA2 
85863080 rs56157503 EBF1_(C-8) 
85863473 rs34731047 p300 
85863683 rs3889743 TFIIIC-110 
85863769 rs11234562 TFIIIC-110 
Full list of the ENCODE TFBS falling at the positions of variants of interest from the NGS project data in the rs3851179 LD block. 
 
 
 
 
 
